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ABSTRACT 
 
Given the strong evidence for a beneficial role of vitamin D in diabetes and CVD 
pathogenesis, and the prevalence of vitamin D deficiency, vitamin D 
supplementation has been advocated for the prevention of cardiometabolic disease.  
To provide information on the effects of 5,000IU (125µg) vitamin D3 on 
cardiometabolic risk, a double blind, RCT in a cohort of overweight and obese UK 
adult males with plasma 25(OH)D concentration < 75nmol/L for a duration of 8 
weeks was conducted. To the best of my knowledge, this is the first RCT to 
investigate the effect of 5,000IU (125µg) vitamin D3 on cardiometabolic markers in 
vitamin D insufficient, non-hypertensive and non-diabetic overweight and obese 
adult males. 
Participants in the RCT were randomised to supplement their diet with either, 
5,000IU (125µg) vitamin D3 or placebo daily for 8 weeks. Primary outcomes were 
changes in endothelial function determined by plasma sE-selectin concentrations and 
arterial stiffness determined by pulse wave velocity (PWV) and augmentation index 
(AIx). Fifty-five overweight and obese participants were recruited with mean (±SD) 
age 34.5 ± 12 years, and plasma 25(OH)D concentration of 41.2 ± 17.7nmol/L. 
Although all study participants had suboptimal plasma 25(OH)D concentrations at 
baseline, vitamin D deficiency defined as 25(OH)D < 25nmol/L and ˂ 30nmol/L was 
present in 22.2 % (n = 12) and 35.2 % (n = 19) of the study cohort, independent of 
treatment group.  
After 8 weeks of daily vitamin D3 supplementation, mean (±SD) plasma 25(OH)D 
concentration increased from baseline 38.4 ± 15.9 to 64.2 ± 19.5nmol/L, (P ˂ 0.001) 
at week 4 and 72.8 ± 16.1nmol/L, (P ˂ 0.001) at week 8 in the vitamin D group. The 
change in plasma 25(OH)D concentration was inversely associated with change in 
plasma glucose concentrations (r = -0.408, P = 0.048, as well as change in plasma 
HDL-C concentration (r = -0.503, P = 0.012) and positively associated with change 
in aortic central pulse pressure (r = 0.437, P = 0.033) at 4 weeks. Change in plasma 
25(OH)D concentration post intervention was inversely associated with change in 
brachial augmentation index (r = -0.446, P = 0.029). The association between week 4 
16 
 
change in plasma 25(OH)D concentration with corresponding changes in PPao and 
plasma HDL-C concentration were absent at week 8. 
There was a significant difference between vitamin D and placebo groups, in change 
in mean (±SD) brachial pulse pressure: -2.9 ± 3.4 vs.1.6 ± 0.5 mmHg, (P = 0.027), 
however, no significant difference was observed between the vitamin D and placebo 
group in changes in mean (±SD) sE-selectin − 10.8 ± 1.4 vs. - 17.1 ± 2.9 ng/mL, 
(P = 0.733), PWV -0.1 ± 0.2 vs. -0.2 ± 0.1 m/s, (P = 0.423) and both brachial and 
aortic AIx, 15.4 ± 13.3 vs. 6.1 ± 8.9%, (P = 0.940) and 3.1 ± 0.7 vs. -0.2 ± 3.2%, 
(P = 0.705) respectively, as well as the other cardiometabolic markers measured. 
Overall, the findings from this RCT do not support the hypothesis that a high daily 
dose of vitamin D reduces cardiometabolic disease risk in a cohort of non-
hypertensive and non-diabetic overweight and obese adult males. 
A second study was carried out to determine the prevalence of vitamin D deficiency 
and CVD risk in kidney stone patients. Vitamin D status and its association with 
CVD risk markers was assessed in a cohort of calcium oxalate kidney stones patients 
in the UK. To the best of my knowledge, this is also the first cross-sectional study 
carried out in calcium oxalate kidney stone patients, investigating the association 
between vitamin D status, bone health and selected CVD risk markers. Of the 24 
calcium oxalate kidney stone patients recruited for this study, 3 (12.5%), 7 (29.2%) 
and 18 (75%) had serum 25(OH)D concentrations ≤ 25nmol/L, <30nmol/L and 
<50nmol/L respectively. No significant associations were observed between serum 
25(OH)D concentrations and CVD biomarkers. Although high prevalence of low 
serum 25(OH)D concentrations (75%) was observed in this study, this was not 
associated with the CVD biomarkers.  
Interestingly, significant positive associations were observed between serum sE-
selectin and calcium concentrations (r = 0.53, P = 0.007), serum hs-CRP and calcium 
concentrations (r = 0.58, P = 0.003). Furthermore, modest but significant inverse 
associations were observed between serum sE-selectin and HDL-C concentrations (r 
= - 0.49, P = 0.013). Overall, no clear evidence for an association between serum 
vitamin D levels and cardiovascular disease risk factors was found 
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CRP  C-reactive protein 
CYP2RI  Cytochrome P450 2RI 
CYP24A1  Cytochrome P450 24A1 
CYP27B1  Cytochrome P450 27B1 
CYP3A4  Cytochrome P450 3A4 
CV  Coefficient of variation 
CVD  Cardiovascular disease 
C/EBPα  CCAAT/enhancer binding protein alpha 
DBD  DNA binding domain 
DBP  Diastolic blood pressure 
DH 
DEQAS 
 Department of health 
 Vitamin D External Quality Assessment Scheme 
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DNA  Deoxyribonucleic acid 
DRV  Dietary reference values 
EAR  Estimated average requirement 
ECM  Extracellular matrix 
ED  Ejection duration 
eGFR  Estimated glomerular filtration 
ELISA  Enzyme linked immunosorbent assay 
EFSA  European Food Safety Authority 
EPCs 
EDV 
 Endothelial progenitor cells 
Endothelial dependent vasodilation 
FAS  Fatty acid synthase 
FGF-23  Fibroblast growth factor 23 
FMD  Flow mediated dilatation 
FSM  Fat soluble micro constituents  
FXR  Farnesoid X receptor 
GDM  Gestational diabetes mellitus 
GIT  Gastrointestinal tract 
GLUT  Glucose transporter 
GM-CSF  Granulocyte-macrophage colony-stimulating factor  
HD  Haemodialysis 
HDL-C  High density lipoprotein cholesterol 
HIV  Human immunodeficiency virus 
HOMA-IR  Homeostatic model assessment- insulin resistance 
HUVEC  Human umbilical vein endothelial cells 
HR  Heart rate 
hs-CRP  High sensitivity-C-reactive protein  
IL  Interleukin 
IOM  US Institute of Medicine  
IFN-y  Interferon gamma 
IOM  Institute of Medicine 
LBD  Ligand binding domain 
LDL-C  Low density lipoprotein cholesterol 
MDA  Malondialdehyde 
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MAP                    Mean arterial pressure 
MAPK 
MCP-1 
Mitogen activated protein kinase 
Monocyte chemo attractant protein-1 
MI  Myocardial infarction 
MIF  Macrophage migration inhibitory factor 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NC  Nephrocalcin 
NDNS  National Diet and Nutrition Survey 
NFAT  Nuclear factor of activated T-cells 
NFkB  Nuclear factor -kappaB 
NGAL  Neutrophil gelatinase associated lipocalin 
NHANES  National Health and Nutrition Examination Survey 
NICE  National Institute for Health and Care Excellence 
Nmol/l  Nanomoles per litre 
NO  Nitric oxide 
NOS  National Osteoporosis Society 
OPN  Osteopontin 
PAD  Peripheral artery disease 
PHE  Public Health England 
PIS  Participant information sheet  
PP  Pulse pressure 
PPao  Aortic pulse pressure 
PPARγ  Peroxisome proliferator- activated receptor gamma 
PRA  Plasma renin activity 
Parathyroid gland PTG  
PTH  Parathyroid hormone  
PWV  Pulse wave velocity 
RAS  Renin-Angiotensin System 
RDA  Recommended daily allowance 
ROS  Reactive oxygen species 
RCT  Randomised controlled trial 
RHI  Reactive hyperaemia index 
RH-PAT  Reactive hyperaemia peripheral arterial tonometry. 
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RT  Return time 
RUNX2  Runt-related transcription factor 2 
RXR  Retinoid X receptor 
SACN  Scientific Advisory Committee of Nutrition 
SBP  Systolic blood pressure 
SDMA  Symmetric-dimethylarginine 
SLE  Systemic lupus erythematosus 
SBPao  Aortic central systolic blood pressure 
SWL  Shock wave lithotripsy 
sICAM-1  Soluble intracellular molecule-1 
sVCAM-1  Soluble vascular cell adhesion molecule-1 
TAG  Triacylglycerol 
THP  Tamm-Horsefall protein  
TBARS  Thiobarbituric acid reactive substances  
TC  Total cholesterol 
Th,  T helper 
THP  Tamm-Horsfall protein 
TLR  Toll like receptors 
TNF-α  Tumor necrosis factor alpha  
T2DM  Type 2 diabetes mellitus 
TRPV6  Transient Receptor Potential Cation Channel Subfamily V 
Member 6  
UK  United Kingdom. 
UTI  Urinary tract infections 
UTPF-1  Urinary prothrombin fragment 1  
UVB  Ultra violet B radiation 
UTR  Untranslated  
VDR  Vitamin D receptor 
VDRE  Vitamin D response element 
VDBP 
VEGF 
 Vitamin D binding protein 
Vascular endothelial growth factor 
Vitamin 
D2 
 Ergocalciferol 
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Vitamin 
D3 
 Cholecalciferol 
VLDL-C  Very-low density lipoproteins-C 
VSMC  Vascular smooth muscle cell 
vWF  Von willebrand factor 
WC,  Waist circumference 
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1.0 GENERAL INTRODUCTION 
1.1 VITAMIN D 
Vitamin D is a fat soluble secosteroid hormone which imparts both endocrine and 
autocrine functions (Vanchinathan & Lim, 2012). The principal endocrine function 
of vitamin D is supporting calcium and phosphorus homeostasis, which is achieved 
through the modulation of intestinal/kidney calcium absorption (Lee, O'Keefe, Bell, 
Hensrud, & Holick, 2008), and resorption from the bones (Pfeifer, Begerow, & 
Minne, 2002). Vitamin D also performs non-skeletal functions due to the presence of 
vitamin D receptors (VDR) in the nucleus of many tissues and cells of the human 
body, including cells of the parathyroid gland, skin, immune system, colon, pituitary 
gland, ovary, breast, prostate, liver, pancreas, heart, vascular smooth muscle 
endothelial cells and skeletal muscle amongst others (Brewer, Michos, & Reis, 2011; 
Holick, 2007). Studies have shown that several hundred genes throughout the body 
are being regulated by the VDR directly and indirectly in order to modulate cellular 
differentiation, proliferation, angiogenesis and apoptosis (Nagpal, Na, & 
Rathnachalam, 2005). Changes in the nucleotide sequence of a gene that is distinct to 
a particular cell type expressing the VDR can be described as the autocrine function 
of vitamin D. Some of the autocrine effects of vitamin D include its role in cancer, 
immune system and cardiovascular disease (CVD) amongst others. Vitamin D exerts 
these beneficial effects by promoting and obstructing cell reproduction, programmed 
cell death, and the modulation of inflammatory pathways (Cohen-Lahav, 
Douvdevani, Chaimovitz, & Shany, 2007; Heaney, 2008).  
1.2 FORMS OF VITAMIN D  
There are two important natural forms of vitamin D, vitamin D2 or ergocalciferol 
(C28H44O) with a molecular mass of 396.65g/moL (Fig.1.1) and vitamin D3 or 
cholecalciferol (C27H44O) with a molecular mass of 384.64g/moL (Fig.1.2). Vitamin 
D2 is a 28 carbon molecule formed in plants and fungi by the ultra violet (UV) 
irradiation of the plant sterol ergosterol whilst vitamin D3 is a 27 carbon molecule 
produced in the human skin from exposure to the sun (Holick, 2006). The major 
difference between vitamin D2 and D3 is the structure of the side chain to the sterol 
skeleton, which consists of an additional methyl group on carbon 24 and a double 
bond between carbon atoms 22 and 23 (Houghton & Vieth, 2006; Norman, 2008). 
24 
 
Although both forms have been reported to have similar molecular actions, vitamin 
D3 has been reported to be more potent compared to vitamin D2 regarding its 
bioavailability and the maintenance of vitamin D status (Armas, Hollis, & Heaney, 
2004; Heaney, Recker, Grote, Horst, & Armas, 2011; Lehmann et al., 2013). A 
systematic review and meta-analysis performed by (Tripkovic et al., 2012) showed 
that vitamin D3 was significantly more effective at increasing serum 25(OH)D 
concentrations compared with vitamin D2 (P = 0.001) in 8 out of 10 RCTs identified, 
thus vitamin D3 maybe a better choice for supplementation. There is evidence 
however, that vitamin D2 is as efficient as D3 in maintaining serum 25(OH)D3 
concentrations (Biancuzzo et al., 2010; Holick et al., 2008). 
                         
                         
         
                        
 
Fig.1.1 Molecular structure of ergocalciferol (D2) 
Fig.1.2. Molecular structure of cholecalciferol (D3) 
 
 
25 
 
1.3 SOURCES OF VITAMIN D 
Vitamin D is a fat-soluble micronutrient and the primary source of this vitamin is 
through sunlight synthesis, dietary intake, supplements and fortified foods are 
secondary sources of vitamin D. 
1.3.1 Sunlight irradiation 
Exposure of the skin to sunlight provides most of the vitamin D requirements for 
humans (Holick, 2004), thus, an individual increased sun exposure leads to improved 
vitamin D status.  Vitamin D is synthesised by the skin following sunlight irradiation 
between 1000 h and 1500 h during summer and spring (Holick, 2007; Moan, 
Porojnicu, Dahlback, & Setlow, 2008). Vitamin D synthesised by the skin is more 
likely to last for an extended period in the blood compared with ingested vitamin D 
(Haddad, Matsuoka, Hollis, Hu, & Wortsman, 1993). The amount of vitamin D 
produced when an uncovered human adult skin is exposed to one minimal erythemal 
dose of UV radiation (a slight pinkness to the skin 24 h after exposure), is equivalent 
to ingesting between 10,000 IU (250µg) and 25,000 IU (625µg) vitamin D (Holick & 
Chen, 2008). Vitamin D synthesis by UVB irradiation is discussed in detail in section 
1.7.1. 
1.3.2 Dietary sources 
Diet is a secondary source of vitamin D and plays a limited role in vitamin D status, 
as few foods naturally contain vitamin D (Lu et al., 2007). Animal food products and 
fortified foods are the main dietary sources of vitamin D in the UK (Schmid & 
Walther, 2013). Vitamin D is naturally more abundant in animal and fish products 
compared to plant products. In a cross-sectional analysis of 2107 White men and 
women (1388 meat eaters, 210 fish eaters, 89 vegans and 420 vegetarians), Crowe et 
al., (2011), reported reduced plasma 25(OH)D concentrations in both vegetarians and 
vegans compared to meat and fish eaters in a UK study. Vitamin D3 and its 
precursor, 7 dehydrocholesterol (7DHC), a derivative of cholesterol has been found 
to occur in microalgae and in the leaves of plants including vegetables such as 
potato, tomato and pepper, even though their vitamin D content differs and there is 
lack of evidence whether the edible portions also contain vitamin D2 (Japelt & 
Jakobsen, 2013). It is important to note that the vitamin D content of oily fish varies 
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widely within species and farmed salmon have been found to contain about one 
quarter of the vitamin D found in wild salmon. Wild mushroom, a rich dietary source 
of vitamin D2 (13-30µg/100g), also contains more vitamin D2 than cultivated 
mushrooms (which are grown in the dark) (Teichmann, Dutta, Staffas, & Jägerstad, 
2007). UK Dietary surveys in White non-breastfed infants and very young children, 
found formula milk to be the main contributor to dietary vitamin D status, as it 
provides an average of 85% vitamin D intake for children aged 4–6 months. In the 
UK, formula milk contributed 80% and 72% vitamin D for infants aged 7–9 months 
and 10–11 months respectively, and 29% for children aged 12–18 months (Lennox, 
Sommerville, Ong, Henderson, & Allen, 2013). For children aged 1.5–3 years and 4–
10 years milk and milk products provided 24 and 13% respectively of vitamin D 
intake (Bates et al., 2014). The vitamin D content of the major dietary sources of 
vitamin D is shown in Table 1.1. 
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Table 1.1. Vitamin D content of foodstuffs (DH, 2013 and SACN, 2016) 
Food source Vitamin D (µg/100g) 
Fish 
Mackerel raw  8.0 
Salmon, raw 5.9 
Sardines raw  4.0 
Yellow fin tuna raw  3.2 
Cod chilled/frozen, raw  Trace 
Prawns, king, raw Trace 
Meat 
Pork leg joint, raw 0.9 
Lamb chop, raw 0.8 
Liver (lamb, fried) 0.9 
Liver (calf, fried) 0.3 
Beef (rump steak, fried) 0.7 
Eggs 
Eggs (whole boiled) 3.2 
Eggs (yolk, boiled) 12.6 
Fortified foods  
Bran flakes 4.2 
Corn flakes 4.2 
Rice cereal 4.2 
Fat spreads (reduced fat 62-75% 
polyunsaturated) 
7.5 
 
1.4 VITAMIN D FOOD FORTIFICATION 
The National Diet and Nutrition Survey report shows that over one-fifth of the UK 
population had circulating serum 25(OH)D concentration < 25 nmol/L (Bates et al., 
2014). This low concentration occurs mainly in people (particularly children) with 
reduced exposure to the sun or poor dietary intake of vitamin D.  Fortification with 
vitamin D of some foodstuffs has been accepted as a strategy to improve serum 
25(OH)D concentrations, however, mandatory and voluntary fortification differs 
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between countries. In the UK, it was mandatory to fortify margarine with 7.05 μg and 
8.82 μg vitamin D from 1940, until this requirement was removed in 2013 as part of 
the Government’s Red Tape Challenge, with the aim of reducing the overall burden 
of regulation (SACN, 2016). Nevertheless, infant formulas are still mandatorily 
fortified and most margarine, fat spreads, powdered or evaporated milk and some 
breakfast cereals are fortified with vitamin D on a voluntary basis (SACN, 2015). 
Findings from a systematic review and meta-analysis of 16 randomised controlled 
trials (RCTs) worldwide showed that vitamin–D fortified foods raised 25(OH)D 
concentrations in a dose-dependent manner. The average daily individual intake of 
approximately 11 μg vitamin D (3–25 μg/day) from fortified foods raised serum 
25(OH)D by 19.4 nmol/L equivalent to a 1.2 nmol/L increase for each 1 μg ingested 
(Black, Seamans, Cashman, & Kiely, 2012).  
In Canada, milk and margarine are fortified mandatorily with 1µg/100ml and 
13.3µg/100g of vitamin D respectively (Health Canada, 2014). In the US, 75% of 
ready to eat breakfast cereals, almost all liquid milk, 8-14% of cheeses, juices, and 
spreads, approximately a quarter of yoghurts, and slightly more than half of all milk 
substitutes are fortified with vitamin D (Yetley, 2008). Since 2007, Sweden has 
adopted a policy of mandatory fortification of milk (in the range 3.8–5.0 μg/L) and 
margarines and fat spreads were fortified with vitamin D in the range of 7.5–
10 μg/100 g (Helidan, Kosonen, & Tapanainen, 2013). Vitamin D fortification of 
liquid milk products (0.5µg/dL milk) and margarines (10µg/100g) were introduced in 
Finland in February 2003. A major drawback of vitamin D fortification of milk is 
that it would not be beneficial to individuals with lactose intolerance and non-
consumers of fortified milk (Spiro & Buttriss, 2014).   
1.5 VITAMIN D SUPPLEMENTATION 
Vitamin D supplements contain either D2 or D3 and are present in a wide range of 
licensed medicines and food supplements including calcium supplements and fish oil 
products, which contain up to 500 IU (12.5µg). Multivitamins which contain 400 IU 
(10µg) are readily available in capsules and tablets and oil preparations that contain 
100,000 IU (2,500µg) (Holick, 2005).    
 
29 
 
1.6 VITAMIN D INTAKE IN THE UK 
The mean dietary vitamin D intake from all sources including dietary supplements in 
breast fed and non-breast fed infants and the general UK populations are shown in 
Table1.2  
Table 1.2. Mean dietary vitamin D intake for the UK population (SACN, 2016) 
Age 
groups 
Mean intake 
in breast fed 
infants 
(µg/day) 
Mean intake 
in non-breast 
fed infants 
(µg/day) 
Mean intake in 
young 
children/adults 
(µg/day) 
RNI 
(µg/day) 
4-11m 3.5-3.8 7.7- 10  8.5-10µg 
12-18 m 2.6 - 3.9  10µg 
1.5-18Y - - 2.3-2.7 10µg 
19-65+ - - 3.6-5.1 10µg 
 
1.7 VITAMIN D METABOLISM 
Vitamin D is synthesised endogenously (sunlight exposure) and exogenously (dietary 
intake). 
1.7.1 Synthesis in the skin from UVB irradiation 
Exposure of the basal and supra-basal layer of the epidermis of the skin to UVB light 
at a wavelength of 290-315nm, induces the photolytic conversion of 10-15% 7-DHC 
also referred to as provitamin D3, present on the epidermis and dermis of the skin 
(Lehmann & Meurer, 2010). Photolysis causes isomerisation, which results in the 
activation of double bonds between C-9 and C-10, leading to the opening up of the B 
rings. The B rings rearrange to form 9, 10 secosterol, a steroid with a broken ring 
also known as previtamin D3, a thermodynamically unstable isomer. Previtamin D3 
undergoes non-enzymatic thermal isomerisation, which is a temperature-sensitive 
rearrangement of three double bonds to form the biologically inactive vitamin D3 
(cholecalciferol) (Fig.1.3). This process occurs in the plasma membrane of both the 
dermis and epidermis over the duration of three days (Holick, 2010). It has been 
reported that 50% of previtamin D3 is capable of isomerising to vitamin D3 within 
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2.5 hours in the skin, explaining the rapid increase in serum levels of vitamin D3 on 
exposure to UVB (Holick, MacLaughlin, & Doppelt, 1981). It is important to note 
that, increased UVB exposure, does not lead to the production of more previtamin 
D3, but instead, it is converted to biologically inactive metabolites such as lumisterol, 
pyrocalciferol, and tachysterol, to prevent the build-up of vitamin D3 at toxic levels. 
Cutaneous vitamin D3 is reversibly photo-converted and isomerised into suprasterol I 
and II and to 5, 6-trans-vitamin D3 which are made available when previtamin D3 
concentrations fall (Hossein-nezhad & Holick, 2013; Norval, Bjorn, & de Gruijl, 
2010).  
1.7.1.1 Hydroxylation to 25(OH)D3 
As fat soluble molecules with low aqueous solubility, vitamin D metabolites must be 
transported bound to plasma proteins such as the vitamin D binding protein (VDBP) 
(Dusso, Brown, & Slatopolsky, 2005). Before inactive vitamin D3 undergoes 
hydroxylation, it must first bind to the VDBP, which transports inactive D2 and D3 
through blood and lymph to the liver. In the liver, they are hydroxylated at position 
C-25 by an enzyme CYP2RI, also known as 25-hydroxylase to produce 25 hydroxy-
vitamin D3 (25(OH)D3) also known as calcidiol (Fig.1.3). The 25 - hydroxylation has 
also been shown to occur in some extra- hepatic tissues such as, cardiomyocytes, 
endothelium, vascular smooth muscle and pancreatic β cells amongst others 
(DeLuca, 2008). The primary circulating form used in establishing an individual’s 
serum/plasma vitamin D status is 25(OH)D, as it has a circulating half-life of 15 days 
(Byrdwell et al., 2008). The use of 25(OH)D as the ideal marker of vitamin D status 
was as a result of its association with the risk of hip fracture (Lips, 2007). The 
hydroxylation of vitamin D3 to 25(OH)D3 in the liver has little or no regulation.  
1.7.1.2 VDBP 
VDBP is an α-globulin, 58kDa glycoprotein belonging to the serum albumin 
superfamily, it is a binding protein for all vitamin D metabolites in the serum, 
although it has 20 times more binding affinity for 25(OH)D3 compared to active 
vitamin D (Christakos, Dhawan, Verstuyf, Verlinden, & Carmeliet, 2016). This 
indicates that, it may significantly influence 25(OH)D-mediated intracrine responses 
(Chun et al., 2014). VDBP binds to fatty acids and acts as a chemical stimulus that 
attracts macrophages to site of inflammation, as it is capable of recruiting neutrophils 
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(Chun, 2012; Trujillo et al., 2013). This is supported by evidence that neutrophil 
recruitment is hindered in VDBP null mice. Additionally, there are noticeable 
reductions in serum 1,25(OH)2D3 and 25(OH)D3 concentrations in VDBP null mice 
even though serum PTH, calcium and phosphorus concentrations remains normal 
(Safadi et al., 1999). Hence, maintenance of normal serum concentrations of calcium 
may be attributed to the ability of the VDR to concentrate vitamin D in tissues due to 
its high affinity for vitamin D resulting in the upregulation of calcium homeostasis 
maintenance genes. 
VDBP bound vitamin D metabolites have a longer circulating half-life, as they are at 
minimal risk of hepatic metabolism and biliary excretion. Unbound metabolites are 
incapable of reaching target cells and are hence, unable to exert biological activity. 
VDBP has been reported to prevent toxicity by buffering the free concentrations of 
active form of vitamin D (Christakos et al., 2016). Active vitamin D concentration 
does not regulate VDBP, as its concentrations are reduced by malnutrition, renal and 
hepatic disease, and are increased during pregnancy and estrogen therapy (Dusso et 
al., 2005). VDBP is greatly polymorphic, and this affects its protein function as 
shown in 3 common variants: GC1F, GC1S, and GC2. The prevalence of these 
polymorphisms is influenced by race (Engelman et al., 2008). Blacks and Asians 
carry the polymorphisms in Gc1f, whereas whites carry the Gc1s form of DBP. The 
Gc2 form rarely occurs in blacks but is more prevalent in people of European and 
Asian ethnicity (Christakos et al., 2016). Polymorphism in the VDBP amino acid 
sequence alters the binding affinity of VDBP for vitamin D ligands, Gc1f and Gc2 
have the highest and lowest affinity respectively (Bouillon, van Baelen, & de Moor, 
1980). Circulating concentrations of 25(OH)D are associated with polymorphisms of 
Gc1s and Gc2 as reported by genome–wide association studies (Ahn et al., 2010; 
Wang et al., 2010). Associations with reduced 25(OH)D3 concentrations have been 
reported in TT carriers for Gc1s and AA carriers for Gc2. These polymorphisms may 
affect the bioavailability of vitamin D (Chun et al., 2014). 
.7.1.3 Hydroxylation to 1, 25(OH)2 D3 
VDBP binds to 25(OH)D3 forming a complex that is transported to the kidneys with 
the aid of megalin for glomerular filtration. Megalin, a 600-kDa transmembrane 
protein and cell surface receptor for VDBP, stimulates 25(OH)D3 absorption in the 
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tubular epithelial cells through endocytosis (Chun et al., 2014). The ability of 
megalin to effect renal absorption of 25(OH)D3 is noteworthy, as mice deficient in 
megalin, have been shown to lose 25(OH)D3 and VDBP complex in the urine and 
also have defects of bone metabolism (Nykjaer et al., 1999). A cytoplasmic adaptor 
protein disabled 2 (dab 2), works together with megalin to enable the cellular uptake 
of VDBP/25(OH)D3 in the kidneys by triggering the exact routing of megalin by 
binding to the cytoplasmic tail of megalin (Morris, Tallquist, Rock, & Cooper, 2002; 
Willnow & Nykjaer, 2010). Cubulin, present in the proximal tubule, is another cell 
surface receptor for VDBP, it works together with megalin to internalise the 
25(OH)D3 and VDBP complex (Nykjaer et al., 2001). On reaching the proximal 
renal tubules of the kidneys, 25(OH)D3 undergoes final hydroxylation at position C-1 
of the A ring, resulting in the formation of the biological and functional active form 
called 1,25(OH)2D3 or calcitriol. This process is catalysed by 1α hydroxylase 
(mitochondrial CYP2B1) (Fig.1.3). It is important to note that the active form is not 
a good indicator of vitamin D status as a result of its presence in circulation only in 
picomolar quantities and it has a short circulating half-life of 15 hours (Deeb, Trump, 
& Johnson, 2007; Jones, 2008). The mitochondrial 1α hydroxylase enzyme 
CYP27B1 is significant, because despite regular vitamin D consumption, vitamin D 
dependency rickets type 1 (pseudovitamin D deficiency rickets) have been reported 
to occur following mutations which results in deleted or inactive CYP27B1 
(Kitanaka et al., 1998). The metabolism of 25(OH)D3 depends on the calcium needs 
of an individual. An increased need for calcium results in 1 α hydroxylation, whilst 
excess calcium leads to 24-hydroxylation (DeLuca, 2008). 
1.7.1.4 Inactivation of 25(OH)D3 
In addition to the conversion of 25(OH)D3 to 1,25(OH)2D3 in the kidneys by 
CYP27B1, 25(OH)D3 can also be inactivated by CYP24A1, a 24 hydroxylase, 
through its conversion to 24, 25(OH)2D3 by hydroxylation at position C-24 yielding 
calcitroic acid or 1,25(OH)2D3-26,23S-lactone (Fig.1.3.) (Carlberg & Molnár, 2012). 
CYP24A1 is a mitochondrial inner membrane cytochrome P-450 enzyme present in 
all cells containing the VDR. CYP24A1 modulates the circulating levels of 
1,25(OH)2D3, following increased serum concentration by catalysing the conversion 
of 1,25(OH)2D3 into 24-hydroxylated products targeted for excretion or by forming 
24,25(OH)2D3 thereby reducing the concentration of 25(OH)D3 available for 1α- 
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hydroxylation. In addition, it regulates 1,25(OH)2D3 concentration within cells, 
leading to correct cellular response (Jones, Prosser, & Kaufmann, 2012). It is 
important to note that 1,25(OH)2D3 analogues (synthetic analogues of 1,25(OH)2D3, 
most of which are modified in their aliphatic side chain, are used to improve the 
biological profile of 1,25(OH)2D3 for therapeutic purposes) are metabolised by same 
CYP enzymes, however, the efficiency with which this is done is varied resulting in 
different metabolic profiles (Carlberg & Molnar, 2012; Verstuyf, Carmeliet, 
Bouillon, & Mathieu, 2010). 
 
 
Fig.1.3. Metabolic pathway of vitamin D synthesis (Holick, 1996). 
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1.7.2 Factors affecting cutaneous vitamin D3 synthesis 
Prior to interacting with 7DHC, levels of UVB may be reduced by several factors 
which affect skin synthesis of vitamin D3 and they include: zenith angle, latitude, 
season, time of the day, sunscreen use/protective clothing, temperature, exposure to 
radiation and the activity of 7DHC (Lehmann & Meurer, 2010). 
1.7.2.1. Zenith angle, season and latitude 
Approximately 1% of UVB radiation reaches the earth’s surface even in summer as 
the stratospheric ozone layer absorbs approximately 99% of UVB radiation, hence 
living at a latitude above 33o during winter produces little or no vitamin D3 from sun 
exposure from the months of November through to February (Caldwell & Flint, 
1994; Ladizesky et al., 1995; Webb, Kline, & Holick, 1988). The zenith angle of the 
sun is more oblique and is comparable to winter sun in the early mornings and late 
afternoons and as a result the best time for the synthesis of vitamin D3 is between 10 
am and after 3pm (Holick, 2010). Seasons of the year also affect vitamin D3 
synthesis. A study aimed at determining the prevalence of hypovitaminosis D in 
7437 white British people found it to be highest during winter and spring. However, 
circulating 25(OH)D peaked in September (Hypponen & Power, 2007). The higher 
the altitude, the shorter the path length travelled by UVB radiation in the atmosphere 
leading to increased previtamin D3 synthesis (Holick, Chen, Lu, & Sauter, 2007). 
1.7.2.2 Air pollutants, glass windows, sunscreen use and skin thickness   
Air pollutants including nitrous oxide and ozone which are common in large cities 
absorb solar UVB radiation thus, reducing the normal synthesis of vitamin D3 by the 
skin (Spina et al., 2005). Exposure of the skin to sunlight which has passed through 
glass windows or plastic does not result in vitamin D3 synthesis (Holick, 1994). 
Sunscreens with a sun protection factor of 30 absorbs approximately 95-98% of 
UVB radiation, hence reducing skin vitamin D3 synthetic capacity by 95-98% 
(Holick, 2007). Farmers who always wore sunscreen during summer for more than a 
year whilst outdoors, were reported to have low circulating 25(OH)D concentrations 
compared to controls (Matsuoka, Wortsman, Hanifan, & Holick, 1988). Skin 
thickness decreases linearly with age in humans after the age of 20 years. Therefore 
the skin of an elderly person will only produce 25% of the vitamin D3 compared to 
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the amount a younger person will synthesise (MacLaughlin & Holick, 1985). 
Populations at risk of vitamin D deficiency are discussed in section 1.15. 
1.7.3 Dietary absorption of vitamin D  
The absorption mechanism discussed herein is for non-hydroxylated forms of 
vitamin D (vitamin D2 and D3), as no data is available yet for the hydroxylated 
(25(OH)D3) forms. Vitamin D as well as other fat soluble vitamins have similar 
absorption in the human upper gastrointestinal tract (GIT), including emulsification, 
solubilisation in mixed micelles, diffusion across the unstirred water layer and its 
penetration through the enterocytes to the circulation (Tso & Fujimoto, 1991). The 
specific site of vitamin D absorption in humans is not yet known, however, in rats the 
ileum has been reported to be the main site (Reboul et al., 2011). After ingesting 
vitamin D from the diet, it is released from the food/supplement matrix in which it is 
embedded. To aid digestion, vitamin D is emulsified into smaller emulsion droplets 
by bile salts and phospholipids without any chemical modification (Reboul et al., 
2006). This emulsification enables digestive enzymes including pancreatic lipase to 
digest vitamin D (Reboul et al., 2006). Following digestion, vitamin D2 or D3 is 
solubilised in mixed micelles by bile salts and phospholipids, and diffuse into the 
enterocytes where they are absorbed (Borel, Caillaud, & Cano, 2015; Reboul et al., 
2006). Once inside the enterocyte vitamin D is incorporated into chylomicrons and 
first enters the lymphatic system then the blood stream before it enters the liver. The 
more vitamin D is incorporated into chylomicrons, the higher the rate of absorption 
or bioaccessibility (Borel et al., 2015; Reboul et al., 2006).  Following this, they are 
absorbed through the lymphatic route into the systemic circulation, whilst 25(OH)D3 
undergoes absorption via the portal route (Borel et al., 2015; Reboul, 2015). The 
absorption of 25(OH)D3 is about three times higher compared to vitamin D2 & D3, as 
it is more polar and does not depend on bile acids for absorption (Compston, Merrett, 
Hammett, & Magill, 1981; Maislos, Silver, & Fainaru, 1981). An in vivo study in rats 
demonstrated that lack of biliary salts did not affect absorption of 25(OH)D3 but did 
reduce and impede the absorption of vitamin D2 and D3 by (Maislos & Shany, 1987). 
The absorption of 25(OH)D3 is assumed to be a non saturable passive diffusion 
process. It is important to note that, intestinal cell membrane proteins such as 
scavenger receptor class B type 1 (SR-B1), cluster determinant 36 (CD36) and 
Niemann- Pick C1 like 1 (NPC1L1) are also involved in the apical absorption of 
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cholesterol and other fat soluble vitamins. It has been discovered that at low dietary 
vitamin D concentrations, absorption is protein mediated but at high dietary vitamin 
D concentration, absorption is passive (Reboul et al., 2011).  
The vehicle for vitamin D transport is significant particularly in people with fat 
malabsorption problems (Grossmann & Tangpricha, 2010; Tangpricha et al., 2012). 
Thus, to maximise absorption from vitamin D supplementation, there is need to 
know the most efficient vehicle for its transport. As a result, the vehicle in which 
vitamin D is carried is significant in its absorption, however, available evidence is 
conflicting. Vitamin D in an oil vehicle has been reported to be more bioavailable 
than in a powder based vehicle (cellulose or lactose) or in ethanol (Grossmann & 
Tangpricha, 2010). However, another clinical trial discovered vitamin D to be more 
bioavailable from a lactose capsule compared to an oily drop formulation (Coelho et 
al., 2010).  
Vitamin D2 and D3 have been reported to have equal intestinal absorption. In healthy 
subjects both receiving 1000 IU (25µg) of D2 and D3, serum 25(OH)D increased 
equally in all the supplemented group (Holick et al., 2008).  Another study with D2 
and D3 fortified orange juice or in a supplement was shown to give similar serum 
25(OH)D3 responses suggesting similar bioavailability (Biancuzzo et al., 2010). 
However, Romagnoli et al.,(2008), found a higher bioavailability of D3 than D2 after 
administering same large doses of both forms to elderly subjects. The possible reason 
given for the difference in bioavailability has been attributed to different affinities of 
D2 and D3 for the VDR (Borel et al., 2015).  
1.7.3.1 Effectors of dietary vitamin D absorption 
The components of a meal (particularly lipids), or gut enzymes secreted after a meal 
have been suggested to improve vitamin D absorption (Mulligan & Licata, 2010). 
Lipids improve the absorption of fat soluble micro constituents (FSM) by stimulating 
its release from the food matrix and providing a hydrophobic phase where FSM 
could be solubilized. By stimulating biliary secretion and micelle synthesis and by 
inducing chylomicron synthesis which in turn enhances FSM transport outside the 
enterocytes, thus, increasing FSM absorption (Borel et al., 2015). The rate of 
absorption of fat soluble vitamins can be improved by nanoparticles and compounds 
capable of forming micelles. The water-soluble form of vitamin E (Tocopheryl 
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succinate polyethylene glycol 1000 TPGS) has been employed to enhance vitamin D 
absorption, as it is capable of solubilising lipophilic compounds. A clinical study in 
children aged 5-19 years with severe cholestasis, found higher absorption of vitamin 
D administered in a mixture with TPGS (Argao, Heubi, Hollis, & Tsang, 1992). 
The vitamin D status of the host is significant in its intestinal absorption, although 
there is limited available data on this. The intestinal absorption and hydroxylation in 
the liver of vitamin D3 in rats were found to be higher in vitamin D deficient rats 
compared to the non-deficient rats (Apukhovskaia, Khrestovaia, Antonenko, 
Omel'chenko, & Dotsenko, 1990). From this finding, it could be deduced that 
intestinal absorption of vitamin D is higher in vitamin D deficient individuals.  
1.7.3.2 Inhibitors of dietary vitamin D absorption 
Several lipid lowering drugs such as tetrahydrolipstatin (orlistat) and olestra reduce 
the absorption of cholesterol, triacylglycerols and vitamin D, since vitamin D and 
lipids have similar fate in the GIT (McDuffie, Calis, Booth, Uwaifo, & Yanovski, 
2002). Phytosterols may also reduce vitamin D absorption by impairing its 
solubilisation in mixed micelles, a finding supported by an in vitro study in mice 
showed that phytosterols compete with vitamin D for incorporation into mixed 
micelles as well as for apical uptake (Goncalves et al., 2011). A study by Reboul et 
al., (2011), found high concentrations of vitamin E to significantly disrupt vitamin D 
absorption. The interactions observed between vitamin D and other fat-soluble 
vitamins could be attributed to them sharing a similar mechanism of absorption. 
Genetic factors may be significant in vitamin D absorption, as protein expression and 
activity are regulated by genes involved in the cellular uptake of vitamin D, although 
there are no available data on this (Ahn et al., 2010; Karohl et al., 2010). Genetic 
variations resulting in functional modifications in the amino acid sequence of 
proteins will simultaneously diminish the ability of these proteins to correctly 
perform their function in vitamin D metabolism (Borel, 2012; Lindqvist, Sharvill, 
Sharvill, & Andersson, 2007). Diseases including obstructive jaundice, cystic fibrosis 
and coeliac disease which are characterised by impaired fat absorption may obstruct 
vitamin D absorption. A study by Farraye et al., (2011) showed cystic fibrosis 
patients absorbed less than one third or one half (Lark et al., 2001) the quantity of 
oral vitamin D2 that was absorbed by healthy patients. The detrimental effect of these 
38 
 
diseases on vitamin D bioavailability can be improved by administering 
hydroxylated forms of vitamin D as patients with intestinal fat malabsorption 
syndrome had improved absorption of 25(OH)D3, which is absorbed directly through 
the portal vein (Leichtmann, Bengoa, Bolt, & Sitrin, 1991) or can be, to some extent 
corrected by sun exposure (Robberecht, Vandewalle, Wehlou, Kaufman, & De 
Schepper, 2011). A study by Aarts et al., (2011) on studying the effect of gastric 
surgery on vitamin D bioavailability found peak serum vitamin D3 concentrations to 
be 30% lower after Roux-en-Y gastric bypass than before surgery. 
Aging has not been found to be associated with vitamin D absorption. A study by 
(Harris & Dawson-Hughes) in 2002 of 25 young men aged 18-35years and 25 older 
men aged 62-79 years who were administered  a daily dose of 800 IU (20µg) of 
vitamin D3  did not find a significant effect of aging on vitamin D absorption. The 
low vitamin D status in older people may be due to reduced dietary intake and the 
reduced capacity of skin to synthesise vitamin D/reduced hydroxylation by the liver 
and little exposure to sunlight (Borel et al., 2015). 
1.8 REGULATION OF VITAMIN D METABOLISM 
Renal regulation of vitamin D is influenced by four parameters: direct negative 
feedback by vitamin D, parathyroid hormone (PTH), calcitonin and fibroblast growth 
factor 23 (FGF-23). 
1.8.1 Regulation by calcium/PTH 
Increased PTH due to hypocalcemia is the principal signal that results in the 
activation of vitamin D synthesis in the kidneys (Bikle, 2014; Henry, 2011). The 
upregulation of CYP27B1 transcription which leads to calcitriol synthesis following 
raised PTH is mediated by the nuclear orphan receptor 4A2 (NR4A2) (Zierold, 
Nehring, & DeLuca, 2007). Vitamin D in turn directly inhibits the production of 
PTH in the parathyroid gland at the level of human PTH transcription promoter 
(Koszewski, Alimov, Park-Sarge, & Malluche, 2004) and indirectly by raising serum 
calcium concentrations and by activating calcium sensing receptor expression and 
transcription (Canaff & Hendy, 2002). 
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1.8.2 Feedback regulation by vitamin D 
Vitamin D regulates its own production by forming a complex with VDR, this 
represses CYP27B1 expression (Henry, 2011), decreases PTH release and stimulates 
its own breakdown to water soluble compounds that are excreted through bile by 
triggering the production of CYP24A1 (Holick, 2011; Norman, 2008). 
1.8.3 Regulation by phosphate/FGF23 
FGF-23 is a 32 kDa glycoprotein expressed primarily in osteoblasts and osteocytes, 
belonging to the F19 subfamily and it is different from other FGFs, as it acts in an 
endocrine pattern (Hu, Shiizaki, Kuro-o, & Moe, 2013; Quarles, 2012). FGF23 is 
synthesised in response to increased phosphate concentrations, as it stimulates renal 
phosphate excretion in the urine by decreasing its reabsorption in the proximal renal 
tubules of the kidney (Liu et al., 2006; Segawa et al., 2007). Alpha Klotho (α klotho), 
a 130 kDa transmembrane protein expressed in the distal renal tubules of the kidneys 
acts as a obligate co-receptor for FGF23, αKlotho forms complexes with FGFR1c, 
FGFR3c  and FGFR4 which enhances the FGF23 activation of FGFRs and as a result 
FGF23 together with αKlotho suppresses vitamin D synthesis by downregulating 
CYP27B1 whilst upregulating CYP24A1 involved in vitamin D catabolism 
(Bergwitz & Juppner, 2010). Deficiency in FGF23 or αKlotho leads to increased 
vitamin D synthesis, premature aging and ectopic calcification (Shimada, Kakitani, et 
al., 2004). FGF-23 is increased in chronic kidney disease (CKD), this leads to 
suppression of vitamin D and increased PTH synthesis. The increase in FGF-23, has 
been suggested to be an early biomarker of CKD, as FGF-23 increases due to loss of 
functional renal mass and impaired calcium-phosphate homeostasis (Quarles, 2012).  
1.8.4 Regulation by calcitonin 
In addition to decreasing blood calcium by downregulating osteoclasts under high 
blood calcium concentrations, calcitonin also triggers renal CYP27B1 expression 
which leads to increases in plasma 25(OH)D concentration under normal calcium 
conditions (Shinki, Ueno, DeLuca, & Suda, 1999). There is evidence that calcitonin 
upregulates CYP27B1 transcription in the cells of the kidneys (Zhong, Armbrecht, & 
Christakos, 2009). 
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1.9 PROPOSED MECHANISM OF ACTION OF VITAMIN D 
1.9.1 VDR 
The VDR is responsible for mediating the biological (genomic and non-genomic) 
actions of vitamin D and its analogues. VDR belongs to the nuclear receptor 
superfamily which includes adrenal steroids, retinoic acid, thyroid and sex hormones 
(Margolis & Christakos, 2010). The VDR is distinct from other members of the 
nuclear receptor superfamily as it is coded by only one gene (Carlberg & Molnár, 
2012) located on chromosome 12 and consist of 8 coding exons (Zella, Kim, Shevde, 
& Pike, 2006), 6 non-coding exons and at least 2 promoters (Zella et al., 2010). 
Human VDR protein contains 427 amino acids which heterodimerise with retinoid X 
receptor (RXR) for the stimulation of vitamin D target genes (Pike & Meyer, 2010; 
Zella et al., 2006).  
The NH2-terminal DNA binding domain (DBD) and COOH-terminal ligand binding 
domain (LBD) are the two principal functional domains of the VDR. DBD contains a 
cysteine- rich zinc finger region and there are 2 zinc fingers each of which consists of 
a single zinc atom in a tetrahedral arrangement with 4 invariant cysteine residues 
(DeLuca, 2008; Pike & Meyer, 2010). LBD contains a minimum of 12 α helices (H1-
H12) (Rochel, Wurtz, Mitschler, Klaholz, & Moras, 2000). Vitamin D binding to 
LBD causes a conformational change that promotes its interaction with coregulatory 
complexes and RXR, and this is essential for target genes transcription and the 
recruitment of coactivator proteins (Rochel et al., 2000; Shaffer, McDonnell, & 
Gewirth, 2005). The VDR gene is greatly expressed in metabolic tissues including 
the bone, kidneys, liver and intestine, but it is low to moderately expressed in the 
other approximately 250 different human tissues (Verstuyf et al., 2010). 
1.9.2 Genomic mechanism of action of vitamin D   
On reaching a target cell, vitamin D detaches from VDBP and binds to the VDR, 
which in turn is phosphorylated to regulate its genomic efficiency and potency, after 
binding, the VDR/vitamin D complex moves from the cytoplasm to the nucleus 
(Haussler, Jurutka, Mizwicki, & Norman, 2011; Smolders et al., 2009). In the 
nucleus, the VDR/vitamin D complex forms a heterodimer by binding with 9-cis- 
RXR (Fig.1.4.), this heterodimer improves the affinity of the VDR transcriptional 
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response to DNA bindingand assembles cofactors which form a powerful 
transcriptional complex. The transcriptional complex recognises and binds with 
specific DNA sequences called vitamin D response element (VDRE) (Fig.1.4.) at the 
promoter region of approximately 3,000 vitamin D target genes in the human 
genome (Bouillon et al., 2008; Christakos, Dhawan, Liu, Peng, & Porta, 2003; 
DeLuca, 2008; Haussler et al., 2011). Following the binding of vitamin D/VDR/RXR 
heterodimer to VDRE, changes in gene expression are either facilitated or repressed 
due to the ability of the liganded receptor to recruit transcriptional co-activators or 
co-repressors, resulting in the induction or suppression of protein synthesis (Haussler 
et al., 2011). It is important to note that VDR upregulation by vitamin D analogues 
such as paricalcitol will assemble a different cofactor from the ones assembled by 
vitamin D. This is a possible explanation for the difference observed between vitamin 
D and its analogues in their impact on the atherosclerotic process (Issa, Leong, 
Sutherland, & Eisman, 2002).   
 
Fig.1.4. Genomic mechanism of action of vitamin D through the VDR adapted 
from Smolders et al.,(2009). 
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1.9.3 Non-genomic mechanism of action of vitamin D 
Vitamin D binds to VDR associated with caveolae (cholesterol-rich invaginations 
present in endothelial cells and vascular smooth muscle cell (VSMC), the source of 
the rapid response signal transduction pathway) of the plasma membrane to stimulate 
non-genomic responses (Huhtakangas, Olivera, Bishop, Zanello, & Norman, 2004). 
This leads to the activation of rapid response signal transduction pathways including 
phosphatidylinositol-3′-kinase (PI3K), phospholipase C, or protein kinase C (PKC); 
which may open voltage-gated calcium or chloride channels (Haussler et al., 2011). 
1.10 VDR GENE POLYMORPHISMS 
Over 60 VDR polymorphisms located in the promoter region in and around exons 2-
9 and in the 3′ untranslated (UTR) region have been discovered, however, only few 
have been studied (McCullough, Bostick, & Mayo, 2009). Polymorphisms occur 
following genetic alterations of the VDR gene, this may lead to dysfunctional gene 
expression, affecting the endocrine/autocrine/paracrine functions of vitamin D 
(Valdivielso & Fernandez, 2006). The location of the VDR gene determines it 
function, as it differs amongst ethnic groups (Zhou, Xu, & Gu, 2009). A meta-
analysis aimed at evaluating the relationship between Graves` disease (also known as 
toxic diffuse goiter,  an autoimmune disease that affects the thyroid) and VDR gene 
polymorphism, found that the restriction enzymes Bsml, Fokl and Apal 
polymorphisms were likely to be associated with Graves` disease in Asians but not in 
Caucasians (Zhou et al., 2009).  
The possible role of VDR gene polymorphisms in the development of a variety of 
diseases has garnered attention recently, as roles in coronary artery disease (CAD) 
(Monraats et al., 2010) and diabetes have been reported (Rivera-Leon et al., 2015). A 
recent meta-analysis aimed at accurately assessing the association between VDR 
genetic polymorphisms and CAD risk, found Taq1 polymorphism to be significantly 
associated with increase in CAD risk. They also reported increased risk in Apa1 
polymorphism in CAD patients without type 2 diabetes mellitus (T2DM) and Bsm1 
polymorphism in Caucasians. Fok1 polymorphism they report may possibly play a 
protective role in CAD (Lu et al., 2016). Individual variations occur in vitamin D 
synthesis, which could be due to genetic variation represented by polymorphisms of 
certain genes in the vitamin D metabolic pathway, especially polymorphisms of the 
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enzyme 7DHC reductase in the skin, 25-hydroxylase in the liver and VDBP in the 
circulation (Ahn et al., 2010). 
1.11. PHYSIOLOGICAL FUNCTIONS OF VITAMIN D 
1.11.1 Classical functions of vitamin D 
The regulation of intestinal/kidney calcium absorption and maintaining calcium 
homeostasis are the main classical functions of vitamin D and the VDR (Christakos 
et al., 2016).  
1.11.1.1 Intestinal calcium absorption 
Vitamin D regulated intestinal calcium absorption is mediated by facilitated 
diffusion, through active transcellular transport of calcium across the luminal brush 
border membrane, cell interior and the active extrusion of calcium from the 
basolateral membrane into the calcium-selective channel known as Transient 
Receptor Potential Cation Channel Subfamily V Member 6 (TRPV6) (Peng, Brown, 
& Hediger, 2003). On reaching TRPV6, calcium binds with a calcium binding 
protein called calbindin-D9k, this increases calcium release by intestinal plasma 
membrane ATPase (PMCA1b) across the basolateral membrane into the circulation. 
When dietary calcium levels are low, PMCA1b is upregulated by vitamin D 
(Christakos, Lieben, Masuyama, & Carmeliet, 2014). TRPV6 and calbindin-D9k are 
the primary intestinal target of vitamin D as they are expressed in all the parts of the 
intestine and a strong relationship exist between their expression and efficient 
transcellular calcium absorption (Replogle, Li, Wang, Zhang, & Fleet, 2014; Song et 
al., 2003). There is evidence that rickets and osteomalacia were prevented on feeding 
VDR null mice a diet high in calcium and lactose. This shows that impaired intestinal 
calcium absorption leads to impaired bone mineralisation due to a defect in VDR 
signalling (Amling et al., 1999; Masuyama et al., 2003).  
1.11.1.2 Renal calcium absorption 
Vitamin D regulates the reabsorption of filtered calcium in the distal tubules of the 
kidneys through active transcellular mechanism (Riccardi & Brown, 2010). Calcium 
enters through the apical membrane TRPV5 and is transported to the cytoplasm by 
binding to calbindin-D9k and calbindin-D28k, following this, calcium is released by 
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PMCA1b and the sodium /calcium exchanger (NCX1). Reabsorption by TRPV5 is 
the rate limiting step in renal calcium absorption (Christakos et al., 2016). 
Hypercalciuria results from downregulation of TRPV5 (Hoenderop et al., 2003). 
Evidence shows there is reduced expression of TRPV5, calbindin-D9k and calbindin-
D28k, NCX1 and PMCA1b in Cyp27b1 null mice which improved after vitamin D 
supplementation (Hoenderop et al., 2002). TRPV5 abundance at the apical 
membrane is regulated by FGF-23 and αKlotho through FGF-23 signalling 
performed by the FGFR1- αKlotho complex at the basolateral membrane, in addition 
to its regulation  by vitamin D and PTH (Andrukhova et al., 2014).  
1.11.1.3 Bone resorption 
The concentration of circulating calcium in the blood depends on the movement of 
calcium in and out of bone, as bone morphology depends on sufficient calcium 
supply. Approximately 99% of body calcium is stored in the bone, and 1% is present 
in the extracellular and intracellular spaces (Blaine, Chonchol, & Levi, 2015). When 
intestinal calcium absorption is inadequate in the case of negative calcium balance, 
calcitriol levels increase and act directly on osteoblasts/osteocytes to shift calcium 
from the skeleton to blood so as to maintain normal concentrations (Christakos et al., 
2014). To maintain normal calcium homeostasis, VDR signalling stimulates bone 
resorption indirectly by acting on osteoblast and osteoprogenitors which directly 
induce the transcriptional expression of RANKL, a significant osteoclastogenic 
factor (Kim, Yamazaki, Zella, Shevde, & Pike, 2006). RANKL then binds to its 
cognate receptor RANK in osteoclast precursors stimulating osteoclast formation and 
action as well as osteoprotegrin (OPG), a decoy receptor of RANKL (Christakos et 
al., 2016), thereby decreasing bone mass and inhibiting bone matrix mineralisation 
but maintaining sufficient serum calcium concentrations (Lieben & Carmeliet, 2013).  
1.11.1.4 Maintenance of calcium homeostasis 
The maintenance of calcium homeostasis is crucial for bone mineralisation and 
neuro-muscular functions (Fig.1.5) (DeLuca, 2008; Holick, 2011). Calcium 
concentration is tightly regulated at approximately 1mmol/L and 2.5mmol/L for 
ionised and total calcium respectively (Blaine et al., 2015). PTH, calcitonin and 
vitamin D together regulate calcium homeostasis, with PTH being the most 
significant regulator (Blaine et al., 2015). As serum calcium concentrations fall 
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below normal, calcium sensing proteins in the parathyroid gland (PTG) stimulate 
PTH secretion into the circulation within seconds in response and PTH raises 
calcium concentration by stimulating calcium release from bone, by stimulating bone 
resorption. PTH decreases urinary loss of calcium by stimulating calcium 
reabsorption and finally stimulates intestinal calcium absorption by inducing 
synthesis of vitamin D in the kidney. The PTG cascade of events stops as calcium 
concentration increase (Blaine et al., 2015), but when serum calcium concentration 
surpasses the set point of the calcium sensing system, the thyroid gland is stimulated 
to produce calcitonin. Calcitonin lowers serum calcium concentration by obstructing 
calcium mobilisation from bone to restore homeostasis (Zierold, Mings, & DeLuca, 
2003). 
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Fig.1.5. The maintenance of calcium homeostasis 
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1.12 VITAMIN D STATUS 
A general agreement has been reached globally that circulating 25(OH)D 
concentrations ˂25 nmol/L (10 ng/mL) is regarded as vitamin D deficiency. 
However, no agreement has been reached on standard definition of ‘optimal’ vitamin 
D (Cancer Research UK, 2010; SACN, 2007) , as for some organs and tissues, 
vitamin D acts as a threshold nutrient (Heaney, 2008). The absence of an agreement 
and definition between countries has led to the use of associated values to describe 
vitamin D status, including the terms ‘deficiency’, ‘insufficiency’, ‘adequacy’ and 
‘optimal’. Due to difference in the cut-off levels used together with the 
interchangeable terminologies, it is difficult to make correct comparisons of reported 
prevalence (Hilger et al., 2014; Thacher & Clarke, 2011). A 25(OH)D concentration 
of  ˂25 nmol/L is used as the cut-off value defining vitamin D deficiency in the UK 
(SACN, 2016) . This cut-off value was set with regards to preventing bone diseases 
including rickets and/or symptomatic osteomalacia.  
The US Institute of Medicine (IOM), defined deficiency as serum 25(OH)D 
concentration <30 nmol/L, serum 25(OH)D concentration of 30–50 nmol/L as 
insufficient in some people and serum 25(OH)D concentration >50 nmol/L as 
sufficient for 97.5% of the population (Ross et al., 2011). This report however, does 
not support the proposal that all adults should have plasma concentrations of 
25(OH)D >75nmol/L. The UK National Osteoporosis Society, suggested the IOM 
vitamin D thresholds be adopted by UK practitioners (National Osteoporosis Society, 
2013). The Endocrine Society Task Force does not support the IOM 
recommendations and thus published a clinical practice guideline that defined 
deficiency as serum 25(OH)D <50 nmol/L. The guideline recommended that 
25(OH)D concentration should be ˃75 nmol/L to exert the beneficial effects of 
vitamin D on calcium, bone and muscle metabolism (Holick, Binkley, Bischoff-
Ferrari, Gordon, Hanley, Heaney, Murad, Weaver, et al., 2011).  Additionally, the 
World Health Organisation (WHO) also defined deficiency and insufficiency as 
serum 25(OH)D ˂25 nmol/L and 50 nmol/L respectively (Lamberg-Allardt, Brustad, 
Meyer, & Steingrimsdottir, 2013). Based on a study investigating the effect of 
vitamin D intervention on bone quality in the elderly (Weggemans, Schaafsma, & 
Kromhout, 2009), the Health Council of the Netherlands, set at least 50 nmol/L for 
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optimal serum 25(OH)D level all year round for women aged 50 and over, and for 
men aged 70 and over (Health Council of the Netherlands, 2012).  
Based on critical discussions in the consensus for optimal serum 25(OH)D 
concentrations from Central Europe, including Poland, Hungary, Belarus, Estonia, 
Czech Republic and Ukraine (Pludowski et al., 2013). Serum 25(OH)D 
concentrations were established as <50 nmol/L, 50-75 nmol/L and 75-125 nmol/L for 
deficiency, insufficiency and optimal respectively. However, evidence to support the 
requirement to aim for significantly higher serum 25(OH)D concentrations of 
>75 nmol/L is unclear (Bouillon et al., 2013). The basis for optimal vitamin D status 
has moved away from being defined as the 25(OH)D required for skeletal functions 
to that which will portray maximum benefits on non-skeletal functions (Thacher & 
Clarke, 2011). (Garland, French, Baggerly, & Heaney) in 2011, suggested that serum 
25(OH)D concentration of 150-200nmol/L (60-80ng/mL) was required to reduce 
cancer risk. In 2009, (Ginde, Mansbach, & Camargo) discovered that the protective 
effect of vitamin D from upper respiratory infections is a serum 25(OH)D 
concentration ˃75nmol/L (30ng/mL). The optimal vitamin D concentration for 
reducing insulin resistance has been shown to be 80-119nmol/L (Takiishi, 
Gysemans, Bouillon, & Mathieu, 2010). 
The difficulty in defining the exact thresholds of 25(OH)D concentrations may be 
due to difficulty in comparing results across studies due to assay variations of 
25(OH)D concentrations between different laboratories/a lack of standardisation of 
methodology. To amend this, the International Vitamin D External Quality 
Assessment Scheme (DEQAS) was created in 1989 to monitor the accuracy of 
individual laboratories. Laboratories which participate get a certificate when 80% of 
their results from the five quarterly samples issued by (DEQAS) are within 30% of 
the DEQAS All - Laboratory Trimmed Mean (ALTM) (Carter et al., 2010). A pass 
mark by DEQAS simply means the method is relatively correct (Carter, 2009). 
According to the first vitamin D standardisation certification program administered 
by the US Centers for Disease Control and Prevention, annual certification of 
laboratories is obtained when test results have a bias of ±5% and a reproducibility of 
≤ 10% (Glendenning, 2015). The standardisation of methodology is critical to 
conclude on reliable thresholds for deficiency and insufficiency and to identify poor 
1,25(OH)2D3  status effectively (Spiro & Buttriss, 2014). 
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1.12.1 Vitamin D toxicity  
 
Vitamin D toxicity is characterised by hypercalcaemia and hyperphosphataemia, 
which results in deposition of calcium in soft tissues. Vitamin D toxicity occurs by 
very high and inappropriate high dose treatment or overdosing (Hathcock, Shao, 
Vieth, & Heaney, 2007), however, a daily dose of  10,000IU (250μg) is reported as 
safe (Heaney, Davies, Chen, Holick, & Barger-Lux, 2003), as food supplements 
containing up to 10,000 IU (250μg) of vitamin D per daily dose are available in the 
UK (SACN, 2016). However, doses equal to or above 50,000IU/day for several 
weeks or months are associated with toxicity and hypercalcaemia. Toxicity, defined 
by hypercalcaemia has not been observed with a serum 25(OH)D concentration < 
500nmol/L (National Osteoporosis Society, 2013). 
1.13 RECOMMENDATIONS FOR VITAMIN D INTAKE 
The Dietary reference values/recommendations for vitamin D from national 
authorities differ among countries (Prentice, 2002). The Scientific Advisory 
Committee on Nutrition on Vitamin D and health published on 21st July 2016 
proposed an RNI in the UK population. A dose of 400 IU (10µg) daily was proposed 
from ages four and above, including at risk groups, 8.5 - 10µg daily for all infants 
from birth to one year including exclusively breast fed infants and 10µg daily for 
children aged one to four years (Table 1.3). The chosen dose is the average amount 
required to maintain a serum 25(OH)D concentration ˃ 25nmol/L and to protect 
musculoskeletal health (SACN, 2016).   
Table1.3. Reference Nutrient Intake for vitamin D in the UK (µg/d) (SACN, 
2016) 
Age RNI (µg/day)   
0-12 months 8.5-10µg/day 
12 months - 4 years 10 µg/day 
4years and above 10µg/day 
Populations at risk of 
deficiency 
10µg/day 
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The United States Endocrine Society’s Clinical Practice Guideline recommends 600-
1000 IU/d (15-25µg) for children aged one or more, and 1500-2000 IU/d (37.5-50 
µg) for adults aged 19 years and above (Holick, Binkley, Bischoff-Ferrari, Gordon, 
Hanley, Heaney, Murad, & Weaver, 2011). This is aimed at maintaining 25(OH)D 
above the optimal level of 75nmol/L. The IOM recommended 400 IU (10 μg/d) for 
infants between 0-12 months, 600 IU (15µg) for people between age 1 – 70 years, 
including pregnant and lactating women and 800 IU for people > 70 years (Ross et 
al., 2011). The predictive regression equation study for vitamin D replacement 
suggested that a daily dose of 5,000 IU (125µg) vitamin D would be required to 
effect a 25nmol/L increase in 25(0H)D, as they discovered each IU of vitamin D 
results in a 0.005nmol/L (10/0.002) = 5000) increase. The vitamin D dose ≥ 2,000 IU 
(50µg) was recommended for maintenance (Singh & Bonham, 2014). The findings 
of this analysis are similar to the recommendations made by the Endocrine Society. 
The Endocrine Society suggested that in obese and malabsorption syndromes 
patients, patients on medications inhibiting vitamin D metabolism, a daily dose of at 
least 6,000 IU (150µg) to 10,000 IU (250µg) of vitamin D is required to treat vitamin 
D deficiency and to maintain 25(OH)D ˃75nmol/L. This should be followed by a 
daily maintenance therapy of 3000 (75µg) to 6000 IU (150µg) once vitamin D 
deficiency has been improved (Holick, Binkley, Bischoff-Ferrari, Gordon, Hanley, 
Heaney, Murad, Weaver, et al., 2011).  
1.14 PREVALENCE OF VITAMIN D DEFICIENCY IN THE UK 
Data from the National Diet and Nutrition Survey, the Health Survey for England, 
the Low Income Diet and Nutrition Survey, the UK Diet and Nutrition Survey of 
Infants and Young Children and the Scottish Health Survey were used to assess the 
vitamin D status of the UK population (SACN, 2016). Results from these surveys in 
UK show that around a fifth of adults aged 19 to 64 years and adults aged 65 years 
and over and a sixth of children aged 11 to 18 years had 25(OH)D concentrations ˂ 
25nmol/L (Bates et al., 2014). The prevalence of vitamin D deficiency in the UK by 
sex and age groups in infants, young children and the rest of the UK population are 
shown in Fig.1.6 and 1.7. 
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Fig.1.6. Prevalence of vitamin D deficiency in infants and young children in the 
UK (SACN, 2016) 
 
       
Fig.1.7. Prevalence of vitamin D deficiency in the UK by sex and age groups 
(SACN, 2016) 
 
Several sub-populations of young and older adults have shown particularly low 
vitamin D concentrations within the UK (Lawson & Thomas, 1999), particularly in 
children, adolescents and women of south Asian and African Caribbean origin. It has 
been reported that ≥ 50% of pregnant women from ethnic minorities in UK, 18% of 
pregnant women in southern England had a serum 25(OH)D concentration ≤ 
25nmol/L and 31% had a 25(OH)D concentration ≤ 50nmol/L indicating a high 
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prevalence in Whites (Datta et al., 2002). Low dietary intake of vitamin D in the UK 
has been implicated as the cause (Javaid et al., 2006). Regional differences of 
25(OH)D concentrations have been observed in the UK. A nationwide cohort study 
by Hypponen and Power (2007), found women of European ancestry, particularly 
those living in Scotland to have a higher prevalence of 25(OH)D ≤ 25nmol/L, than 
those living in the South of England. A longitudinal study in young South Asian 
women living in the UK reported that serum 25(OH)D concentrations ≤ 25 nmol/L 
were highly prevalent in South Asian women of child bearing age during winter 
(81%) and autumn (79.2%) (Darling et al., 2013). 
1.15 POPULATIONS AT RISK FOR VITAMIN D DEFICIENCY 
Several populations have been identified to be at risk of vitamin D deficiency and 
they include: 
1.15.1 Infants 
Infancy is characterised by a high rate of skeletal growth/ossification and with tooth 
enamel formation, as a consequence, infants are more vulnerable to vitamin D 
deficiency (Harvey, Dennison, & Cooper, 2014). Exclusively breast-fed infants are 
particularly at risk because of decreased concentrations of vitamin D and its 
metabolites in human breast milk which provides <25IU/L (0.62µg) to 78IU/L 
(1.99µg). An infant’s vitamin D status is determined by the mother’s vitamin D 
status during pregnancy (Holick, Binkley, Bischoff-Ferrari, Gordon, Hanley, 
Heaney, Murad, & Weaver, 2011).  Hollis and Wagner (2004), reported that a dose 
of 400 IU (10µg/d) vitamin D supplementation during lactation is insufficient to raise 
breast milk vitamin D and infant 25(OH)D concentrations and thus recommended a 
higher dose. 
1.15.2 Older people 
Age can negatively affect the concentrations of previtamin D3 as the proportion of 
7DHC available in skin decreases with age (Webb & Engelsen, 2006). Older adults, 
particularly those living in institutions are at higher risk of deficiency due to age 
related decline in dermal synthesis and decline in the rate of renal hydroxylation 
which results in the active hormonal form. Limited skin exposure as well as target 
tissue response as observed in bone, also affects the concentration of previtamin D3 
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(Shearer, 1997). Under equal exposure to sunlight a 70 year old will produce 75% 
less vitamin D than a 20 year old (Hagenau et al., 2009). Studies in rats have shown 
that renal CYP24A1 increases with increasing age (Armbrecht, Zenser, & Davis, 
1980; Matkovits & Christakos, 1995). 
1.15.3 People with dark skin 
People with black skin have lower serum 25(OH)D concentrations in winter and 
summer compared to Whites (Harris & Dawson-Hughes, 1998). This is because the 
pigment melanin in dark skin has an absorption spectrum of 290-700 nm and thus 
effectively absorbs UVB radiation which reduces the skin’s ability to synthesise 
vitamin D from sunlight (Jablonski & Chaplin, 2000). Thus, people with darker skin 
require a longer period of UVB exposure to produce an equivalent amount of vitamin 
D than a fairer skinned person (Chen et al., 2007). Evidence has shown that 4% of 
white and 42% of black women aged 15 to 49 years had serum 25(OH)D 
concentrations ˂ 37.5 nmol/L in the National Health and Nutrition Examination 
Survey (NHANES) from the US. This equates to 20 times higher risk for Blacks than 
for non-Hispanic whites (Nesby-O'Dell et al., 2002). Another reason for lower serum 
25(OH)D concentrations may be ascribed to the lower concentrations of VDBP in 
blacks compared to whites (Schwalfenberg & Genuis, 2010). The lower 25(OH)D 
concentrations observed could be attributed to the high prevalence of VDBP genetic 
polymorphisms (rs7041 and rs4588), as Blacks have a greater chance than whites of 
having the T allele at rs7041. The T allele at rs7041 is associated with decreased 
concentrations of VDBP, however, this low VDBP may protect against the adverse 
effects of vitamin D deficiency (Powe et al., 2013). 
1.15.4 Fat and intestinal malabsorption syndrome. 
As previously mentioned in section 1.7.3.1, vitamin D being fat soluble, requires 
some dietary fat in the gut for absorption, thus people with reduced tendency to 
absorb dietary fat including people with cystic fibrosis, coeliac, inflammatory bowel 
disease, such as Crohn's and ulcerative colitis and gastric bypass individuals will 
require supplementation (Adams & Hewison, 2010). Individuals who suffer from 
severe malabsorption syndromes are more likely to be vitamin D deficient because 
the small intestine cannot absorb this vitamin (Holick, 2006). Individuals taking 
plasma cholesterol reducing medications such as bile acid-binding polymers 
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including colestyramine and colestipol would also have impaired vitamin D 
absorption (Holick, 2007; Tsiaras & Weinstock, 2011).  
1.15.5 Overweight /Obese individuals 
Obese/overweight (defined as a BMI ≥ 30 and BMI of 25-29.9kg/m2 respectively)  
(Caballero, 2007) individuals compared with normal weight individuals (BMI 
between 18.5 -24.9kg/m2) have a high prevalence of serum 25(OH)D concentration ˂ 
50nmol/L (Forrest & Stuhldreher, 2011). Studies have shown associations between 
25(OH)D concentrations and obesity (Blum et al., 2008; Drincic, Armas, Van Diest, 
& Heaney, 2012; Vimaleswaran et al., 2013). The study by Blum et al. (2008), found 
lower serum concentration of vitamins D3 and D2 in 50% of obese compared with 
non-obese individuals. The increased risk of low serum 25(OH)D concentrations in 
overweight and obese individuals was attributed to increase in metabolic clearance of 
vitamin D through enhanced sequestering by adipose tissue. This may be due to the 
dilution of ingested or cutaneously synthesised vitamin D in the enlarged fat mass 
(Drincic et al., 2012). A bi-directional genetic study that adjusted for confounding 
concluded that a higher BMI leads to reduced 25(OH)D concentration, as each unit 
increase in BMI was found to be associated with 1.15% reduced serum 25(OH)D 
concentrations (Vimaleswaran et al., 2013).  
Additionally, there is reduced rate of 25(OH)D synthesis due to hepatic steatosis 
(Targher et al., 2007), and the suppression of 25(OH)D synthesis by adipocytokines, 
macrophage migration inhibitory factor (MIF) and interleukin 6 (IL-6) secreted by 
adipose tissue (Ding, Parameswaran, Blizzard, Burgess, & Jones, 2010). Non-
genomic mechanisms including protein expression, oxidative stress, inflammation 
and cellular metabolism also link vitamin D to obesity (vinh quoc Lu'o'ng & Nguyen, 
2013). Overweight/obese individuals are likely to be physically inactive, and spend 
more time indoors, hence reducing their exposure to sunlight. A study performed in 
Australia reported that the efficacy of vitamin D supplementation depends on BMI, 
as overweight and obese people who are vitamin D insufficient may require higher 
doses of vitamin D to achieve vitamin D repletion compared with non-
obese/overweight individuals (Lee, Greenfield, Seibel, Eisman, & Center, 2009). 
Forsythe et al. (2012), suggested that an individual’s BMI be considered when 
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deciding sufficient winter dietary vitamin D intake for healthy adults residing at 
higher latitudes.  
1.15.6 Pregnant women 
There is evidence that vitamin D deficiency during pregnancy is linked with 
numerous adverse health outcomes in mothers, neonates and children (Dawodu & 
Akinbi, 2013; Fernandez-Alonso et al., 2012; Vandevijvere, Amsalkhir, Van Oyen, 
& Moreno-Reyes, 2012). The infants of vitamin D deficient mothers are at higher 
risk of vitamin D deficiency if they are exclusively fed breast milk for an extended 
period (Shaw & Mughal, 2013), compared to formula fed infants, as baby formulas 
are vitamin D fortified (NICE 2007; EFSA 2012). A randomised controlled trial 
(RCT) conducted in the USA in which pregnant women received either 400 IU 
(10µg), 2000 IU (50µg) or 4,000 IU(100µg/d) of vitamin D3 until delivery, found 
4000 IU/d (100µg) supplementation to be most effective in achieving vitamin D 
sufficiency throughout pregnancy without an increased risk of toxicity. Thus, it has 
been advocated that the current vitamin D estimated average requirement (EAR) and 
recommended daily allowance (RDA) for pregnant women be raised to a daily dose 
4,000IU (100µg) of vitamin D3. The RDA should be administered irrespective of 
race, for ideal nutritional and hormonal vitamin D status throughout pregnancy 
(Hollis, Johnson, Hulsey, Ebeling, & Wagner, 2011).  
1.15.7 People living at high latitudes 
Solar UVB radiation varies with latitude, time of the day and year. It is particularly 
lower at northern latitudes during winter, this is because mean concentrations of 
25(OH)D follow a north to south gradient, therefore people living in northern 
latitudes tend to have lower 25(OH)D than people living in the south. From mid-
October to the beginning of April at latitudes of about 520 and above (UK is at 
latitude 50-60o N), there is no UVB radiation of appropriate wavelength for the 
photosynthesis of previtamin D3. Thus, little or no vitamin D3 is produced in the skin 
during the winter for the remaining months of the year (Chapuy et al., 1997).   
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1.16 NON-CLASSICAL FUNCTIONS OF VITAMIN D 
Vitamin D also performs non-classical functions due to the presence of  the VDR in 
all tissues and cells of the human body (Holick, 2007). Studies have shown that 
vitamin D through direct and indirect mechanisms regulate more than 200 genes 
including cellular differentiation, proliferation, angiogenesis and apoptosis (Nagpal 
et al., 2005). Vitamin D has been reported to play significant roles in numerous 
diseases (Lai & Fang, 2013), thus, associations between low vitamin D concentration 
with cardiometabolic disease has been observed (Zittermann & Koerfer, 2008). 
Large observational studies and meta-analyses have shown that low 25(OH)D 
concentrations are a significant risk marker for a broad range of cardiometabolic risk 
factors including hypertension, dyslipidaemia, abnormal glucose homeostasis and 
atherosclerosis (Grandi, Breitling, & Brenner, 2010; Parker et al., 2010; Pilz et al., 
2011; Pittas et al., 2010; Wang, Song, et al., 2012). 
1.16.1 Vitamin D and the immune system 
Due to the presence of VDR in macrophages, dendrites, T and B cells (Toubi & 
Shoenfeld, 2010), calcitriol is capable of regulating both adaptive and innate immune 
defence against bacterial infections by upregulating cathelicidins, an antimicrobial 
peptide found within the lysosomes of macrophages, keratinocytes, lung epithelial 
cells and polymorphonuclear leukocytes amongst others (Schauber et al., 2007; 
Segaert, 2008; Yim, Dhawan, Ragunath, Christakos, & Diamond, 2007). Cathelicidin 
regulates the transcription of VDR at the promoter region (Gombart, Borregaard, & 
Koeffler, 2005), thus, repressing the onset of many inflammatory diseases including 
lyme arthritis, T1DM, thyroiditis and inflammatory bowel disease amongst others 
(Adorini et al., 2004; Hayes, Nashold, Spach, & Pedersen, 2003). Vitamin D 
deficiency has been reported to be associated with the loss of immune tolerance 
(Kamen & Aranow, 2008). Calcitriol has been shown to be immunosuppressive as it 
has been associated with a decrease in IL-2, IFN γ and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) mRNA level by inhibiting the formation of the 
nuclear factor of activated T-cells/ activator protein 1 (NFATp/AP-1) complex 
through the VDR/RXR heterodimer  (Raghuwanshi, Joshi, & Christakos, 2008). A 
high prevalence of vitamin D deficiency has been reported to be associated with 
increased disease activity in systemic lupus erythematosus (SLE) patients (Kamen et 
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al., 2005). An inverse association was observed between serum 25(OH)D 
concentration and disease activity in 198 African American and Hispanic SLE 
patients (r  = − 0.234, P = 0.002) indicating a high prevalence of vitamin D deficiency 
in SLE (Ben-Zvi et al., 2010). A systematic review and meta-analysis of 7 
observational studies has demonstrated that patients with tuberculosis have lower 
circulating serum 25(OH)D concentrations compared to healthy same sex and age 
matched controls (Nnoaham & Clarke, 2008). This observation suggests low serum 
25(OH)D concentrations may alter cell-mediated immunity resulting in tuberculosis 
(Nnoaham & Clarke, 2008). 
1.16.2. Vitamin D and cancer 
Calcitriol plays protective roles in prostate, breast and colon cancer (Zittermann, 
2003), and may be useful in the treatment of leukaemia and other myeloproliferative 
disorders, as it inhibits the proliferation of some human leukaemia cell lines and 
promotes the differentiation of normal and leukaemic myeloid precursor. This 
increases the maturation and reduces the potency of potential leukemic cells (Abe et 
al., 1981). Calcitriol exerts a protective role against cancer cells by regulating cell 
maturation, differentiation and apoptosis (Zittermann, 2003). This inhibits the 
expression of anti-apoptotic proteins such as Bcl2 in cancer cells and the arrest of 
cell cycle in GO/G1, which in turn reduces the rate of proliferation (Welsh, 2007). 
Calcitriol also exerts a protective role by promoting the transcription of cyclin-
dependent kinase inhibitor p21 (regulator of cell cycle progression), which inhibits 
the growth and stimulate the differentiation of monocyte-macrophage cell lineage 
(Liu, Lee, Cohen, Bommakanti, & Freedman, 1996). Calcitriol promotes the 
synthesis of the cyclin–dependent kinase inhibitor p27 (Li et al., 2004) and 
suppresses the TGF-α/EGFR growth pathway. The over-expression of this pathway 
leads to the proliferation of tumour cells (Cordero et al., 2002). Additionally, 
calcitriol triggers the expression of C/EBPβ, which alters the carcinogenic cell cycle 
protein D1 (Lamb et al., 2003) and prevents the proliferation of C/EBPβ isoform LIP 
which enhances the activity of carcinogenic cyclin D1 (Zahnow, 2002).  
Breast cancer is a common disease and a leading cause of death in women 
(Khodarahmi & Azadbakht, 2014), and calcitriol exerts vital roles in the  mammary 
gland by modulating calcium transport during lactation, differentiation of hormones, 
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and milk protein production (Khan et al., 2014). There is evidence that calcitriol 
reduces benign epithelial proliferation disorders and subsequently the breast cancer 
risk by decreasing breast mammographic density as well as its antiproliferative and 
prodifferentiation activities (Chen et al., 2010). It has been reported that increased 
serum 25(OH)D concentrations is associated with lower breast cancer risk 
(Chlebowski, 2011).  A review of 37 articles aimed at investigating the relationship 
between breast cancer and vitamin D synthesised by skin, by diet or supplementation 
found an inverse association between plasma 25(OH)D concentration and breast 
cancer risk (Stoll, Akladios, & Mathelin, 2013).  Additionally, a meta-analysis of 5 
prospective cohort studies with a follow-up of 2.7–24 years among breast cancer 
patients also demonstrated that increased serum 25(OH)D concentrations had a 
significant reduced risk of overall mortality (hazard ratio [HR] =0.62, 95% CI = 
0.49–0.78) and breast cancer-specific mortality (HR = 0.57, 95% CI = 0.38–0.84) 
compared to patients with low 25(OH)D serum concentrations (Maalmi, Ordonez-
Mena, Schottker, & Brenner, 2014). 
1.16.3 Vitamin D in diabetes mellitus, kidney and cardiometabolic disease 
Calcitriol regulates blood pressure, electrolyte levels and volume status through a 
negative feedback on the renin-angiotensin system (RAS), thus, vitamin D deficient 
patients may be predisposed to hypertension or diseases associated with high plasma 
renin activity (Li, 2003). Knockout mice lacking VDR showed significant increase in 
BP, cardiac hypertrophy and water retention as a result of increased circulating renin, 
angiotensin II concentrations (Li et al., 2002). Paricalcitol, a vitamin D analogue has 
been reported to inhibit renal interstitial myofibroblast (Tan, Li, & Liu, 2006), hence, 
inhibiting the development of renal interstitial fibrosis (Foltyn et al., 2005) through 
its anti-inflammatory and anti-fibrotic effect (Tan, Wen, & Liu, 2008). Vitamin D 
deficiency causes disruptions in insulin secretion and the immune system, hence, its 
association with chronic diabetes mellitus (Lai & Fang, 2013). A study in type 1 
diabetes mellitus (T1DM) patients with low vitamin D status compared to healthy 
age matched controls found out that 3 major genes controlling 25(OH)D3 were 
implicated in T1DM incidence (Cooper et al., 2011). Evidence from in vivo and in 
vitro studies showed that calcitriol prevents the destruction of pancreatic β cells, 
reducing TIDM incidence (Zittermann & Gummert, 2010).  
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Calcitriol maintains cardiovascular health by binding to VDR on myocardial cells, 
thereby, regulating the hypertrophy of myocardial cells and both synthesis and 
release of atrial natriuretic peptide (Wu, Garami, Cao, Li, & Gardner, 1995; Wu, 
Garami, Cheng, & Gardner, 1996). Calcitriol inhibits vascular calcification by 
regulating the activities of interleukins (Schurgers et al., 2001) and by inhibiting 
angiogenesis and inflammatory cytokines such as TNF-α and increasing matrix Gla-
protein synthesis (Muller et al., 1992). Calcitriol inhibits the proliferation and 
migration of VSMCs and reduces endothelial cell oxidative stress (Menezes, Lamb, 
Lavie, & DiNicolantonio, 2014).  
Given the reported evidence for a beneficial role of vitamin D in diabetes and CVD 
pathogenesis and the prevalence of vitamin D deficiency, it is important to 
investigate the effects of vitamin D on selected cardiometabolic markers and to 
evaluate whether improving vitamin D status in a cohort with insufficient vitamin D 
concentrations would decrease cardiometabolic disease risk (discussed in detail in 
chapter 3). Additionally, due to the reported renoprotective role of vitamin D in the 
kidneys, it also important to investigate the prevalence of vitamin D deficiency and 
the association of vitamin D status with selected CVD markers in calcium oxalate 
kidney stones patients.  
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• A systematic review on the effect of vitamin D supplementation on endothelial 
and inflammatory markers carried out as a basis for the literature review of this 
chapter was presented at the 19th  International  Vitamin D Workshop, 29th -31st  
March, 2016, at Boston, USA (Appendix 10). 
 
• A research article entitled, “Impact of vitamin D supplementation on endothelial 
and inflammatory markers in adults: A systematic review” was published in the 
Journal of Steroid Biochemistry and Molecular Biology (Agbalalah, Hughes, 
Freeborn, & Mushtaq). 
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2.0 THE EFFECT OF VITAMIN D SUPPLEMENTATION AND 
CARDIOMETABOLIC RISK IN A COHORT OF OBESE/OVERWEIGHT 
ADULT MALES IN UK 
2.1 INTRODUCTION 
2.1.1 CARDIOMETABOLIC DISEASE RISK 
Cardiometabolic disease risk are various interrelated risk factors including insulin 
resistance, inflammation, abdominal obesity, dyslipidaemia, oxidative stress and 
hypertension that increase the risk of T2DM and atherosclerosis (Aschner, 2010; 
Kassi, Pervanidou, Kaltsas, & Chrousos, 2011). Atherosclerosis, reported to be 
responsible for majority of CVD events, is an inflammatory disease of the intima and 
is characterised by lipoprotein accumulation and oxidation, vascular smooth muscle 
cell migration, foam cell development and calcium deposition (Aschner, 2010; 
Hansson, 2005). 
2.1.2. EPIDEMIOLOGY OF CVD AND T2DM IN THE UK 
CVD is responsible for 17.3 million deaths globally (Naghavi et al., 2015), and for 
over 45% and 26% of all deaths in Europe and UK respectively (Townsend et al., 
2016). The major cause of CVD death in the UK has been attributed to coronary 
heart disease (CHD), as it accounts for approximately 70,000 annual CVD deaths in 
the UK (Townsend et al., 2016). Stroke, another major cause of CVD death, second 
to CHD is responsible for 40,000 deaths in the UK (Townsend et al., 2016). 
Currently, it has been estimated that 7 million people live with CVD in the UK (3.5 
million men and 3.5 million women) (Townsend et al., 2016).   
Diabetes has been reported to affect 4.5 million people in the UK, 90% of which 
suffer from T2DM and over 1 million people are estimated to be currently living 
with undiagnosed T2DM in the UK, 56% of which are men (Townsend et al., 2016). 
Data from the Health Survey for England estimates that 10.7% of the English 
population (approximately 5 million people) are at increased risk of T2DM with an 
HbA1c concentration between 42-46 mmoL/moL (6.0-6.4)(Public Health England, 
2015).    
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2.1.3. PATHOGENESIS OF ATHEROSCLEROSIS 
The 3 layers of the artery are intrinsic to understanding plaque formation in the 
endothelium. The inner layer (tunica intima) of the artery is lined by endothelial cells 
that limit larger molecules from crossing it (Reymond, d'Água, & Ridley, 2013). The 
middle layer (tunica media) of the artery consist of VSMCs embedded within an 
extracellular matrix consisting of collagen and elastin (Ponticos & Smith, 2014). The 
outermost layer (tunica externa) of the artery contains fibroblasts collagenous tissue 
(Libby & Hansson, 2015) (Fig 2.1). Atherosclerosis begins with the disruption of 
endothelial cell homeostasis which upsets the balance between vasoconstriction and 
vasodilation resulting in endothelial dysfunction (Davignon & Ganz, 2004; Harja et 
al., 2008). In response to endothelial dysfunction, lipoproteins particularly LDL-C 
accumulate in the sub-endothelial space of the damaged endothelium and become 
oxidised and modified by the reactive oxygen species (ROS) produced by both 
endothelial and VSMCs (Perrotta & Aquila, 2015). The ensuing endothelial 
dysfunction, oxidation and modification of LDL-C directly stimulates the 
inflammatory tissue cascade by promoting the infiltration of inflammatory cells, 
including monocytes, into the intima layer, and indirectly, through the induction of 
cytokines and other inflammatory mediators (Fig 2.1) (Davignon & Ganz, 2004; 
Harja et al., 2008).  
On reaching the intima layer, the monocytes transform into a macrophage and engulf 
the LDL-C collected in the damaged endothelium. These macrophages die off whilst 
engulfing LDL-C to become foam cells also known as lipid laden macrophages, 
which in turn accumulate to form the atherosclerotic plaque (Fig 2.1) (Shaw, 2004). 
The foam cells formed, produce pro-inflammatory mediators, ROS, and tissue factor 
pro-coagulants that intensify local inflammation and stimulate thrombotic 
complications (Fuentes Q et al., 2013; Ross, 1999). The inflammation stimulated by 
dead macrophages in the plaque core activate T cells, which differentiate to T helper 
cell 1 (Th1) that secretes cytokine interferon gamma (IFNγ) that maintains the 
inflammatory state in the plaque (Hansson & Hermansson, 2011).  
VSMCs in the inflammatory state, migrate from the media layer into the intima or 
fatty plaque and go on to produce extracellular matrix (ECM) components and a 
fibrous cap made up of collagen and elastin protein that cover the plaque (Fig 2.1). 
The VSMCs also induce calcium deposition in the plaque core which hardens or 
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calcifies as a result (Orr, Yurdagul Jr, & Patel, 2014). A rupture in the fibrous cap 
may lead to a large thrombus formation, which will in turn restrict blood flow or 
occlude the artery. If the thrombus occludes a cerebral artery, a stroke may result and 
if it occludes a coronary artery, myocardial infarction (MI) may result (Fig 2.1) (Orr 
et al., 2014; Roberts, 2013). The fibrous cap may remain intact and the plaque would 
continue to increase in size and may eventually obstruct the artery (ischaemic) where 
it is present/or which houses it. On the other hand, the media beneath the plaque may 
rupture and weaken the vascular wall (aneurysm) (Bentzon, Otsuka, Virmani, & 
Falk, 2014). 
 
 
Fig.2.1. Development of atherosclerotic plaque (Libby, Ridker, & Hansson, 
2011). 
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2.1.4. PREVALENCE OF OVERWEIGHT AND OBESITY IN THE UK 
A meta- analysis of the global burden of disease reports the prevalence of overweight 
and obesity in the UK to be 68% for both overweight and obese men aged ≥ 20 
years. The prevalence for women of same age was 59% for overweight and obese 
women (Ng et al., 2014). In England, most people are overweight or obese, this 
includes 61.3% of adults and 30% of children aged between 2 and 15 years (DH, 
2013).  
2.1.4.1 Adiposity and cardiometabolic disease  
The pathogenesis of atherosclerosis has been attributed to a number of metabolic risk 
factors associated with T2DM, including obesity (Bastard et al., 2006), as obesity 
accounts for 80–85% of the overall risk of developing T2DM and underlies the 
current global spread of the condition (Frederich et al., 2015). Obesity, characterised 
by increased adipose are both independent risk factors of CVD and are also 
associated with low concentrations of serum 25(OH)D, suggesting a non-causal 
explanation for their association (Miettinen et al., 2014). Inflammation, a major 
feature of atherosclerosis is a characteristic of obesity, as adipose tissues, in addition 
to being a storage site for vitamin D and an energy store, secrete pro-inflammatory 
cytokines including IL-6, IL-8, TNF-α, and resistin that may induce a low-grade 
inflammatory state (Christen et al., 2016; Maury & Brichard, 2010). Adiposity is also 
characterised by increased circulating free fatty acids as well as decreased secretion 
of anti–inflammatory cytokines including adiponectin (Badawi et al., 2010; Bray, 
Clearfield, Fintel, & Nelinson, 2009; Van Gaal, Mertens, & De Block, 2006).  
The increased secretion of fatty acids by adipocytes stimulates the production of 
ROS by upregulating nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, and downregulating the expression of anti-oxidative enzymes (Goncharov, 
Avdonin, Nadeev, Zharkikh, & Jenkins, 2015). The increased expression of NADPH 
oxidase subunit p47phox in the endothelium of overweight/obese adults have been 
shown to promote endothelial oxidative stress compared to people with normal 
weight. The endothelial oxidative stress leads to systemic inflammation and 
endothelial dysfunction, important in the development of cardiometabolic disease 
(Matsuda & Shimomura, 2013; Otani, 2011; Silver et al., 2007). Due to the existing 
relationship between obesity and cardiometabolic disease, vitamin D deficiency may 
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be considered one of the mechanisms linking obesity and increased cardiometabolic 
disease risk. As a result of this association, it has been suggested that vitamin D 
deficiency be considered a non-traditional risk factor for cardiometabolic disease (Da 
Costa et al., 2012; James, 2008; Lu et al., 2007; Martins et al., 2014).  
2.1.4.2 Associations between vitamin D and adiposity  
Associations between vitamin D deficiency, adiposity and cardiometabolic health 
have been reported (Bray & Bellanger, 2006; Turer, Lin, & Flores, 2013), as vitamin 
D synthesis, action and storage modulate and are modulated by adiposity, since 
human adipocytes express VDR, CYP3A4, CYP27B1 and the catabolic CYP24A1 
(Earthman, Beckman, Masodkar, & Sibley, 2012; Ellero et al., 2010; Romacho, 
Elsen, Rohrborn, & Eckel, 2014). A potential mechanism by which vitamin D may 
interact with adipose tissue may be by hindering lipid accumulation and important 
adipogenic transcription factors during adipocyte differentiation (Ding, Gao, 
Wilding, Trayhurn, & Bing, 2012). There is evidence that vitamin D impedes the 
differentiation of pre-adipocytes to mature adipocytes in vitro by suppressing the 
expression of key activators of adipogenesis such as the CCAAT/enhancer binding 
protein alpha (C/EBPα) and peroxisome proliferator- activated receptor gamma 
(PPARγ) (Kong & Li, 2006). These activators induce the expression of various genes 
associated with lipogenesis, lipolysis and insulin sensitivity including glucose 
transporter (GLUT 4) and fatty acid synthase (Madsen, Siersbaek, Boergesen, 
Nielsen, & Mandrup, 2014). Thus, by inhibiting C/EBPα mRNA expression and 
PPARγ activity, vitamin D also inhibits fatty acid synthase (FAS) enzyme expression 
resulting in reduced lipid accumulation (Madsen et al., 2014). Vitamin D has also 
been reported to inhibit chronic inflammation in adipose tissues (Abbas, 2016). A 
study in preadipocytes isolated from human subcutaneous white adipocytes has 
shown reductions in TNF-α, MCP-1 after vitamin D3 treatment (Lorente-Cebrian et 
al., 2012). In cultured human adipocytes vitamin D3 could be anti-inflammatory, as it 
decreases macrophage induced chemokines, cytokines release by adipocytes and the 
chemotaxis of monocytes by inhibiting the NFkB and MAPK signalling pathways 
(Ding, Wilding, & Bing, 2013). 
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2.1.4.3 Observational studies  
Several studies have shown associations between obesity and vitamin D deficiency 
(Blum et al., 2008; Earthman et al., 2012; Gonzalez-Molero et al., 2013; Nwudu, 
2015; Pereira-Santos, Costa, Assis, Santos, & Santos, 2015; Vimaleswaran et al., 
2013). A recent UK cross-sectional observational study performed in autumn and 
spring in 223 normal-weight, overweight, and obese adults aged 25-75 years, found 
that mean serum 25(OH)D was lower in overweight (45nmol/L) and obese subjects 
(40.8nmol/L) compared to normal weight (58.6 nmol/L) subjects. This study also 
found an inverse association between serum 25(OH)D with BMI (r = -0.296, P < 
0.001) in autumn, spring and winter, and for every 5 unit increase in BMI, 25(OH)D 
decreased by 12.3% (95% CI: 7.7%, 16.6%; P < 0.001) (Walsh et al., 2016). A meta-
analysis of 23 observational studies performed in Brazil by Pereira-Santos et al., 
reported vitamin D deficiency to be higher in obese subjects compared to normal 
weight subjects (PR: 1.35; 95% CI: 1.21–1.50) and 24% higher than in the 
overweight group (PR: 1.24; 95% CI: 1.14–1.34) regardless of age and threshold 
used to define vitamin D deficiency (Pereira-Santos et al., 2015).   
2.1.4.4   RCT 
In contrast to the findings from the above observational studies, a 26 week RCT 
performed in Denmark did not find a significant effect of 7,000 IU (175µg)/d vitamin 
D3 on body fat, subcutaneous and visceral adipose tissue in 52 healthy obese adults 
aged 18-50 years with BMI > 30kg/m2 and a plasma 25(OH)D concentration <50 
nmol/L in both treatment groups (Wamberg, Kampmann, et al., 2013). The high dose 
vitamin D improved plasma 25(OH)D concentration from 33nmol/L to 110nmol/L, 
but was unable to reduce lipid accumulation, this may suggest that vitamin D 
treatment is unable to inhibit fatty acid synthase enzyme as reported (Madsen et al., 
2014).  
2.1.5 VITAMIN D AND CARDIOMETABOLIC RISK 
Vitamin D deficiency or insufficiency is associated with an increased risk of 
cardiometabolic disease and progression of atherosclerosis (Kassi, Adamopoulos, 
Basdra, & Papavassiliou, 2013). The role of vitamin D in CVD pathogenesis mostly 
arises from observational studies, one of which reported a rise in CV events at 
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increased distance from the equator during winter (Motiwala & Wang, 2012). The 
first observation was from rats placed on a vitamin D deficient diet for 9 weeks. The 
rats showed raised systolic blood pressure (SBP) and enhanced ventricular and 
vascular muscle contractile function, suggesting a role of vitamin D deficiency in 
CVD (Weishaar & Simpson, 1987). There is also evidence from a community based 
case control study in 179 MI patients with age and sex matched controls. In this 
study, the MI patients had significantly lower mean 25(OH)D concentrations than 
controls (32.0 vs. 35.5 nmol/L, P = 0.017), and the case-control differences were 
greatest during winter and spring (Scragg, Jackson, Holdaway, Lim, & Beaglehole, 
1990). These evidence have been considered to be adequate to establish vitamin D 
deficiency as a CVD risk factor (Kienreich, Grübler, et al., 2013; Weyland, Grant, & 
Howie-Esquivel, 2014). 
Vitamin D exerts multiple vaso-protective effects by improving endothelial 
dysfunction, inhibiting VSMC proliferation and migration, downregulating the 
inflammatory process (Wang et al., 2013), and indirectly protects against 
atherosclerosis by decreasing insulin resistance, improving lipid profile and blood 
pressure  parameters (Lee et al., 2008). Inverse associations between vitamin D and 
cardiometabolic disease risk (Elamin et al., 2011; Pittas et al., 2010), including 
inflammation (Ngo, Sverdlov, McNeil, & Horowitz, 2010), insulin resistance (Afzal, 
Bojesen, & Nordestgaard, 2013; Mezza et al., 2012), hypertension (Jungert, Roth, & 
Neuhauser-Berthold, 2012), dyslipidaemia (Wang, Xia, Yang, & Peng, 2012), 
endothelial dysfunction (Muscogiuri et al., 2012) oxidative stress (de Almeida et al., 
2016) and arterial stiffness (Rodriguez, Scott, Srikanth, & Ebeling, 2016; Sunbul et 
al., 2016) have been reported. These associations arise from evidence that all the 
pathways and cell types involved in CVD are modulated by vitamin D metabolites, 
as most CV and inflammatory cells express VDR and CYP27B1 (Dickie et al., 2010; 
Krivosikova, Gajdos, & Sebekova, 2015). Since these cardiometabolic risk factors 
are the primary stimulants for the development of atherosclerosis, it is therefore 
important to know the effect of vitamin D on each of these cardiometabolic risk 
markers.  
 
 
68 
 
2.1.6. VITAMIN D AND ENDOTHELIAL DYSFUNCTION  
The endothelium is a significant vessel wall component involved in the initiation and 
progression of atherosclerosis, as impaired endothelial function is the first 
abnormality demonstrated by the vessel wall (Endemann & Schiffrin, 2004; Kassi et 
al., 2013; Nadar, Blann, & Lip, 2004). Endothelial cells are single layered cells that 
line the inner surface of blood vessels and are the structural and functional barriers 
between blood and the vessel wall and they modulate both vascular tone and 
inflammation (Marti et al., 2012; McGorisk & Treasure, 1996; Munzel, Sinning, 
Post, Warnholtz, & Schulz, 2008). Endothelial cells prevent platelet and leukocyte 
adhesion and aggregation whilst regulating blood flow (Marti et al., 2012), and 
maintain vascular health by secreting nitric oxide (NO) and prostacyclin which exerts 
anti-aggregatory effects on platelets. Additionally, endothelial cells also secrete 
heparin and protein that exerts anti-coagulatory or fibrinolytic effects and as well 
suppressing proliferation of the vessel wall (MacLaren & Stringer, 2007).   
2.1.6.1 Pathomechanisms of endothelial dysfunction 
Endothelial dysfunction is the result of an imbalance between the secretion of 
vasodilators and vasoconstrictors by the endothelium (Muniyappa & Yavuz, 2013). 
Endothelial dysfunction is characterised by a change in the properties of endothelial 
cells towards reductions in the potent vasodilator NO, increased production of ROS 
and the development of pro-inflammatory and prothrombotic states (Kassi et al., 
2013; Widlansky, Gokce, Keaney, & Vita, 2003). Endothelial dysfunction reduces 
the anti-coagulatory property of endothelial cells and increases endothelial 
production of plasminogen activator inhibitor-1 and tissue factor, an inflammatory 
response gene implicated in the increased risk of thrombosis and atherosclerosis 
(Brewer et al., 2011; Ha, Oh, & Lee, 2009; McGorisk & Treasure, 1996).  
2.1.6.2 Proposed effects of vitamin D on the endothelium 
Vitamin D is essential in the maintenance of a stable endothelium due to the presence 
of both CYP27B1 and VDR on endothelial cells (Dalan, Liew, Tan, Chew, & Leow, 
2014). CYP27B1 and VDR both upregulate the vascular endothelial growth factor 
(VEGF) which increases NO synthesis (Norman & Powell, 2005) and inhibits the 
increased expression of p22 (phox), NADPH oxidase (the primary enzyme that 
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produces ROS). CYP27B1 and VDR also improve the coupling of endothelial NO 
synthase, thus decreasing the production of ROS (Kassi et al., 2013; Norman & 
Powell, 2005). Vitamin D maintains vascular tone by regulating the calcium 
dependent secretion of endothelium derived contracting factors, a vasoconstrictor 
metabolite of arachidonic acid (Wallis, Penckofer, & Sizemore, 2008). As a result of 
decreasing calcium influx into endothelial cells, vitamin D decreases the production 
of endothelium-derived contracting factor (Bischoff-Ferrari et al., 2010). The 
calcium independent mechanism by which vitamin D decreases the production of 
endothelium derived contracting factors is by downregulating cyclooxygenase-1 
expression, the primary source of endothelium derived contracting factors (Melamed, 
Michos, Post, & Astor, 2008). 
Vitamin D protects the endothelium from the damaging effects of advanced glycation 
end products (AGEs) by suppressing the expression of RAGE, IL-6 and IL-8 
(Zitman-Gal, Golan, Green, Bernheim, & Benchetrit, 2012). In addition to 
suppressing the migration and proliferation of endothelial cells (Mantell, Owens, 
Bundred, Mawer, & Canfield, 2000), vitamin D also decreases platelet activation and 
the expression of vascular adhesion markers on endothelial cells (Dalan et al., 2014). 
Through the anti-proliferative effect of both endothelin and epidermal growth factor, 
vitamin D may also modulate both VSMC function and homeostasis  as VSMCs 
express the VDR and CYP27B1 (Kassi et al., 2013). Vitamin D modulates VSMC 
morphology by stabilising its musculo-elastic multilayer whilst increasing elastin 
generation through the regulation of vessel wall scaffolding proteins including 
collagen type 1, elastin and matrix metalloproteinase-9 (Norman & Powell, 2005). 
Vitamin D affects endothelial function by indirectly reducing blood pressure by 
suppressing the RAS (Li et al., 2002) or by reducing vascular resistance (Norman & 
Powell, 2005). VDR signalling represses atherosclerosis to some extent by impeding 
the upregulation of the local RAS in macrophages (Li, 2013).  
2.1.6.3 Observational studies 
Observational studies have established an association between serum 25(OH)D 
concentrations and endothelial dysfunction. In 23 asymptomatic vitamin D deficient 
(25(OH)D <25nmol/L) adults with mean (±SD) age of 23.3 ± 3.0 years, endothelial 
function determined by flow mediated dilatation (FMD) measurements were 
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significantly lower in the vitamin D deficient participants compared to vitamin D 
sufficient controls (25(OH)D = 75nmol/L). In this study, the low serum 25(OH)D 
concentrations in the vitamin D deficient participants was positively associated with 
FMD (r = 0.45; P = 0.001) (Tarcin et al., 2009).  Another study in 81 early 
Parkinson’s disease (PD) patients with mean (±SD) age of 67.4 ± 8.1 and 52 age 
matched healthy controls, found lower serum mean (±SD) 25(OH)D concentrations 
of 54.5 ± 23.8 vs. 63.0 ± 23.3 nmol/L, (P < 0.05) and FMD 7.1 ± 1.8 vs. 8.1 ± 2.1 %, 
(P < 0.05) in PD patients’ than in the healthy controls. Low serum 25(OH)D 
concentrations in the PD patients was positively associated with FMD (R2 = 0.331, β 
= 0.494, P < 0.001) (Yoon, Park, Yong, & Hong, 2015). 
2.1.6.4. RCTs 
Several RCTs have evaluated the effect of vitamin D supplementation on endothelial 
function but results have been inconsistent. In a US cohort of 45 overweight and 
obese African Americans, mean (±SD) age 31 ± 2 years and baseline plasma 
25(OH)D concentrations of 34.3 ± 2.2nmol/L,  60,000IU, (1500µg) vitamin D3 was 
administered every 4 weeks for 16 weeks resulted in significant reductions (54 ± 6s - 
43 ± 3s, P = 0.02) in mean ± (SD) FMD in the vitamin D group (Harris et al., 2011). 
Similarly, another 4 months UK RCT in 55 stroke patients with mean (± SD) age 
72.9 ± 8.7 years and baseline 25(OH)D concentration of 40.8 ± 16.8nmol/L, found 
significant reductions in  mean (±SD) FMD from baseline to week 8 (6.9 ± 3.5% vs 
3.7 ± 3.1 %, P = 0.007) after receiving a single large dose of 100,000IU (2500µg) 
vitamin D2 compared to placebo (Witham, Dove, Sugden, Doney, & Struthers, 
2012). However, contrary to these findings, a US study in 84 non-diabetic and non-
hypertensive overweight or obese participants with a baseline plasma 25(OH)D 
concentrations <50nmol/L and a mean (±SD) age of 39 ± 13 years, did not find 
significant improvement with the weekly administration of 50,000IU (1250µg) 
vitamin D2 for 8 weeks on endothelial-dependent vasodilation (EDV) determined by 
brachial artery ultrasound. In this study plasma 25(OH)D concentrations increased 
from a median (range) value of 37.5 (28.5-43.8) nmol/L at baseline to 66.3 (57.5-
81.8) nmol/L at 4 weeks and 71.8 (63.5-90.8) nmol/L at 8 weeks in the vitamin D 
group (Borgi et al., 2016). Similarly, findings from a RCT conducted in Singapore 
did not show significant improvement on endothelial function assessed by reactive 
hyperaemia index (RHI) after administering 4,000IU(100µg/d) vitamin D3 for 
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16 weeks to 64 multi-ethnic vitamin D deficient T2DM patients with baseline serum 
25(OH)D ≤ 50 nmol/L and mean (±SD) age of 53.5 ± 9.5 years (Dalan et al., 2016). 
The reason for the non-significant improvement in this study may be due to the fact 
that participants already had advanced T2DM.  
2.1.7. VITAMIN D, INFLAMMATION AND CARDIOMETABOLIC RISK 
Inflammation plays a major role in all phases of atherogenesis (Wong, Meredith, Lin, 
& McManus, 2012). Inflammation mechanisms mediate the gradual advancement of 
atherosclerosis and its various complications, as both innate and adaptive immune 
responses are implicated in the atherogenic process (Kassi et al., 2013; Ross, 1999). 
T cells including T helper (Th)1, Th2, Th17, T regulatory cells, B cells, in addition to 
leucocytes and transformed monocytes have been reported to be present in 
atherosclerotic lesions (Holick, Binkley, Bischoff-Ferrari, Gordon, Hanley, Heaney, 
Murad, & Weaver, 2011). Th1 is responsible for activating the inflammatory 
response observed in the atherogenic process, as it stimulates the secretion of pro-
atherogenic cytokines including IL-6, IL-12, interferon-γ and TNF-α (Danik & 
Manson, 2012; Holick, Binkley, Bischoff-Ferrari, Gordon, Hanley, Heaney, Murad, 
& Weaver, 2011).  
2.1.7.1 Role of vitamin D in inflammation 
Macrophages, dendritic and activated T cells express both VDR and CYP27B1 
enabling vitamin D to regulate the proliferation, function and differentiation of 
inflammatory and immune cells (Guillot, Semerano, Saidenberg-Kermanac'h, 
Falgarone, & Boissier, 2010; Lahoute, Herbin, Mallat, & Tedgui, 2011). Vitamin D 
may decrease the secretion of pro-inflammatory cytokines by stimulating Th2 to 
secrete anti-inflammatory cytokines including 1L-5, IL-10 and IL-13 which 
counteract the Th1 pro-inflammatory response (Cantorna, Zhu, Froicu, & Wittke, 
2004). Vitamin D has been shown to suppress the secretion of IL-6 or TNFα in 
monocytes through the inhibition of p38 MAP kinase by stimulating MAPK 
phosphatase-1 which dephosphorylates and therefore decreases its activation (Zhang 
et al., 2012). Vitamin D also upregulates IL-10 secretion, and a deficiency in IL-10 
has been associated with acute atherosclerosis in experimental animals (Cohen-
Lahav, Shany, Tobvin, Chaimovitz, & Douvdevani, 2006; Mallat et al., 1999). 
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2.1.7.2 Observational studies 
Vitamin D deficiency has been reported to be associated with an increase in 
circulating inflammatory proteins (Ngo et al., 2010; Peterson & Heffernan, 2008). A 
deficiency in vitamin D has been associated with vascular endothelial inflammation, 
elevated NFkB signalling-related suppression of vascular endothelial function, and 
decreased vascular endothelial VDR and CYP27B1 expression (Jablonski, Chonchol, 
Pierce, Walker, & Seals, 2011). Inflammation has been shown to reduce with 
increasing 25(OH)D concentrations, as inflammation increases vitamin D catabolism 
(Toloza, Cole, Gladman, Ibanez, & Urowitz, 2010).  
2.1.7.3 RCTs 
In recent years, RCTs which have investigated the effect of vitamin D 
supplementation has been increasing. A 12 month German RCT showed that a daily 
dose of 3,332IU (83.3µg) vitamin D3 significantly decreased serum mean (±SD) 
TNF-α concentration from baseline 7.8 ± 3.2 to -7.0 ± 2.3 pg/mL, (P = 0.049) in 165 
healthy overweight/obese subjects with mean (±SD) baseline 25(OH)D concentration 
of  30.0 ± 17.5 nmol/L and  age of 47.4  ± 10.3 years (Zittermann et al., 2009). 
Additionally, a 9 week RCT conducted in Iran reported a significant decrease in 
serum mean (±SD) hs-CRP concentrations from 4.5 ± 0.6 at baseline to 3.1 ± 0.5 
µg/ml, (P = 0.01) post intervention in the vitamin D group after administering 400IU 
(10µg)/d vitamin D3 in 48 healthy pregnant women aged 18-40 years  at 25 weeks of 
gestation with mean (±SD) baseline 25(OH)D concentration of 17.8 ± 1.3µg/L 
(Asemi, Samimi, Tabassi, Shakeri, & Esmaillzadeh, 2013). Furthermore, a UK RCT 
which administered a single large dose of 100,000 IU (2500 µg) vitamin D3 at 
baseline, 8 and 26 weeks to 74 patients with a history of MI and mean (±SD) age of 
25.3 ± 4.2 years and baseline 25(OH)D concentration of 44.5 ± 3.3 nmol/L, found 
vitamin D3 significantly decreased mean (±SD) CRP by –1.3 ± 5.4 mg/L in the 
vitamin D group vs. +2 ± 6.8 mg/L in the placebo group, (P = 0.03). The 74 MI 
patients had a (Witham et al., 2013).  
In contrast, a recent Iranian RCT did not find a significant effect of 50,000IU 
(1250µg) vitamin D3 for 8 weeks on serum hs-CRP in 40 patients with major 
depressive disorder compared with the placebo (Sepehrmanesh et al., 2016). Mean 
(±SD) baseline serum 25(OH)D concentration, BMI and age was 9.2 ± 6.0 µg/L, 
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26.9 ± 3.8 kg/m2 and 36.1 ± 6.9 years respectively for the patients. This study was 
unable to examine whether the favourable effects of vitamin D supplementation were 
greater in vitamin D deficient individuals than in those without a deficiency. A 
systematic review of 11 RCTs which administered vitamin D orally in any dose, 
duration and form among adult overweight and obese participants aged ≥18 years 
demonstrated that there was no effect of vitamin D supplementation on inflammatory 
markers (Zuk, Fitzpatrick, & Rosella, 2016). Besides being limited by a small 
number of eligible studies, most of the included trials were aimed at investigating the 
effect of vitamin D supplementation on body weight, muscle function and skeletal 
outcomes, thus, most included studies were not originally designed to investigate the 
effect of vitamin D on inflammatory markers (Zuk et al., 2016). A meta-analysis of 
13 RCTs which supplemented with a dose ranging between 1000-12000 IU/d and a 
study duration of 12-52 weeks in overweight and obese subjects showed that 
supplementation with vitamin D did not affect CRP, TNF-α and IL-6 in the obese 
and overweight subjects between the age range of 9-75 years (Jamka, Woźniewicz, 
Walkowiak, et al., 2015). This meta-analysis was limited by 4 RCTs that combined 
vitamin D and calcium supplementation, which makes it difficult to draw adequate 
conclusions on the effect of vitamin D in the analysed studies due to calcium effect. 
Additionally, study durations were different and could influence the full 
interpretation of the collected data (Jamka, Woźniewicz, Walkowiak, et al., 2015). 
2.1.8. VITAMIN D AND INSULIN SECRETION/INSULIN RESISTANCE 
The development of atherosclerosis is accelerated by T2DM (Chait & Bornfeldt, 
2009). T2DM is defined by altered insulin secretion, reduced glucose tolerance, 
severe hyper-glycaemia and complications that arise from the stimulation of pro-
oxidants (Heshmat et al., 2012).  Insulin resistance (IR) is defined as the resistance of 
target organs to the effects of insulin on glucose metabolism and absorption. Insulin 
resistance is characterised by partial inhibition of hepatic glucose output and 
weakened insulin-mediated glucose uptake in skeletal muscle and adipose, resulting 
in increased insulin requirements (Kahn & Flier, 2000; Pittas, Joseph, & Greenberg, 
2004). Associations have been found between vitamin D deficiency and insulin 
resistance, as pancreatic β cells that secrete insulin express both VDR and CYP27B1, 
enabling it convert 25(OH)D to 1,25(OH)2D3 (Bland et al., 2004; Deleskog et al., 
2012; Forouhi et al., 2012; Martin & Campbell, 2011).  
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Since insulin secretion depends on calcium, and as vitamin D regulates calcium flux 
and intracellular cytosolic calcium pool within pancreatic β cells, vitamin D 
deficiency may decrease the capability of calcium to affect insulin secretion (Chiu, 
Chu, Go, & Saad, 2004; Pittas, Lau, Hu, & Dawson-Hughes, 2007). Vitamin D 
regulation of calcium flux is essential for insulin-mediated intracellular processes in 
insulin-responsive tissues particularly adipose tissues (Williams, Caterson, Cooney, 
Zilkens, & Turtle, 1990), as insulin is the main regulator of essentially all stages of 
adipocyte biology, hence, T2DM risk increases as body fat increases (Kahn & Flier, 
2000). Vitamin D plays vital roles in glucose metabolism by enhancing both insulin 
exocytosis and absorption of glucose by peripheral tissues, directly stimulating 
insulin receptor and improving insulin resistance (Bajaj et al., 2014; Mitri, Dawson-
Hughes, Hu, & Pittas, 2011). Gene polymorphisms of the DBP,VDR, or CYP27B1 
genes may affect insulin release and result in insulin resistance which in turn disrupts 
vitamin D synthesis, transport and action (Blanton et al., 2011).  
2.1.8.1 The inflammatory role of vitamin D in T2DM 
T2DM, apart from being a vascular and hyperglycaemic disease, is an inflammatory 
disease (Taha et al., 2014), as increased pro-inflammatory cytokines are involved in 
β-cell dysfunction and elicit β-cell apoptosis (Pradhan, 2007). Vitamin D deficiency 
induces TNF-α pro-inflammatory and NF-kB actions by downregulating the inhibitor 
of NF-kB (IkB) and increasing IkB phosphorylation (Baker, Hayden, & Ghosh, 
2011; Chagas, Borges, Martini, & Rogero, 2012; Cohen-Lahav et al., 2006; Riachy 
et al., 2002). Due to its immune-modulating properties vitamin D may directly and/or 
indirectly reduce the effects of systemic inflammation observed in T2DM patients in 
various ways, firstly, by inhibiting NF-kB pathway, a major transcription factor for 
TNF-α and secondly by inhibiting the pro-inflammatory cytokines responsible for 
mediating acute inflammation and fibrogenesis (Chagas et al., 2012; Cohen-Lahav et 
al., 2007; Flores, 2005; Takiishi et al., 2010). Additionally, vitamin D represses 
lymphocyte multiplication, dendritic cell differentiation, foam cell formation and 
cholesterol absorption by macrophages (Oh et al., 2009; van Etten & Mathieu, 2005), 
by reducing the expression of toll like receptors (TLR) (Ahmad et al., 2012; Calton, 
Keane, Newsholme, & Soares, 2015). TLR is a transmembrane protein that initiates 
classical signalling cascades leading to the activation of transcription factors, 
including NFκB and cytokine production (Ahmad et al., 2012; Calton et al., 2015) 
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2.1.8.2 Vitamin D and insulin sensitivity 
The promoter region of the insulin receptor gene consists of VDRE suggesting a 
direct modulation of its transcription by CYP27B1 (Bland et al., 2004). It is therefore 
expected that vitamin D may improve insulin sensitivity by directly stimulating the 
expression of insulin receptors, which improves insulin responsiveness for glucose 
transport/insulin sensitivity (Maestro, Campion, Davila, & Calle, 2000). Vitamin D 
may also stimulate the peroxisome proliferator-activated receptor delta (PPAR-δ), a 
transcription factor that modulates fatty acid metabolism in adipose tissue and 
skeletal muscle (Dunlop et al., 2005).  
2.1.8.3 Observational studies   
Several cross-sectional studies have shown inverse associations between low serum 
25(OH)D concentrations and insulin resistance (Chiu et al., 2004; Liu et al., 2009; 
Zhao, Ford, & Li, 2010). A cross-sectional study in 668 elderly subjects aged 70-74 
years, with serum 25(OH)D ≤ 50 nmol/L had a higher risk of developing T2DM. 
Serum 25(OH)D concentrations ˃ 50 nmol/L was inversely associated with several 
indicators of glucose metabolism, including HbA1c (r = −0.10; P = 0.01), fasting 
plasma insulin (r = −0.10; P = 0.01), HOMA-IR (r = −0.10; P = 0.01), and HOMA-B 
(r = −0.10; P = 0.01) (Dalgard, Petersen, Weihe, & Grandjean, 2011).  
2.1.8.4 RCTs 
Several RCTs have been performed using various doses, time scales and populations 
and some of these RCTs have reported that vitamin D supplementation improves 
insulin resistance. A 6 months RCT conducted in New Zealand in 81 insulin resistant 
South Asian women, aged 23-68 years with baseline serum 25(OH)D concentration 
< 50nmol/L found that 4,000IU (100µg)/d vitamin D3 caused a significantly reduced 
median (range) HOMA1-IR by -20·3 (0·2, 20·8) in the vitamin D group and an 
increased HOMA-IR +0·4 (1·2, 20·4), (P = 0·03) in the placebo group. There was 
also a significant difference in change in fasting serum median insulin between 
groups with a decrease of -11·2 (7.9, 11·9) in the vitamin D group and an increase of 
+13·1 (10·2, 17·3), (P = 0·02) in the placebo group (von Hurst, Stonehouse, & Coad, 
2010). Similarly a 6 weeks Indian RCT which administered 120,000IU (3,000µg) 
vitamin D3 fortnightly to 71 healthy centrally obese men aged ≥ 35 years with mean 
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(±SD) baseline serum 25(OH)D concentration 36.5 ± 14.6 nmol/L, showed 
significant difference in changes in oral mean (± SD) glucose insulin sensitivity by 
21.2 ± 67.8 in the vitamin D group to -11.4 ± 60.9, (P = 0.038) in the placebo group 
(Nagpal, Pande, & Bhartia, 2009). In addition, a 9 week Iranian RCT which 
administered 400 IU (10µg) vitamin D3 in 48 healthy pregnant women aged 18-40 
years at 25 weeks of gestation and a baseline mean (±SD) serum 25(OH)D 
concentration of 17.8 ± 1.3µg/L, showed a significant decrease in mean insulin 
concentrations in the vitamin D but not in the placebo groups -1.0 vs. +2.6 μIU/mL, 
(P = 0.04). This study also found a significant decrease in fasting mean plasma 
glucose (vitamin D vs. placebo groups: -0.65 vs. -0.12 mmol/L, (P = 0.01) (Asemi, 
Samimi, et al., 2013).  
Contrary to studies which demonstrated significant effects of vitamin D 
supplementation on glucose homeostasis parameters, some studies have found no 
significant effects. A 12 week US RCT which administered either 400IU (10µg) or 
2,000 IU (50µg) /d of vitamin D3 showed no significant effect of both doses on β-cell 
function and insulin action in 51 obese adolescents, mean (±SD) age 15.0 ± 1.9 years 
and baseline serum 25(OH)D concentration of 24.0 ± 8.1µg/L (Javed et al., 2015). 
The obese adolescents recruited for this study were vitamin D sufficient with no 
prediabetes or diabetes and the small increase in 25(OH)D concentration of 3.1 xg/L 
in the group treated with daily 2,000IU vitamin D3 compared with the 0.8 xg/L 
increase in the group treated with 400 IU/d may not be sufficient for generating 
marked changes in insulin sensitivity. Additionally, a 12 week RCT performed in 
Denmark did not show significant improvement in insulin sensitivity in 16 T2DM  
patients with mean (±SD) age of 61.6 ± 4.4 years and baseline serum 25(OH)D 
concentration of 31.0 ± 4.9nmol/L, compared to the placebo group following the 
administration of 11,200 IU (280 μg)/d for 2 weeks and 5,600 IU (140 μg/d vitamin 
D3 for 10 weeks (Kampmann et al., 2014). Even though supplementation increased 
patients’ vitamin D concentrations to recommended levels, insulin sensitivity did not 
significantly improve, as patients in this study already had established and 
widespread CVD. The established CVD could have led to irreparable anatomical 
changes in the vascular wall, enough to prevent positive impact of the active 
treatment. 
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2.1.9. VITAMIN D AND OXIDATIVE STRESS   
Atherosclerosis results from the oxidative modification of LDL-C in the arterial wall 
by ROS, and common risk factors for atherosclerosis increase the risk of the 
production of free ROS from endothelial, vascular smooth muscle and adventitial 
cells (Vogiatzi, Tousoulis, & Stefanadis, 2009; Vural et al., 2012). Under normal 
physiological conditions there is balance between the production of free oxygen 
radicals and the antioxidants defence mechanisms against toxicity. However, an 
imbalance between oxidants and antioxidants results in cellular damage and leads to 
a pro-oxidant process known as oxidative stress (Deng, Cheng, & Shen, 2016). 
Oxidative stress also results from increased production and/or decreased clearance of 
free radicals, which may alter the DNA, proteins and lipids leading to endothelial 
dysfunction and death by apoptosis or necrosis thus promoting atherosclerosis, cell 
death, tissue damage, and organ dysfunction (Haas, Jafri, Wehmeier, Onstead-Haas, 
& Mooradian, 2016; McCord & Edeas, 2005). Vitamin D acts as an antioxidant, thus 
maintaining redox homeostasis (Djordjevic, Zvezdanovic, & Cosic, 2008; Van Laer, 
Hamilton, & Messens, 2013), however, studies relating to the antioxidant properties 
of vitamin D are sparse (Nikooyeh & Neyestani, 2016). Vitamin D protects against 
oxidative stress by mediating the gene expression and protein synthesis of anti-
oxidants such as catalase (CAT), superoxide dismutase and glutathione peroxidases 
in cell lines and animal models.  Vitamin D does this by improving cell viability and 
reducing the production of ROS, and inhibiting cellular damage promoted by 
hydrogen peroxide (Benhusein, Mutch, Aburawi, & Williams, 2010; Tohari, Zhou, & 
Shu, 2016). Vitamin D also has the capacity to protect endothelial cells from 
oxidative stress by preventing superoxide anion generation, thus inhibiting ROS and 
hindering apoptosis (Wong, Delansorne, Man, & Vanhoutte, 2008). 
2.1.9.1. Observational studies 
There is evidence that low serum or plasma 25(OH)D concentrations results in 
increased oxidative stress (Codoner-Franch et al., 2012; Krivosikova et al., 2015).  A 
cross-sectional clinical study in 66 obese Caucasian children with hepatitis C virus 
showed that vitamin D deficiency increased endothelial activation, inflammation and 
oxidative/ nitrosative stress (Codoner-Franch et al., 2012). Another study in rat 
models showed that vitamin D deficiency leads to mild oxidative stress in the 
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muscle, which may act as a trigger for increased proteolysis in the vitamin D 
deficient muscle (Krivosikova et al., 2015).  
2.1.9.2. In vitro studies 
Studies in human cell lines have also reported the protective effect of vitamin D 
against oxidative stress (Haas et al., 2016; Uberti et al., 2014). A study aimed at 
evaluating the ability of vitamin D to suppress hyperglycaemia-induced oxidative 
stress in human primary endothelial cell found vitamin D treatment to protect 
vascular endothelial cells from oxidative stress (Haas et al., 2016). Similarly, a study 
which used cultured human umbilical vein endothelial cells (HUVEC) undergoing 
oxidative stress demonstrated that vitamin D may prevent endothelial cell death by 
modulating the interplay between apoptosis and autophagy, resulting in the inhibition 
of superoxide anion generation and the stimulation of NO production (Uberti et al., 
2014).  
2.1.9.3 RCTs  
There is evidence that vitamin D supplementation protects cells against oxidative 
stress mediated complications and strengthens antioxidant defences. One 8 week 
Iranian RCT in 40 patients between 18 and 65 years with major depressive disorder  
and baseline mean (±SD) serum 25(OH)D concentration of 9.2 ± 6.0µg/L, showed a 
significant mean increase in the anti-oxidant glutathione in the vitamin D group 
compared to the placebo group by +170 vs. -213 µmol/L, (P = 0.04) after 
administering a single large dose of 50,000IU (1250µg) vitamin D3 (Sepehrmanesh 
et al., 2016). Similarly, in 53 non-alcoholic fatty liver disease patients with mean 
(±SD) age 40.3 ± 8.7 years and baseline median (range) serum 25(OH)D 
concentration of 28.8 (22.0-71.0 nmol/L), 50,000IU (1250 µg) vitamin D3 every 2 
weeks for 4 months significantly decreased mean oxidative stress measured by serum 
malondialdehyde (MDA) by -2.1 vs. -1.2 ng/mL, (P = 0.03) in the vitamin D 
compared to placebo group (Sharifi, Amani, Hajiani, & Cheraghian, 2014). Contrary 
to these findings, another Iranian RCT in 54 pregnant women with gestational 
diabetes with baseline mean (±SD) age of 31.7 ± 5.6 years and serum 25(OH)D 
concentration of 51 ± 35.8 nmol/L, demonstrated that 50,000 IU vitamin D3 for 6 
weeks did not affect oxidative stress determined by total glutathione (Asemi, 
Hashemi, Karamali, Samimi, & Esmaillzadeh, 2013). A limitation of this study is 
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that it did not investigate the effect of vitamin D supplementation on other 
biomarkers of oxidative stress such as catalase and superoxide dismutase which may 
have shown significant improvements.  
2.1.10. VITAMIN D AND LIPID METABOLISM 
Dyslipidaemia is the most important risk factor for atherosclerosis, as abnormalities 
in lipid metabolism, particularly in LDL-C lead to the development of atherosclerosis 
(Koba & Hirano, 2011). However, the association of vitamin D with lipids is the 
least investigated, as mechanisms through which vitamin D influences lipid 
metabolism are unknown (Kassi et al., 2013). Since vitamin D is synthesised from 
7DHC, a derivative of cholesterol, it has been deduced that vitamin D deficiency 
may result in increased cholesterol synthesis (Jastrzebski, Kortas, Kaczor, & 
Antosiewicz, 2016).  
2.1.10.1. Role of vitamin D in lipid metabolism 
Vitamin D has been reported to affect lipids in several ways, and one such effect is 
its role in the improvement of cholesterol metabolism. A study which administered 
vitamin D in differentiating macrophages reported reduced acetylated and oxidised 
LDL-C absorption, thus decreasing foam cell formation by inhibiting cholesteryl 
ester formation whilst enhancing cholesterol clearance compared with vitamin D 
deficient macrophages (Riek, Oh, & Bernal-Mizrachi, 2013). Vitamin D is capable of 
inhibiting bile acid synthesis through the interaction of its VDR with farnesoid X 
receptor (FXR). As a result of this interaction, FGF15 is induced to a level required 
to inhibit the expression of Cyp7a1, the rate limiting enzyme in bile acid synthesis. 
The repression of cyp7a1 in turn inhibits bile acid synthesis which leads to reduced 
cholesterol concentrations (Gonzalez & Moschetta, 2014; Schmidt et al., 2010).  
Vitamin D indirectly affects lipids, by inhibiting PTH secretion, as PTH has been 
reported to reduce lipolysis in vitro (Zemel, Shi, Greer, Dirienzo, & Zemel, 2000). 
Additionally, vitamin D may affect serum lipid concentration by increasing calcium 
concentrations which in turn may reduce hepatic TAG synthesis and/or secretion 
(Zittermann et al., 2009). Furthermore, the ability of vitamin D to improve both 
insulin secretion and sensitivity may indirectly influence lipid metabolism 
(Kamycheva, Jorde, Figenschau, & Haug, 2007). Decreasing the level of TAG and 
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LDL-C is also another mechanism by which vitamin D may protect against 
atherosclerosis, as vitamin D increases lipoprotein lipase activity in cultured 
adipocytes (Kassi et al., 2013). 
2.1.10.2. Observational studies 
There is evidence to show that high serum 25(OH)D concentrations lead to 
improvements in lipid profile compared to low serum 25(OH)D concentrations 
(Chaudhuri et al., 2013; Kelishadi, Farajzadegan, & Bahreynian, 2014). A review of 
22 cross sectional studies found serum 25(OH)D concentration to be positively 
associated with serum HDL-C concentration (Jorde & Grimnes, 2011). Additionally, 
a longitudinal study where participants were followed for 14 years reported an 
inverse association between serum 25(OH)D and TAG concentrations (Jorde, 
Figenschau, Hutchinson, Emaus, & Grimnes, 2010). 
2.1.10.3 RCTs 
RCTs have also reported beneficial effect of vitamin D supplementation on lipid 
profile in humans. A daily dose of 3,320 IU (83µg) vitamin D3 for 12 months 
significantly reduced TAG in the vitamin D compared to placebo group by -13.5 vs. 
+3.0%, (P ˂ 0.001) in 165 overweight/obese subject with mean (±SD) age of 47.4 ± 
10.3 years and baseline 25(OH)D concentration of 30 ± 17.5 nmol/L    (Zittermann et 
al., 2009). In another study, 12 weeks of daily 4,000IU (100µg) vitamin D3 
administration in 44 HIV- infected people with mean (±SD) age of 47 ± 8 years and 
a baseline 25(OH)D concentration < 50nmol/L, led to significant reductions in 
median TC -9.0 (-25.0-4.0) vs. -1.0 (-18-12), (P = 0.009) and non–HDL-C -7 (-21-8) 
vs. -2 (-11-11), (P = 0.022) in the vitamin D compared to placebo group respectively 
(Longenecker et al., 2012). In contrast to these findings, a 16 week RCT conducted 
in Norway did not find a significant effect of either 400 or 1,000 IU (10 or 25 µg) 
vitamin D3 on lipid profile in 215 healthy South Asians aged 18-50 years and a 
baseline 25(OH)D concentration < 50nmol/L (Madar et al., 2014). This study was 
designed primarily for muscular strength outcome, and the duration of the study may 
not have been sufficient to raise serum concentrations of 25(OH)D to affect the lipid 
profile markers. Additionally, the daily dose of 1,000IU (25µg) administered to 
vitamin D deficient individuals may have been inadequate to replete vitamin D stores 
and exert potential cardio-protective effects. The use of a higher daily dose e.g. 5,000 
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IU (125µg) in individuals with 25(OH)D concentrations ˂55 nmol/L has been 
recommended (Chel, Wijnhoven, Smit, Ooms, & Lips, 2008). Furthermore, the 
administration of 11,200 IU (280 μg) /d for 2 weeks and 5600IU (140 μg)/d vitamin 
D3 for 10 weeks did not significantly affect lipid profile in T2DM patients with mean 
(±SD) age 61.6 ± 4.4 years and baseline serum 25(OH)D concentration 31.0 ± 4.9 
nmol/L compared to the placebo group (Kampmann et al., 2014). It may be possible 
that vitamin D supplementation may in fact not elicit clinical/health effects on the 
T2DM patients, as T2DM is a disease state characterised with impaired endothelial 
progenitor cells or endothelial dysfunction (Fadini et al., 2005).  
2.1.11. VITAMIN D AND ARTERIAL STIFFNESS 
Arterial stiffness and atherosclerosis share some common pathophysiological 
mechanisms even though arterial stiffening reflects the degenerative changes of 
ECM in the media layer of the artery whilst atherosclerosis reflects degenerative 
changes in the intima layer of the artery (Palombo & Kozakova, 2016). Some of the 
shared pathophysiological mechanisms include impaired endothelial function, 
chronic inflammation and insulin resistance. As a result, both arterial stiffness and 
atherosclerosis could be regarded as 2 synergic processes that may increase the effect 
of each other in the development of vascular changes underlying CVD (Palombo & 
Kozakova, 2016). Arterial stiffness is defined as the reduced compliance/elasticity of 
an artery in response to pressure change along the arterial tree (Cecelja & 
Chowienczyk, 2012). Arterial stiffening develops from alterations in the cellular and 
structural elements of the vessel wall, due to an imbalance of its scaffolding proteins, 
particularly collagen and elastin which interact to maintain stability of the vessel wall 
(Cecelja & Chowienczyk, 2012). 
Any disease state characterised by increased proinflammatory cytokine secretion and 
hypertension would cause an imbalance in these scaffolding proteins leading to 
overproduction of deformed collagen and reduced levels of normal elastin (Zieman, 
Melenovsky, & Kass, 2005). This results in the loss of compliance of the vascular 
wall, which triggers an increase in SBP and a decrease in diastolic blood (DBP), 
resulting in increased pulse pressure associated with an increase in aPWV with early 
wave reflections (Brunet et al., 2011). Consequently, these haemodynamic alterations 
lead to left ventricular hypertrophy and a decrease in coronary perfusion (London & 
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Guerin, 1999). In the presence of atherosclerosis, arterial stiffness is increased, thus 
arterial stiffness may be a useful marker of atherosclerosis of the aorta (Hopkins, 
Lehmann, & Gosling, 1994).  
Arterial stiffness is modulated by endothelial cell signalling and VSMC tone, as the 
latter may be disrupted by paracrine mediators including endothelin known to 
regulate vascular stiffness (Zieman et al., 2005). Angiotensin II, another paracrine 
mediator may also alter vascular tone by stimulating collagen generation whilst 
reducing elastin synthesis thereby increasing oxidative stress and stimulating 
cytokines and vascular hypertrophy (Zieman et al., 2005). Advanced glycation end 
products (AGEs) increase arterial stiffness contributing to endothelial dysfunction by 
reducing NO production, activating both stress signals and inflammatory responses, 
whilst increasing the expression of vascular adhesion molecules, growth factors, free 
radicals, and NF-kB (Kuzuya et al., 2001; Rojas et al., 2000).  
AGEs have been reported to produce irreversible non enzymatic cross-links between 
collagen and elastin, making it stiffer leading to deformity (Konova, Baydanoff, 
Atanasova, & Velkova, 2004). Disease, aging and other exposures in most people 
may reduce the elastic whilst stimulating the inelastic (collagen) component of the 
vessel wall (Lakatta & Levy, 2003; Lantelme, Mestre, Lievre, Gressard, & Milon, 
2002). Arterial stiffness is measured by PWV, a gold standard method and reliable 
indicator of damaged vessel wall (Colaci et al., 2012). PWV is defined as the speed 
at which pulse pressure or wave travels along the arterial tree, however, limitations 
of the method include a lack of an established reference value and the absence of a 
standardisation of method (Farro et al., 2012; Laurent et al., 2006). 
2.1.11.1. Observational studies 
Observational studies have reported an inverse association between vitamin D 
deficiency and indices of arterial stiffness such as PWV and AIX. One Italian 
observational study in 150 postmenopausal women showed reported inverse 
associations between 25(OH)D concentrations ˂ 75nmol/L with aPWV (rho = -0.23, 
P = 0.006) (Pirro et al., 2012). A study in 554 men and women showed that lower 
serum 25(OH)D concentrations was associated with increased arterial stiffness 
assessed by PWV (r = - 0.190, P ˂ 0.001) and AIx (r = - 0.170, P ˂ 0.001) (Al Mheid 
et al., 2011).  
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2.1.11.2 RCTs 
Several RCTs aimed at assessing the effect of vitamin D supplementation on arterial 
stiffness have been conducted, some of which have found vitamin D supplementation 
to improve arterial stiffness parameters. A 6 month US RCT in 534 prehypertension 
patients with mean (±SD) age 40.4 ± 75 years and baseline serum 25(OH)D 
˂62.5nmol/L, found that 4,000IU (100µg) significantly decreased mean (±SD) AIx 
and augmentation pressure by 12.3 ± 5.3%, (P = 0.047) and 4.0 ± 1.5 mmHg, (P = 
0.02) respectively (Zaleski et al., 2015). Additionally, the 2 week administration of 
2000 IU (50 µg)/d vitamin D3 in 15 healthy adults aged 19-53 years, showed 
significant reductions in mean (± SD) PWV from 7.45 ± 1.55 to 6.11 ± 1.89 m/s, (P 
= 0.04) (Al-Dujaili, Munir, & Iniesta, 2016). Contrary to these findings, a meta-
analysis of 7 RCTs with doses of vitamin D3 ranging from 1,000IU (25µg/d) to 
120,000 IU (3,000µg)/m over a duration of 2-12 months showed no improvement in 
arterial stiffness markers such as PWV and AIx following vitamin D 
supplementation (Upala, Sanguankeo, Congrete, & Jaruvongvanich, 2016). The 
absence of a significant effect on arterial stiffness in this study may be explained by 
the methodological differences among the devices used to measure PWV. 
Consequently, this may limit the interpretation of results as previous studies have 
shown different outcomes using these devices (Davies, Bailey, Griffin, & Scott, 
2012; Shahin, Barakat, Barnes, & Chetter, 2013). This study also used heterogeneous 
doses of vitamin D supplements, thus, caution should be taken into account when 
interpreting the data. A second meta-analysis of 18 RCTs with vitamin D3 doses 
ranging from 1,000IU to 5,700 IU/d (25-142.5µg) and follow up times of 1-12 
months also demonstrated that vitamin D replacement had no positive effect on PWV 
and AIx compared with the placebo group (Rodriguez et al., 2016). The lack of 
access to primary data was a limitation in the statistical analyses performed in this 
meta-analysis, as well as the data being extracted by a single reviewer. A more recent 
RCT performed in Denmark which was not included in any of these meta-analyses, 
also showed a lack of improvement in PWV and AIX after 3,000IU (75µg)/d vitamin 
D3 supplementation for 16 weeks in 40 healthy normotensive adults aged > 18 years 
with baseline serum 25(OH)D concentration ≤ 50nmol/L (Bressendorff et al., 2016). 
This study may not have found a significant effect of supplementation because of 
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small sample size, even though trial was large enough to detect a difference in PWV 
and AIx based on sample size calculations.  
2.1.12. VITAMIN D AND RENIN-ANGIOTENSIN SYSTEM  
The presence of hypertension and other atherosclerotic risk factors are associated 
with increased vascular angiotensin II generation and activity (Dzau, 2001), as 
angiotensin II has been implicated in the pathogenesis of atherosclerosis (Werner, 
Pöss, & Böhm, 2010). The RAS is a hormone system that regulates blood volume 
and arterial pressure and maintains the homeostatic balance between water and 
electrolytes. Vitamin D suppresses RAS endogenously by blocking the activity of the 
cyclic adenosine monophosphate (cAMP) response element in the renin gene 
promoter region (Li, 2003; Li et al., 2002). Vitamin D also inhibits the expression of 
angiotensinogen gene by blocking the NF-kB pathway (Deb et al., 2009). The 
association between vitamin D and the RAS may be attributed to the fact that both 
angiotensin II receptors and VDR are present in the same tissues (Ferder, Inserra, 
Manucha, & Ferder, 2013). 
2.1.12.1 Role of vitamin D in RAS 
The most substantial mechanistic studies associating vitamin D with RAS activity 
and blood pressure regulation were performed in animal models. It has been 
demonstrated that VDR-knockout mice had significant increase in renin activity and 
circulating plasma angiotensin II concentrations (Li et al., 2002). The VDR-knockout 
mice used in this study developed hypertension and cardiac hypertrophy (Li et al., 
2002). Another study in CYP27B1 deficient mice, also showed increased RAS 
activity, hypertension and cardiac hypertrophy that was attenuated with the 
administration of vitamin D (Xiang et al., 2005). These studies suggest that 
disruptions of vitamin D signalling may lead to upregulation of the RAS, 
hypertension and cardiac hypertrophy. In humans vitamin D deficiency has been 
shown to be associated with increased risk of arterial hypertension (Pilz, Tomaschitz, 
Ritz, & Pieber, 2009), as vitamin D deficiency upregulates the RAS, thereby 
contributing to cardiac hypertrophy (Forman, Williams, & Fisher, 2010).  
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2.1.12.2 Observational studies 
Observational studies in humans have shown that lower serum 25(OH)D 
concentrations are associated with upregulated circulating RAS. In 50 Indian obese 
(BMI ≥ 30 kg/m2 hypertensive patients with mean (±SD) age of 49.5 ± 7.8 years, 
plasma renin activity (PRA) was higher in the vitamin D deficient (25(OH)D < 
50nmol/L) compared to the vitamin D insufficient group (25(OH)D < 50-
72.5nmol/L) (3.7 ± 0.9 vs. 3.3 ± 0.6 ng/ml/hr) (Kota et al., 2011). In this study, PRA 
was higher in the overweight and obese compared to the lean patients (2.9 ± 0.7 and 
3.6 ± 0.9 vs. 3.3 ± 0.6 ng/ml/hr) (Kota et al., 2011). A cross-sectional study of 3316 
patients with median (range) age of 63.5 (56.3-70.6) years referred for coronary 
angiography also found that baseline median (range) serum 25(OH)D concentration 
of 15.6 (10.1-23.0) µg/L was inversely associated with increased plasma renin 
concentration (r = -0.105, P = 0.013) and increased plasma angiotensin II 
concentration (r = - 0.046, P = 0.020) (Tomaschitz et al., 2010). 
2.1.12.3 Intervention studies 
Few intervention studies performed in humans have found a significant effect of 
vitamin D therapy on the RAS. Oral weekly 25,000IU (625µg) vitamin D3 for 2 
months in 15 drug-free, essential hypertension patients with mean (range) age of 43.6 
(22-71) years and baseline mean (±SD) serum 25(OH)D concentration of 45.8 ± 7.0 
nmol/L, who were consuming a constant-salt diet found a significant reduction in 
plasma mean (±SD) renin concentration by 13.6 ± 3.4 pg/mL vs 24.0 ± 5.9 
pg/mL, (P < 0.05) and a non-significant decrease in plasma mean (±SD) angiotensin 
II concentration by 9.4 ± 1.5 pg/mL vs 13.0 ± 2.5 pg/mL (Carrara et al., 2014). In 
contrast, a Boston intervention study that evaluated the impact of high-dose 
15,000IU/d vitamin D3 therapy on the tissue sensitivity to Ang II in obese drug free 
hypertensives consuming a constant-salt diet for 1 month with a mean (±SD) age of 
50.0 ± 2.5 years and baseline serum 25(OH)D concentration  of 45.5 ± 4.5 nmol/L, 
did not observe any effect of therapy on circulating RAS components (Vaidya, Sun, 
Larson, Forman, & Williams, 2012). The absence of an effect of vitamin D therapy 
could be due to the short one month duration of vitamin D3 treatment.   
 
86 
 
2.1.13. VITAMIN D AND BLOOD PRESSURE 
Hypertension (˃140/90 mmHg) is a significant cause of atherosclerosis and thus, a 
risk factor for cardiometabolic disease. A major mechanism through which vitamin 
D may impact BP is the RAS (Li, 2003), as the untimely stimulation of the RAS has 
been associated with hypertension. Vitamin D also affects blood pressure via 
paracrine and endocrine mechanisms in the VSMC, endothelium and cardiomyocytes 
(Li et al., 2002). Vitamin D treatment has been shown to reduce plasma renin 
activity, angiotensin II concentrations and blood pressure by decreasing the 
expression of renin gene through a VDR-dependent mechanism, thus decreasing both 
renin and angiotensin II (Zhou et al., 2008). The molecular effects of VDR activation 
which includes suppression of the RAS, nephroprotective actions, or improvements 
in endothelial/vascular function, suggest antihypertensive properties of vitamin D 
(Liu, Woo, Wu, & Ho, 2013). Vitamin D may also regulate BP through effects on 
calcium homeostasis (Bian, Ishibashi, & Bukoski, 1996) regulation of VSMC 
(Somjen et al., 2005) and endothelial cell (Zehnder et al., 2002) function, 
inflammation and insulin sensitivity (Wang et al., 2013).  
2.1.13.1. Observational studies 
Evidence from observational studies and meta-analyses has shown that vitamin D 
deficiency/insufficiency are a significant risk marker for arterial hypertension 
(Kienreich, Grübler, et al., 2013; Kunutsor, Apekey, & Steur, 2013). It is 
hypothesised that if low concentrations of vitamin D cause hypertension, then 
vitamin D repletion may lower blood pressure due to its antihypertensive effects. A 
meta-analysis of 18 observational studies of adults aged 18-96 years reported that 
every 40nmol/L reduction in 25(OH)D concentration was associated with a 16% 
increased risk of hypertension (Burgaz, Orsini, Larsson, & Wolk, 2011).  
2.1.13.2 RCTs 
Several RCTs investigating the effect of vitamin D supplementation on BP have been 
conducted. A recent UK RCT in 15 healthy participants aged 19-53 years found that 
administering 2000 IU (50 µg)/ d vitamin D3 for 2 weeks significantly reduced mean 
(±SD) SBP and DBP from 115.8 ± 17.1 mmHg and 75.4 ± 10.3 mmHg at baseline to 
106.3 ± 10.9, (P = 0.022) and 68.5 ± 10.1 mmHg, (P = 0.012) respectively post 
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intervention (Al-Dujaili et al., 2016). Similarly, a UK RCT which compared the 
effect of single large doses of 100,000 and 200,000 IU (2,500 or 5,000µg) of vitamin 
D3 in 58 T2DM patients with mean (±SD) age of 66.7 ± 9.7 years and baseline 
25(OH)D concentration ˂ 100 nmol/L for 16 weeks, reported a significant decrease 
in mean SBP in both treatment arms than in the placebo group at 8 weeks for the 
individuals given 100,000IU, 141.4 mmHg vs.146.4 mmHg, (P = 0.04) and 200,000 
IU, 136.8 mmHg vs.146.4 mmHg, (P = 0.03) (Witham et al., 2010). A US 4-arm 
RCT in 283 African Americans with median (range) 51 (44-59) years and baseline 
25(OH)D concentration 39.3 (26.8-58.5) nmol/L, which compared the effects of 
daily 1,000, 2,000, or 4,00IU (25, 50 or 100 µg) of vitamin D3 found a difference of 
−0.66 mmHg, −3.4 mmHg and −4.0 mmHg for 1,000, 2,000 and 4,000IU (−1.4 
mmHg for each additional 1,000 IU P = 0.04) in SBP between baseline and 3 months 
(Forman et al., 2013).  
Conflicting results on the effect of vitamin D supplementation on blood pressure 
have also been reported. A 12 month RCT performed in China did not find a 
significant effect of the daily administration of 700 IU (17.5µg) vitamin D in 123 
vitamin D deficient metabolic syndrome patients (Yin et al., 2016). A possible reason 
for lack of an effect following supplementation may be attributed to low dose 
vitamin D administered to vitamin D deficient group as dose may have been too low 
to effect improvements.  A UK meta-analysis of 16 RCTs with a study duration of 5-
56 weeks using a vitamin D dose above 600IU (15µg), reported non-significant 
reductions in both SBP and DBP following vitamin D supplementation (Kunutsor, 
Burgess, Munroe, & Khan, 2014). The majority of trials included in this meta-
analysis had low risk of bias, thus, findings should be interpreted with some caution, 
owing to the potential differences in design and population characteristics of each 
trial. There was substantial heterogeneity among trials of SBP, as a result it was 
argued whether pooled estimates should be presented rather than reporting estimates 
in relevant subgroups, as the presence of heterogeneity makes pooling of risk 
estimates data controversial. Similarly, a RCT conducted in Austria in 188 
hypertensive patients with mean (±SD) age of 60.1 ± 11.3 years and baseline serum 
25(OH)D concentrations of 55.0 ± 13.8 nmol/L, showed no significant effect of 
2,800IU (70µg)/d vitamin D3 on blood pressure measurements after 8 weeks of 
supplementation (Pilz et al., 2015). The limitations of this study include the low 
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prevalence of patients with severe vitamin D deficiency and the relatively short 
treatment period of study, as significant effects of vitamin D in populations with low 
vitamin D concentrations and with longer treatment or different vitamin D cannot be 
excluded. 
2.1.14. STUDY RATIONALE  
Systematic reviews of observational studies have reported that low serum 25(OH)D 
concentrations are inversely associated with a broad range of cardiometabolic risk 
factors including hypertension, dyslipidaemia, abnormal glucose homeostasis and 
atherosclerosis (Grandi et al., 2010; Parker et al., 2010; Pilz et al., 2011; Pittas et al., 
2010; Wang, Song, et al., 2012). The few RCTs of vitamin D supplementation 
completed to date have failed to show a clear beneficial effect on cardiovascular 
events, raising questions about the causal role of vitamin D in CVD (Kienreich, 
Tomaschitz, et al., 2013; Theodoratou, Tzoulaki, Zgaga, & Ioannidis, 2014). As 
much of the observational data collected to date cannot provide strong evidence of 
causality, as they only draw inferences, particularly since increasing BMI leads to an 
inflammatory state resulting in low serum 25(OH)D concentrations and increased 
CVD risk. Prospective RCTs are therefore required to test the hypothesis whether 
high dose vitamin D3 supplementation significantly improve vitamin D status and 
cardiometabolic risk markers. Therefore, a high quality double blind, randomised 
placebo controlled trial of a high daily dose of 5,000IU (125µg) vitamin D3 
supplementation to test whether this intervention could improve markers of vascular 
function, blood pressure, lipid profile, glucose homeostasis, inflammation, oxidative 
stress and the RAS in overweight and obese UK males was conducted. 
2.1.15. RESEARCH PURPOSE 
To investigate the effect of daily dose of 5,000IU (125µg) vitamin D3 for 8 week on 
cardiometabolic risk markers in a cohort of overweight and obese adult males. 
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2.1.16. OBJECTIVES 
Primary 
• To determine whether a daily dose of 5,000IU (125µg) vitamin D3 for 8 
weeks would significantly improve 25(OH)D concentration in a cohort of 
overweight and obese adult males. 
• To determine whether a daily dose of 5,000IU (125µg) vitamin D3 for 8 
weeks would significantly improve the cardiometabolic risk markers 
measured in a cohort of overweight and obese adult males. 
Secondary  
• To investigate the association between change in 25(OH)D concentration 
with corresponding change in the cardiometabolic risk markers measured in 
in a cohort of overweight and obese adult males. 
2.1.17. Hypotheses 
H1: There will be a significant increase in plasma 25(OH)D following 8 weeks 
daily supplementation of oral vitamin D3 at a dose of 5,000 IU (125µg/day). 
H0: There will not be a significant increase in plasma 25(OH)D following 8 
weeks daily supplementation of oral vitamin D3 at a dose of 5,000 IU 
(125µg/day). 
H1: Administering oral vitamin D3 at a dose of 5,000IU (125µg/day) in 
overweight and obese participants for 8 weeks will significantly improve the 
cardiometabolic parameters measured. 
H0: Administering oral vitamin D3 at a dose of 5,000IU (125µg/day) in 
overweight and obese participants for 8 weeks will not significantly improve the 
cardiometabolic parameters measured. 
H1: There will be an association between plasma 25(OH)D concentration and 
cardiometabolic risk markers. 
H0: There will not be an association between plasma 25(OH)D concentration and 
cardiometabolic risk markers. 
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2.2 METHODS 
2.2.1 Study design for vitamin D supplementation study 
A parallel, randomised, double-blind, placebo-controlled trial was conducted in 
accordance with ethical guidelines for research involving human subjects according 
to the Helsinki Declaration (Dale & Salo, 1996). Ethical approval for the present 
study was obtained from the University of Chester Faculty Research Ethics 
Committee (REF: 855/13/AT/CSN) (appendix 1). The trial was registered at 
clinicaltrials.gov (NCT02359214), and conducted following the Consolidated 
Standards of Reporting Trials (CONSORT) statement (appendix 2) (Schulz, Altman, 
Moher, & Group, 2010). To limit the exposure of UVB radiation from the sun, the 
study was conducted between November 2014 to May 2015, and from October 2015 
to January 2016. It is noteworthy that 4 participants finished in early May 2015, 
however, their final vitamin D concentration was not significantly different from the 
remaining group. 
2.2.2 Sample size calculation  
As most RCTs designed to investigate the effect of vitamin D supplementation on 
CVD markers were powered using musculoskeletal outcomes, it is therefore 
important that the design of the present study is based on a CVD outcome. The study 
by (Witham et al., 2012) was the most relevant, as it demonstrated significant 
improvement in FMD at week 8 of vitamin D supplementation. Mean (±SD) FMD 
was significantly higher in the vitamin D group compared to the placebo group, 6.5 ± 
3.5 vs. 3.7 ± 3.1, (P = 0.007) in patients with a history of stroke and with baseline 
serum 25(OH)D concentration below 75nmol/L. Based on this study findings, a 
sample size of 58 (29 per group) that allows for the detection of a treatment 
difference at 95% power, 0.97 effect size and 5% significance was required for the 
present study. To allow for 15% dropout, 33 participants were required in each 
treatment arm, on this basis it was required to screen at least 90 overweight and 
obese adult males. Sample size was calculated using G power software version 3.1 
(G. Power, Düsseldorf, Germany).  
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2.2.3 Randomisation  
Randomisation of participants to the vitamin D or placebo group was performed by 
the third party, with the use of a computer generated random number sequence 
(www.randomisation.com). The tablets were packaged into white plastic coded, 
tamper-proof containers, and sealed in sequentially numbered study packs by the 
third party. Both investigator and participants were blinded from intervention.   
2.2.4 Supplement  
Vitamin D3 supplements containing 5,000IU (125µg) cholecalciferol, calcium 
phosphate, microcrystalline cellulose, magnesium stearate and silica was purchased 
from Bulk Powders, Colchester, UK. Placebo containing lactose was purchased from 
Placebo-world, Powys, UK. The vitamin D3 supplements and placebo were both in 
white tablet form. The dose (5000 IU) of vitamin D3 administered, has been safely 
used in previous intervention studies and it has been shown to significantly increase 
serum/plasma 25(OH)D concentration (Diamond, Wong, & Golombick, 2013; Yap 
et al., 2014; Yiu et al., 2013). Study participants were requested to store the study 
supplements at room temperature. Participants were requested to take one tablet at 
any time of day that was convenient, but to be consistent with the time over the 8 
weeks (56 days). Participants were sent email reminders about taking supplements.  
2.2.5 Assessment of compliance 
The percentage of compliance of the vitamin D3 supplement and placebo of the 49 
participants who completed the intervention was assessed by counting the number of 
tablets left in the containers at the end of the study period. The overall compliance 
was high, compliance was 90% in the vitamin D group and 87% in the placebo group 
and participants attributed missing 2 or more tablets to forgetfulness. No adverse 
events were reported from taking the supplements at the end of the study. 
Percentage compliance was calculated using the equation: 
% compliance = (actual/expected) × 100 
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2.2.6 Research centre  
The trial took place in the Clinical Sciences laboratory within the Department of 
Clinical Sciences and Nutrition at the University of Chester. Prior to commencement 
of the trial, the primary investigator was trained in phlebotomy and basic first aid. 
2.2.7 Participant recruitment 
Participants were recruited from the City of Chester, United Kingdom through the 
following methods: 
• Study posters/leaflets (appendix 3) were displayed on information boards 
at the library, café and lecture halls at the University of Chester.  
• Advert shared within University intranet and both University and local 
newspaper articles.  
• Through an announcement, on a local radio station. 
2.2.8 Inclusion criteria 
Participants were eligible if they were:  
• Males, aged between 18-65 years  
• Males who had a screening plasma 25(OH)D concentration of ≤ 75nmol/L.   
• Body mass index (BMI) > 24.9 kg/m2  
• Not taking vitamin D supplements. 
• Free of clinically diagnosed cardiometabolic, renal and hepatic diseases. 
2.2.9 Exclusion criteria 
The following participants were excluded: 
• Participants with clinical diagnosis of any cardiometabolic, renal, liver or 
gastrointestinal disease.  
• Participants with BMI < 24.9 kg/m2.  
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2.2.10 Clinics  
Clinics were carried out in the Clinical Laboratory at the University of Chester, 
participants attended 4 clinics in total (each lasting 30 minutes). 
 
• Screening clinic: Each participant was given a participant information sheet 
(PIS) (appendix 4) to read, followed by a written informed consent document 
(appendix 5) to sign. Participants were also requested to complete a screening 
questionnaire (appendix 6) after which weight and height were measured 
using a digital scale and wall mounted stadiometer to obtain BMI.  Following 
this, venous blood (1mL) was collected for vitamin D status screening to 
confirm eligibility for the study. Eligible participants with plasma 25(OH)D 
concentrations < 75 nmol/L were invited to partake in the study.   
• Clinic 1 (week 0): Weight, height, waist circumference (WC) and arterial 
function parameters including pulse wave velocity (PWV), augmentation 
index (AIx), aortic central systolic blood pressure (SBPao), return time (RT), 
systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), mean 
arterial pressure (MAP), brachial pulse pressure (PP), aortic pulse pressure 
(PPao), and left ventricle ejection duration (ED) measurements were 
performed. After this, venous blood (20 mL) was collected to assess the 
cardiometabolic risk biomarkers. Randomised supplements in coded 
containers were then distributed to participants. Participants were also 
requested to complete a 3day food diary (appendix 7) to return at the next 
clinic visit. 
• Clinic 2 (week 4): The procedure performed at clinic 1 was repeated in this 
clinic except for height measurement. Completed food diary was collected, 
and a new food diary was given to be returned at the final clinic. 
• Clinic 3 (week 8): Repeat of clinic 2.  
2.2.11 Measurements  
All measurements were performed between 8am and 10am (due to participants 
fasting for 8 hours beforehand) at day 0 (baseline) day 28 (interim) and day 56 (post 
intervention).  
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2.2.11.1 Anthropometric measurements 
Height measurement was performed using a digital wall mounted stadiometer (Seca, 
Hamburg, Germany) calibrated to the nearest 0.1cm precision. Participants removed 
shoes, stood straight facing forward, with the back of their head, shoulder blades, 
buttocks and heels touching the stadiometer. With feet flat and heels brought 
together, the head of the stadiometer was lowered so that hair was pressed flat and 
height was measured.   
Body weight was measured using a digital scale (Seca, Hamburg, Germany) 
calibrated to 0.1 kg. Prior to measurement, participants were requested to remove 
shoes, heavy outer garments and empty pockets. Measurement was taken with 
participants standing still at the centre of the platform, with a gap between heels and 
weight equally distributed on both legs, after which weight was recorded. BMI was 
calculated as weight in kilograms divided by the square of height in metre (kg/m2). 
Whilst participant was standing, WC was measured horizontally around the waist at 
the level of the umbilical cord using a tape measure. 
2.2.11.2 Arterial stiffness and haemodynamic measurements 
Arterial function parameters including pulse wave velocity (PWV), augmentation 
indices (brachial and aortic, AIx), central systolic blood pressure (SBPao), return 
time (RT), systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), 
mean arterial pressure (MAP), brachial pulse pressure (PP), central aortic pulse 
pressure (PPao), and left ventricle ejection duration (ED) were measured non-
invasively at baseline, 4 weeks (interim), and 8 weeks (post intervention) by the 
investigator with the use of a validated (Horvath et al., 2010) automatic oscillometric 
occlusive device known as the Arteriograph (TensioMed, Budapest, Hungary) 
Arteriograph -5-01,v 1.9.   
Arterial stiffness measurement was performed in a quiet room at 22 ± 1oC. Prior to 
measurement participants were given a glass of water and advised not to speak, sleep 
or move until measurement was complete. The distance between jugular (sternal) 
notch and symphysis pubis (distance between the aorta and its bifurcation) was 
measured with participant standing upright using a tape measure. Participants were 
allowed to rest for 10 minutes in a supine position, after which an appropriate cuff 
was placed tightly round the right arm. Three measurements were performed, each 
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lasting 2-3 minutes, with the mean of the last 2 readings recorded. After a 
measurement was taken, the standard deviation (SD) of the PWVao was consulted to 
inform the investigator about the quality of the measurement. If the SD PWVao was 
greater than or equal to 0 and less than or equal to 1.0m/s, the measurement was 
accepted as it was of good quality. However, if the SD PWVao was greater than 
1.0m/s, or appears in red, the measurement was discarded, as it was of unacceptable 
quality and measurement would be repeated. 
Upon operation, the simple upper arm cuff that picks up pressure signal was inflated 
to a pressure 35 mmHg over the SBP. This completely occludes the brachial artery in 
a stop flow condition, and pressure signals are transmitted through the cuff to the 
pressure sensor and are reported to show multiple peaks. As central pressure 
changes, early (direct) systolic wave (P1), late (reflected) systolic wave (P2) and 
diastolic wave (s) (P3) reach the upper arm and cause very small volume pressure 
changes in the cuff. These very small changes are recorded by a high-fidelity 
pressure sensor in the device and transmitted to the edge-position sensor by conduit 
arteries including the subclavian, axillary, or brachial. Arteriograph first measures 
the actual SBP and DBP, then cuff is deflated, and after few seconds cuff is inflated 
again, first to the actual DBP, then to the suprasystolic (actually measured systolic + 
35 mmHg) pressure. Pressure signals are then recorded for 8 s -10 s, after which they 
are transmitted wireless to notebook PC. The data analysis is performed by the 
software of the device. To determine PWVao, arteriograph measures the time 
interval between the peaks of the direct (first) and reflected (late) systolic wave 
(return time – RT). The PWVao was calculated using the formula: PWVao (m/s) = 
Jug-Sy (m) / (RT/2 (s). Augmentation indices were calculated for the aorta and 
brachial arteries using the formula: AIx (%) = (P2-P1)/PP x 100. Where P1 is the 
amplitude of the first (direct) wave, P2 is the amplitude of the late (reflected) systolic 
wave and PP is the pulse pressure.  
2.2.12 Dietary assessment 
To obtain dietary information, 2 copies of a 3-day food diary was given to each 
participant at clinic 1 and 2 to record their eating and drinking on 2 weekdays and 1 
weekend day. This includes food and drink consumed between meals or at night, 
they were also requested to write the day, time, description of meal or drink, portion 
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size and preparation method as well as brand product or recipe as appropriate. 
Participants were also requested to record food that came with any added vitamin or 
minerals. For homemade dishes, they were requested to record the name of the 
recipe, ingredients with the amount and cooking method at the back page of the 
diary. Dietary nutrient analysis software Nutritics v4.25 (Nutritics, Dublin, Ireland) 
was used to estimate mean daily energy, carbohydrate, protein, fat and vitamin D 
intake based on reported consumption from the 3-day food diary. 
2.2.13 Blood sampling 
A fasted (overnight of at least 8 hours) morning (between the hours of 8am and 
10am) whol e blood sample was collected by venepuncture by the investigator from 
the median cubital vein according to standard protocols (appendix 7). Blood samples 
were drawn using a 21g vacutainer needle into 10 mL sterile lithium heparin and 
EDTA tubes to avoid clotting. The collected blood samples were immediately 
transferred into an ice box. Plasma was separated by centrifuging for 10 min at 4ºC at 
2054g. The centrifuged plasma was aliquoted into tubes labelled with participants’ 
ID number and dates, and stored at -80ºC until batch analysis. The first batch analysis 
was performed from May to September 2015 and the final batch analysis between 
December and February 2016. 
2.2.14 Biochemical measurements 
Material Safety Data sheets and COSHH information were adhered to for each 
analyte. Prior to the experiments all reagents, microplate wells, and samples were 
brought to room temperature according to appropriate kit instruction booklet. To 
avoid cross contamination, pipette tips were changed during each standard 
preparation, and screw caps were also not interchanged. Multiple freeze thawed 
samples were not used, and all ELISAs were performed in duplicate. To ensure 
accurate results, only calibrated pipettes were used, kits were used before expiration 
date and reagents were not mixed with those from other sources or lots. Plasma 
samples which had concentrations that exceeded the highest standard were further 
diluted and repeated.  
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Prior to use of each ELISA kit, a QC was run 8 times to obtain the intra-assay CV, 
and the inter-assay CV was obtained from running commercial control assay. The 
CVs were calculated using the formula:   
  
                                                                                      
2.2.14.1 Endothelial function   
2.2.14.1.1 Plasma sE-selectin concentration determination 
Plasma sE-selectin concentration (collected in heparin tubes) was determined using a 
quantitative sandwich enzyme immunoassay quantikine solid-phase ELISA kit 
(R&D Systems Europe, Abingdon, UK). The 96 well plates were pre-coated with a 
monoclonal antibody specific for naturally occurring human sE-selectin. Prior to 
assay, all samples were diluted 10-fold (30 µL of sample and 270 µL of calibrator 
diluent) to yield a final volume of 300 µL. Wash buffer (20 mL) concentrate was 
diluted by adding 480 mL of deionised water to yield a final volume of 500 mL. 
Substrate solutions (Colour A+B) were mixed together in equal volumes within 15 
minutes of use and protected from light. The standard was reconstituted with 1.0 mL 
of deionised water and allowed to sit for at least 15 minutes before making serial 
dilutions.  
Following sample and reagent preparation, assay diluent (100 µL) was pipetted into 
each well. Standard, control, and sample (100µL each) were pipetted into appropriate 
wells, which were covered with adhesive strip and incubated for 2 hours. Following 
incubation, wells were decanted and washed four times manually with 400 mL wash 
buffer. After the final wash, the microplate was inverted and blotted dry against 
absorbent paper towels. Conjugate (200 µL) was pipetted into each well and 
incubated for another 2 hours. After incubation, wells were washed four times and 
blotted dry against absorbent paper towels. Substrate solutions (colour A+B) (7 mL 
each) were mixed thoroughly, after which, 200 µL each of the mix was pipetted into 
wells, the microplate was covered with foil paper to protect from light and left to 
incubate for 30 minutes. Following incubation, 50 µL of stop solution was pipetted 
into each well and plate was tapped gently on bench top to ensure thorough mixing. 
The optical density of each well was determined within 30 minutes at 450nm 
× 100CV = 
S.D 
Mean 
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(primary) and 570nm (reference) and the sE-selectin concentration was obtained 
from the standard curve (see appendix 8 for example standard curve). Obtained 
concentrations were multiplied by the corresponding dilution factor. Intra and inter 
assay coefficient of variation (CV) were 3.4% and 3.4% respectively. 
2.2.14.2 Oxidative stress  
2.2.14.2.1 Plasma 8 - Isoprostane concentration determination 
A competitive in vitro immuno-enzymatic assay was used for the determination of 8-
isoprostane concentration (Abcam, Cambridge, UK) in plasma. Prior to the assay, 10 
x wash buffer was mixed with a stir bar whilst applying low gentle heat until a clear 
colorless solution was obtained. Following this, 25 mL wash buffer solution was 
diluted with 225 mL of deionised water to yield a final volume of 250 mL. One vial 
of horseradish peroxidase (HRP) conjugate (12 µL) was diluted with 12 mL of HRP 
buffer to prepare the 1x HRP conjugate. Sample dilution (25 mL) buffer was diluted 
with 225 mL deionised water to yield a final volume of 250 mL. The enclosed 2 µL 
standard vial filled with inert gas was first centrifuged, before 1.998 mL of 1 x 
sample dilution buffer was added to obtain a 2 mL stock solution. Several serial 
dilutions were made from the stock solution 
Following reagent preparation, 200 µL of 1x sample dilution buffer was pipetted into 
blank wells, 100 µL of 1x sample dilution buffer was pipetted into maximum binding 
control wells. Standard, sample or control (100 µL each) was pipetted into the 
appropriate wells. HRP conjugate (100 µL) was pipetted into all wells except blank 
control wells, which wells were covered with adhesive strip and incubated for 2 
hours. Following incubation, wells were washed manually three times with 400 µL 
wash buffer. After the final wash, the microplate was inverted and blotted dry on 
clean absorbent paper towels. After drying microplate, 200µL of 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate was pipetted into all wells, and incubated for 
15-30 minutes at room temperature. Sulphuric acid (2N, 50 µL) was pipetted into all 
wells, mixed thoroughly before optical density was obtained within 30 minutes at a 
wavelength of 450nm (primary) and 570nm (reference). The concentration of 8-
isoprostane was obtained from the standard curve (see appendix 9 for example 
standard curve). The intra and inter assay CV was 5.9% and 11.1% respectively. 
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2.2.14.3 Lipid profile  
2.2.14.3.1 Plasma TAG concentration determination 
The quantitative enzymatic TAG determination kit measured glycerol, true and total 
TAG concentration in plasma (Sigma-Aldrich, Dorset, UK). Prior to the assay, free 
glycerol reagent (powder) was reconstituted by adding 40 mL of deionised water, the 
solution was mixed thoroughly by inversion and protected from light using foil. TAG 
reagent (powder) was reconstituted by adding 10 mL of deionised water. The 
solution was mixed thoroughly by inversion and protected from light using foil. 
Spectrophotometer wavelength was set at 540nm and water was used as reference.  
Following reagent preparation, 800 µL of free glycerol reagent was pippeted into 
each cuvette. Water, standard, sample and control (10 µL each) were pipetted into 
labelled cuvettes respectively and incubated for 5 minutes at 37oC. Initial absorbance 
(IA) of blank, standard, sample and control were read at 540nm versus water as 
reference. After reading, 200 µL of reconstituted TAG reagent was pippeted into 
each cuvette, mixed thoroughly by inversion and incubated for a further 5 minutes. 
Final absorbance (FA) was read after last incubation at 540 nm versus water as 
reference. 
Concentrations of total TAG were calculated using the formula: 
(FAsample – FAblank)         
(FAstandard – FAblank) 
Intra and inter assay CV for TAG were 2.6% and 6.2% respectively 
2.2.14.3.2 Plasma HDL-C concentration determination  
Plasma HDL-C was measured using a quantitation kit (Sigma-Aldrich, Dorset, UK). 
Samples for HDL-C were first separated by adding equal volumes of precipitation 
buffer (100 µL) with sample (100 µL). The mixture was micro-centrifuged for 10 
minutes at 2000 x g to ensure proper mixing, followed by incubation for 10 minutes. 
After incubation, tubes were further centrifuged for 10 minutes at room temperature, 
after this, the supernatant or HDL fraction was transferred to a new tube. Cholesterol 
standard solution (20 µL) was diluted with 140 µL cholesterol assay buffer to yield a 
0.25 µg/µL standard from which serial dilutions were prepared. Cholesterol esterase 
× concentration of standard 
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and enzyme mix were reconstituted separately by adding 220 µL of cholesterol assay 
buffer to each. The reaction mix contains 44 µL of cholesterol assay, 2 µL each of 
cholesterol probe, reconstituted cholesterol esterase and enzyme mix to yield a final 
volume of 50 µL. 
Following sample and reagent preparation, sample (50 µL) and reaction mix (50 µL) 
were pipetted into each microplate well. This was thoroughly mixed using a 
horizontal plate shaker and incubated for 60 minutes at 37oC whilst protected from 
light. Optical density was read at 570nm. HDL-C concentrations were obtained from 
standard curve (see appendix 9 for example standard curve), obtained concentrations 
were multiplied by the corresponding dilution factor. 
Intra and inter assay CV were 3.4% and 8.1% respectively. 
2.2.14.3.3 Plasma Total cholesterol (TC) concentration determination 
The enzymatic-colorimetric cholesterol liquid (Alpha Laboratories, Eastleigh, UK) 
was used to determine TC concentration in plasma. Prior to the assay, 3 mL of 
deionised water was added to calibrator (lyophilised serum) to make a solution from 
which serial dilutions were produced. After this, 3 µL of standard, control and 
sample were pipetted into appropriate sterilised wells followed by the addition of 
reagent 1 (300 µL).  Following this, microplate was incubated for 10 minutes, after 
incubation, optical density was obtained at a wavelength of 505nm (primary) and 
700nm (reference). TC concentrations were obtained from the standard curve (see 
appendix 11 for example standard curve). Intra and inter assay CV were 5.2% and 
6.4% respectively. 
2.2.14.3.4 Plasma LDL-C concentration determination 
LDL-C concentration was determined using Friedewald formula (Friedewald, Levy, 
& Fredrickson, 1972). 
Plasma LDL-C = Plasma TC – Plasma HDL-C – (TRG/2.2) 
2.2.14.3.5 Plasma Non-High Density Lipoprotein-C (non-HDL-C) concentration 
determination  
Non –HDL-C concentration was determined using the formula: Non-HDL-C = TC - 
HDL-C. 
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2.2.14.4 Renin angiotensin system   
2.2.14.4.1 Plasma renin concentration determination 
Renin concentration in plasma was determined using a solid-phase quantitative 
sandwich ELISA kit (R&D Systems Europe, Abingdon, UK) pre-coated with a 
monoclonal antibody specific for human renin. Prior to the assay, all samples were 
diluted two-fold (sample (75µL) and calibrator diluent (75µL). Wash buffer was 
mixed gently until the crystals dissolved, after mixing, 20 mL was diluted with 480 
mL of deionised water to yield a final volume of 500 mL. Substrate solutions (colour 
A+B) were mixed together in equal volumes within 15 minutes of use and protected 
from light. Calibrator diluent was diluted 1:5 fold with deionised water, standard was 
reconstituted with 1.0 mL of deionised water to produce a stock solution, and was 
allowed to sit for 15 minutes before making serial dilutions. 
Following sample and reagent preparation, 100 µL of assay diluent was pipetted into 
each well. Standard, control, and sample (50 µL each) were also pipetted into 
appropriate wells, which were covered with adhesive strip and incubated for 2 hours. 
After incubation, wells were decanted, washed 3 times manually with wash buffer 
(400 mL) and blotted dry against clean absorbent paper towels. Renin conjugate (200 
µL) was pipetted into each well, and incubated for 2 hours. Following incubation, 
wells were washed and blotted dry. After washing, 200 µL substrate solution was 
pipetted into each well, covered with adhesive strip and foil to protect from light and 
incubated for 30 minutes. Stop solution (50 µL) was pipetted into wells and the plate 
was tapped gently on bench top to ensure thorough mixing. Following thorough 
mixing, optical density was determined within 30 minutes at a wavelength of 450nm 
(primary) and 570nm (reference). Renin concentrations were obtained from a 
standard curve (see appendix 9 for example standard curve). Obtained concentrations 
were multiplied by the corresponding dilution factor. The intra and inter assay CV 
were 8.9 % and 5.3% respectively. 
2.2.14.4.2 Plasma angiotensin II concentration determination 
Plasma angiotensin II concentration was determined using a competitive enzyme 
immunoassay kit (Sigma-Aldrich, Dorset, UK). Assay diluent E (50 µL) was added 
to centrifuged anti-angiotensin II detection antibody to prepare the detection 
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antibody concentrate. The solution was mixed thoroughly and further diluted 100-
fold (50:4950 µL) with assay diluent E to prepare the anti-angiotensin II antibody 
working solution. Biotinylated angiotensin II peptide (10 µL) was added to assay 
diluent E (5 mL) to prepare 20 g/ mL biotinylated angiotensin II. Standard (8 µL) 
was added to 20 pg/ mL biotinylated angiotensin II (792 µL) to prepare angiotensin 
II stock solution from which serial dilutions were made. 
Following reagent preparation, 100 μL anti-target antibodies were pipetted into each 
well, which were covered with adhesive strips and incubated for 1.5 hours at room 
temperature with gentle shaking (1-2 cycles/sec) using a microplate shaker. Wells 
were washed 4 times with 300μL wash buffer. After the wash, wells were blotted dry 
against absorbent paper towels. Standard, control, blank and samples (100 μL each) 
were pipetted into appropriate wells which were covered with adhesive strips and 
incubated for 2.5 hours at room temperature with gentle shaking (1-2 cycles/sec). 
Following incubation, 100μL of HRP-streptavidin solution was pipetted into each 
well and incubated for 45 minutes with gentle shaking at room temperature. After 
incubation, wells were washed 4 times with 300 μL of wash buffer. After the final 
wash, wells were decanted and blotted dry against absorbent paper towels. TMB 
(100μL) was pipetted into each well and incubated for 30 minutes at room 
temperature in the dark with gentle shaking (1-2 cycles/sec). Stop solution (50μL) 
was pipetted into each well and optical density was read immediately at 450 nm. 
Angiotensin II concentrations were obtained from the standard curve (see appendix 9 
for example standard curve). Intra and inter assay CV were 9.5% and 8.9 % 
respectively. 
2.2.14.5 Bone health markers 
2.2.14.5.1 Total plasma 25(OH)D concentration determination 
Plasma total 25(OH)D was measured using mini VIDAS® (BioMẻrieux, Hampshire, 
UK), a compact multi-parametric automated immuno-analyser based on the enzyme 
linked fluorescent assay principles. The 25(OH)D total assay kit contained a ready to 
use solid phase receptacle (SPR) and stabiliser strips coated with vitamin D. Plasma 
(100 µL) was pipetted into each SPR well and inserted in machine. After 40 minutes 
run time, 25(OH)D concentration was obtained. The intra and inter assay CV were 
2.0 % and 7.3 % respectively. 
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2.2.14.5.2 Plasma 25(OH)D concentration determination (ELISA). 
The competitive binding solid phase direct sandwich ELISA kit (Calbiotech, Spring 
valley, USA) precoated with anti-vitamin D antibody, quantitatively determined 
25(OH)D concentration in plasma. The ELISA kit was only used for plasma samples 
with a 25(OH)D concentration ˂ 20.3 nmol/L which could not be detected by the 
automated analyser. Wash buffer (25 mL) was pipetted into 475 mL deionised water 
to yield a final volume of 500 mL. Prior to use, 1x working solution was diluted by 
adding 0.1 mL of the 51x vitamin D-biotin conjugate concentrate to 5 mL of assay 
diluent. 
Following reagent preparation, 10 µL of standards, controls and samples were 
pipetted into appropriate wells. Biotinylated 25(OH)D (200 µL) was pipetted into 
each well, mixed for 20 seconds using a plate shaker set to 300 rpm, covered with an 
adhesive strip, and incubated for 90 minutes at room temperature. Wells were 
washed 3 times with 300 µL of wash buffer, decanted and blotted dry on absorbent 
paper towels. Enzyme conjugate (200 µL) was pipetted into each well, which were 
covered with adhesive strip and incubated for 30 minutes at room temperature. After 
incubation, 200 µL of TMB substrate was pipetted into each well and incubated in 
the dark for 30 minutes at room temperature. Stop solution (50 µL) was pipetted into 
each well, mixed on a shaker for 20-30 seconds. After mixing, optical density was 
determined within 10 minutes at a wavelength of 450nm. Concentrations of 
25(OH)D were obtained from standard curve (see appendix 9 for example standard 
curve). Intra and inter assay CV were 11.3 and 3.6 % respectively. 
2.2.14.5.3 Plasma PTH concentration determination 
A solid phase direct sandwich ELISA kit (Calbiotech, Spring valley, USA) precoated 
with streptavidin, quantitatively determines PTH concentration in plasma. Prior to 
the assay, 25 mL of 1x wash buffer was added to 475 mL deionised water to yield a 
final volume of 500 mL. Stock enzyme conjugate (0.5 mL) was added to assay 
diluent (9.5 mL). 
Following reagent preparation, standard, blank, control and samples (25 µL each) 
were pipetted into appropriate wells. Anti-PTH-biotin reagent (50 µL) and anti-PTH- 
HRP conjugates (50 µL) were pipetted into all wells respectively. The microplate 
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was covered with adhesive strip and incubated at room temperature on a plate shaker 
set at 500-600 rpm for 90 minutes.  
Following incubation, wells were washed 4 times with 300 µL wash buffer, decanted 
and blotted dry on clean absorbent paper towels. Following the wash step, 100 µL of 
TMB substrate was pipetted into all wells, and incubated for 15 minutes at room 
temperature. Stop solution (50 µL) was pipetted into each well and optical density 
was determined within 15 minutes at a wavelength of 450nm (primary) and 630nm 
(reference). PTH concentrations were obtained from a standard curve (see appendix 
9 for example standard curve).  Intra and inter assay CV were 4.7% and 2.6% 
respectively. 
2.2.14.6 Inflammation  
2.2.14.6.1 Plasma hs-CRP concentration determination 
A solid phase direct sandwich ultra-sensitive ELISA kit (Calbiotech, Spring valley, 
USA) precoated with anti-CRP monoclonal antibody, quantitatively determined hs- 
C reactive protein concentration in plasma. Prior to the assay, samples and controls 
were diluted 1:100 fold by adding 5 µL of sample to 495 µL sample diluent. Wash 
buffer (25 mL) was added to 475 mL deionised water to yield a final volume of 500 
mL. 
Following reagent preparation, 10 µL standard, blank, control and sample were 
pipetted into appropriate wells. Enzyme conjugate (100 µL) was pipetted into each 
well, which were covered with adhesive strip, tapped gently on bench top to ensure 
thorough mixing and incubated for 1 hour at room temperature. Wells were washed 
three times with 300 µL wash buffer, decanted and blotted dry on absorbent paper 
towels. TMB substrate (100 µL) was pipetted into all wells, and incubated for 15 
minutes at room temperature. Stop solution (50 µL) was pipetted into each well, after 
which optical density was determined within 15 minutes at a wavelength of 450nm. 
Concentration of hs-CRP were obtained from standard curve (see appendix 9 for 
example standard curve), and obtained concentration was multiplied by the 
corresponding dilution factor. The intra and inter assay CV were 6.0% and 2.3% 
respectively. 
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2.2.14.7 Metabolic disease  
2.2.14.7.1 Plasma insulin concentration determination  
The solid phase direct sandwich ELISA kit (Calbiotech, Spring valley, USA) pre-
coated with anti-insulin monoclonal antibody, quantitatively determined insulin 
concentration in plasma.  Prior to experiment, 25 mL of wash buffer was added to 
475 mL deionised water to yield a final volume of 500 mL. Stock enzyme conjugate 
(0.5 mL) was added to 9.5 mL assay diluent. 
Following reagent preparation, 25 µL standard, blank, control and sample were 
pipetted into appropriate wells. Enzyme conjugate (100 µL) was pipetted into each 
well, which were covered with adhesive strip, mixed by tapping gently for 10 
seconds on bench top and incubated for 60 minutes at room temperature. After 
incubation, wells were washed 3 times with 300 µL wash buffer, wells were 
decanted and blotted dry on absorbent paper towels. TMB substrate (100 µL) was 
pipetted into all wells, and incubated for 15 minutes at room temperature.  After 
incubation, 50 µL of stop solution was added to each well and optical density was 
determined within 15 minutes at a wavelength of 450nm. Sample concentrations 
were obtained from a standard curve (see appendix 9 for example standard curve) 
and obtained concentration was multiplied by the corresponding dilution factor. The 
intra and inter assay CV were 3.4% and 8.9% respectively. 
2.2.14.7.2 Plasma glucose concentration determination 
Fasting plasma glucose concentration was quantitatively determined using a 
colorimetric enzyme reagent kit (Alpha Laboratories, Eastleigh, UK). Prior to the 
assay, 1 vial of chromogen reagent containing mutarotase, glucose oxidase, 
peroxidase, 4-Aminoantipyrine and ascorbate oxidase was dissolved in 150 mL 
buffer. Following reagent preparation, 2 µL of standard, blank, sample and control 
were pipetted into appropriate wells and 300 µL of prepared chromogen reagent was 
pipetted into all wells and incubated for 5 minutes. Following incubation, optical 
density of glucose was obtained from a standard curve (see appendix 9 for example 
standard curve). The intra and inter assay CV was 3.0%. and 5.3% respectively 
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2.2.14.7.3 Insulin resistance 
The homeostasis model assessment of insulin resistance (HOMA-IR) (Haffner, 
Kennedy, Gonzalez, Stern, & Miettinen, 1996), was used to evaluate insulin 
resistance and HOMA was calculated from the formula: HOMA-IR = (fasting 
glucose conc. (mmol/L) × fasting insulin conc (mU/L)/22.5. 
2.2.15 Statistical analysis 
Data analysis was performed using IBM SPSS statistics software (IBM SPSS version 
22, NYC, USA), and statistical significance was accepted at P ˂ 0.05. For continuous 
variables including the arterial function and biochemical parameters, descriptive 
statistics were calculated and reported as mean ± standard deviation (SD). 
Continuous variables were first assessed for normal distribution using Shapiro Wilks 
and homogeneity of variance was assessed by Levenes statistics. Difference in 
baseline characteristics were assessed using independent t- test, and a Mixed Model 
ANOVA was performed to assess changes between week 0, 4 and 8 for continuous 
variables including BMI, weight, SBP, DBP, MAP, HR, RT and non-HDL-C. 
Independent t- test was also used to assess continuous variables that were normally 
distributed with a homogenous variance between groups at either baseline, 4 or 8 
weeks but not at all 3 time points such as in angiotensin II, LDL-C, TC, TAG and 
PWV(week 0 and 4), as well as  PP (week 4 and 8) and PPao (week 0 and 8). Mann 
Whitney U-test was used to assess continuous variables that were not normally 
distributed between groups such as in 25(OH)D, PTH, renin, sE-selectin, 8-
isoprostanes, HDL-C, hs-CRP, glucose, insulin, SBPao, HOMA-IR, WC and AIX 
(peripheral and central) (at all 3 time points) and Angiotensin II, LDL-C, TC, TAG 
and PWV (all at week 8). The assessment of PP, PPao and PWV at week 0, 4 and 8 
respectively was performed using Mann Whitney U-test.  
A paired students t-test was used to assess normally distributed repeated measures at 
week 0, 4 and 8 such as angiotensin II, LDL-C, TC, non-HDL-C, TAG at week 0 and 
4), WC, PP, 25(OH)D, hsCRP and SBPao at week 4 and 8, PPao (week 8). 
Wilcoxon’s t-test was used to assess non-normally distributed repeated measures at 
week 0, 4 and 8 such as glucose, PTH, renin, sE-selectin, insulin, HDL-C, AIX 
(peripheral and central). The continuous variables including WC, PP, 25(OH)D, 
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hsCRP and SBPao WC at week 0, PPao (week 0 and 4) and angiotensin II, LDL-C, 
TC, NHDL-C, TAG at week 8 were also assessed using Wilcoxon’s t-test. 
Association between changes in 25(OH)D at week 4 and 8 with corresponding 
changes in PWV, MAP, SBP, DBP, SBPao, PPao, HR, RT, TC, non-HDL-C, hs-
CRP, sE-selectin, ang II, PTH, BMI, weight, as well as 8 week changes in HDL-C 
and PP and 4 week changes in AIX were all assessed using Pearson's correlation 
coefficient. In addition, the association of 4 and 8 week change in 25(OH)D with 
corresponding changes in TAG, HOMA-IR and insulin, 4 week change PP and HDL-
C as well as 8 week change in AIX were determined using Spearmann`s correlation 
coefficient. 
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2.3 RESULTS 
Of the 91 potential participants that were screened for eligibility, 78 were eligible, 23 
out of the 78 did not attend clinic 2, and hence a total of 55 males were randomised 
to the intervention (28 in the vitamin D group and 27 in the placebo group). During 
the intervention 6 participants were lost to follow-up leaving 49 participants which 
include 7 Africans, 2 Asians and 40 Caucasians (25 in the vitamin D group and 24 in 
the placebo group) to complete the study (Fig 2.3.1.). The rate of compliance was 
high, 90% in the vitamin D group and 87% in the placebo group. No adverse events 
were reported from taking the supplements at the end of the study.  
2.3.1 Baseline characteristics 
There were no significant differences in baseline characteristics between groups 
including age, body weight, BMI, waist circumference, HOMA plasma 25(OH)D, 
PTH, hs-CRP, 8-Isoprostanes, insulin, renin and angiotensin II concentrations except 
for the vitamin D group having a slightly higher mean (±SD) plasma glucose 5.23 ± 
1.45 vs. 4.75 ± 0.82 mmol/L, (P = 0.025) compared to placebo (Table 2.3.1). There 
were also no significant differences in mean baseline plasma sE-selectin, and the 
haemodynamic parameters (Table 2.3.2), as well as baseline TC, non-HDL-C, HDL-
C, LDL-C and TAG (Table 2.3.3). 
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Fig.2.3.1. Study flow diagram of participants in the trial 
 
 
 
Exclusions 
• Not meeting inclusion criteria (n = 13). 
• Declined to participate (n = 17). 
• Other reasons (n = 6) 
 
 
 
Randomised (n = 55) 
 Randomised to vitamin D (n = 28) 
Attended clinic 3 (n = 24) Attended clinic 3 (n = 25) 
Lost to follow up (n = 3) 
 Randomised to placebo (n = 27) 
Attended clinic 4 (n = 24) 
Assessed for eligibility (n = 91) 
Lost to follow up (n = 3) 
Attended clinic 4 (n = 25) 
Analysed (n = 24) Analysed (n = 24) 
Excluded due to non- compliance (n = 1) 
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Table 2.3.1 Baseline characteristics of study participants 
Parameters Vitamin D 
(n = 24) 
Placebo 
(n = 24) 
P Normal ranges References  
Age (years) 35.9 ± 11.8 33.1 ± 12.2 0.248             -  
Body weight (kg) 92.4 ± 10.3 90.4 ± 19.3 0.378             -  
Body mass index (kg/m2) 29.9 ± 3.3 28.4 ± 2.6 0.071 18.5 - 24.9 kg/m2 (Caballero, 2007) 
Waist circumference (cm) 93.5 ± 22.1 91.3 ± 8.0 0.085 ˂ 102 cm (Bei‐Fan, 2002) 
Plasma 25(OH)D (nmol/L) 38.4 ± 15.9 43.9 ± 19.5 0.544 ≥ 75 nmol/L  (Holick, 2007) 
Plasma PTH (pmol/L) 4.3 ± 3.5 4.2 ± 2.8 0.917 1.1-6.8 pmol/L  (Lombardi et al., 2008) 
Plasma insulin (pmol/L) 46.5 ± 27.7 42.1 ± 37.0 0.160 ˂ 174 pmol/L  (Clore, Post, Bailey, Nestler, & Blackard, 1992) 
HOMA-IR 1.6 ± 1.3 1.4 ± 1.6 0.068 1.7- 2.0  (Gayoso-Diz et al., 2013) 
Plasma glucose (mmol/L) 5.2 ± 1.5 4.8 ± 0.8 0.025 ˂ 5.6 mmol/L  (Tirosh et al., 2005) 
Plasma 8-Isoprostanes (pg/ml) 11.2 ± 8.7 8.9 ± 5.7 0.449 35 ± 6 pg/ml (Milne et al., 2007) 
Plasma hs- CRP (mg/L) 2.9 ± 1.9 2.8 ± 2.1 0.480 ˂ 1.0 mg/L (Buckley, Fu, Freeman, Rogers, & Helfand, 2009) 
Plasma renin (pg/mL) 639.8 ± 294 695.1 ± 410.7 0.716 
 
201-1852 pg/ml R&D systems 
Plasma angiotensin II (pg/mL) 32.3 ± 9.6 31.8 ±  9.8 0.810  27 ± 4 pg/ml (Arnold et al., 2013) 
Values are presented as mean ± standard deviation 
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Mean baseline plasma 25(OH)D concentration in both groups was below the normal 
range of  ≥ 75 nmol/L (Holick, 2007) and mean baseline plasma PTH in both groups 
was within the normal range of 1.1-6.8 pmol/L (Lombardi et al., 2008). Fasting mean 
plasma glucose concentration in both groups were within the normal range of ˂ 
5.55mmol/L (Tirosh et al., 2005), fasting mean plasma insulin concentration in both 
groups were also within the normal range of ˂ 174 pmol/L (Clore et al., 1992). Mean 
HOMA-IR in the present study ranged from 1.4-1.6 which were below the normal 
range of 1.7-2.0 (Gayoso-Diz et al., 2013). Mean baseline plasma 8-Isoprostanes 
concentrations in both groups were within the normal concentrations of 8-
Isoprostanes in human plasma 35 ± 6 pg/mL (Milne et al., 2007). Mean baseline 
plasma renin concentrations of participants in both groups were also within the 
normal range of 201-1852 pg/ml, however, the mean baseline plasma angiotensin II 
concentrations of participants in both groups were comparable to the normal range of 
27 ± 4 pg/mL (Arnold et al., 2013). Mean baseline plasma hs-CRP concentration in 
both groups were above the normal range ˂ 1.0 mg/L (Buckley et al., 2009). 
Participants` mean baseline SBP and DBP in both groups were less than the value for 
hypertension (>140 mmHg SBP and/or 90 mmHg DBP) (Lopez, Mathers, Ezzati, 
Jamison, & Murray, 2006; Mancia et al., 2013). Mean baseline PWV in both groups 
was within normal reference of ˂ 9.0m/s (Tensiomed, 2016), however, brachial 
augmentation index normal reference are unknown. Central or aortic augmentation 
index at baseline for both group were within the normal reference ˂33% (Tensiomed, 
2016). Mean baseline aortic central systolic blood pressure for both group were well 
within the normal range of ˂ 140 mmHg (Tensiomed, 2016). Mean baseline 
references for aortic central pulse pressure for both groups were well within the 
normal values of ˂ 50 mmHg (Tensiomed, 2016). Mean baseline return time for both 
groups were within the normal reference of  > 124m/s (Tensiomed, 2016) and mean 
baseline values for heart rate for both groups also were within the normal resting 
heart rate of 40-100 bpm (Lin et al., 2010). Although the normal range for brachial 
pulse pressure is not known, Lokaj et al., has suggested values ˂ 55 mmHg as normal 
and participants fell within this normal range (Lokaj et al., 2011). Mean arterial 
pressure was within the normal range of 70 -105 mmHg (Hohn et al., 2013). Mean 
baseline plasma concentrations of sE-selectin are not comparable with the normal, as 
the normal concentration for sE-selectin is undefined (Table 2.3.2).  
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Table 2.3.2 Baseline markers of endothelial function, blood pressure and arterial stiffness indices 
Parameters Vitamin D 
(n = 24) 
Placebo 
(n = 24) 
P Normal ranges References  
SBP (mmHg) 128.7 ± 11.1 131.2 ± 12.8 0.730 90-139 mmHg (Mancia et al., 2013) 
DBP (mmHg) 77.0 ± 9.7 78.0 ± 12.9 0.797  60-89 mmHg (Mancia et al., 2013) 
PP (mmHg) 53.6 ± 9.2 53.8 ± 9.2 0.846  Not known              - 
MAP (mmHg) 95.1 ± 9.1 95.9 ± 12.0 0.796 70-105 mmHg (Hohn et al., 2013) 
PWV (m/s) 6.5 ± 1.1 6.5 ± 1.1 0.802 ˂ 9.0m/s (Tensiomed, 2016) 
AIx (%) -48.6 ± 25.9 -51.5 ± 22.2 0.953 Not known               - 
AIxao (%) 12.6 ± 13.4 12.7 ± 13.6 0.940 ˂33%          (Tensiomed, 2016) 
SBPao (mmHg) 118.5 ± 12.9 119.5 ± 16.9 0.873 ˂ 140 mmHg (Tensiomed, 2016) 
PPao (mmHg) 41.6 ± 8.8 41.3 ± 8.7 0.927 ˂ 50 mmHg (Tensiomed, 2016) 
Heart rate (bpm) 62.3 ± 12.3 60.9 ± 10.8 0.635 40-100 (Lin et al., 2010) 
Return time (m/s) 153.3 ± 24.4 157.6 ± 24.9 0.443 > 124 m/s (Tensiomed, 2016) 
Plasma sE-selectin (ng/mL) 57.9 ± 31.1 57.5 ± 18.9 0.312 Not known             - 
Values are presented as mean ± standard deviation         
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Table 2.3.3. Baseline lipid profile markers 
Parameters Vitamin D 
(n = 24) 
Placebo 
(n = 24) 
P Normal ranges References 
Plasma TC (mmol/L) 6.5 ± 1.5 6.4 ± 1.6 0.758 ˂ 5.2 mmol/L (Glasziou, Irwig, Heritier, Simes, & Tonkin, 
2008) 
Plasma TAG (mmol/L) 1.7 ± 0.4 1.7 ± 0.3 0.665 ˂ 1.7 mmol/L (Alberti, Zimmet, & Shaw, 2006). 
Non- HDL-C (mmol/L) 6.3 ± 1.8 6.2 ± 2.2 0.893 ˂ 3.4 mmol/L (Blaha, Blumenthal, Brinton, Jacobson, & 
Cholesterol, 2008). 
Plasma HDL-C (mmol/L) 0.6 ± 0.1 0.7 ± 0.2 0.814 1.0-1.3 mmol/L in men (Glasziou et al., 2008). 
LDL –C (mmol/L) 5.2 ± 1.5 5.0 ± 1.6 0.719 ˂ 2.6 mmol/L (Glasziou et al., 2008). 
Values are presented as mean ± standard deviation 
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Mean baseline plasma HDL-C concentrations for both groups were below the normal 
range of 1.0-1.3 mmol/L for men (Glasziou et al., 2008), and mean baseline LDL-C 
mean concentrations for both groups were above the normal range of ˂ 2.6 mmol/L 
(Glasziou et al., 2008). Mean baseline plasma TC concentrations for both groups 
were above the normal range of ˂ 5.2 mmol/L (Glasziou et al., 2008). Mean plasma 
non-HDL-C concentration for both groups was also above the normal range of ˂ 3.4 
mmol/L concentration ideal for individuals at risk of CVD (Blaha et al., 2008). 
However, mean plasma TAG concentrations for both groups were borderline, but not 
˂ 1.7 mmol/L (Alberti et al., 2006). 
2.3.2 Baseline dietary intake of energy and nutrients among treatment group. 
Based on reported consumption from the completed 3-day food diary at weeks 0 and 
4 (n = 42), no significant difference was observed between the intervention and 
placebo group from mean dietary intake of energy, carbohydrate protein, fats and 
vitamin D (Table 2.3.4). 
Table 2.3.4. Baseline dietary energy and nutrients intake among treatment 
group. 
 
Daily mean nutrient intake Vitamin D 
(n = 24) 
Placebo 
(n = 24) 
P 
Energy (kcal/day) 1853.9 ± 500.8 
 
2141.7 ± 663.8 
 
0.194 
 
Energy (MJ/day) 7.48 ± 2.2 
 
8.79 ± 2.9 
 
0.110 
 
Fat (g/day) 68.4 ± 14.2 
 
82. ± 27.4 
 
0.062 
 
Protein (g/day) 83.9 ± 24.5 
 
106.9 ± 56.9 
 
0.147 
 
Carbohydrate (g/day) 219.4 ± 67.5 
 
247.8 ± 85.1 
 
0.251 
 
Vitamin D (µg/day) 1.6 ± 1.2 
 
3.1 ± 3.1 
 
0.060 
 
Values are presented as mean ± standard deviation 
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Table 2.3.5. Baseline dietary intake of energy and nutrients compared to the 
DRV and UK population 
 
Energy and Nutrients Males (n = 42) 
Mean ± SD 
DRV NDNS  
Mean ± SD 
Energy (MJ/day) 8.23 ± 2.6 
 
  - 8.86 ± 2.36 MJ/day 
 
Protein (g/day) 
% energy as protein 
97.1 ± 46.9 
21.6% 
55.5 
15% 
84.6 ± 17.6 g/day 
17.2% 
 
Carbohydrates(g/day) 
% energy as CHO 
235.6 ± 78.4 
45.3% 
- 
50% 
257 ± 76 g/day 
48.5% 
 
Fat (g/day) 
% Energy as fat 
76.2 ± 23.5 
35% 
- 
35% 
76.3 ± 5.5 g/day 
34.2% 
 
Vitamin D (µg/day) 2.5 ± 2.6 10 3.1 ± 2.4 
 
 
The mean dietary energy intake in MJ/day was comparable to the values reported for 
the corresponding age group in the recent National Dietary and Nutrition Survey 
(Public Health England, 2016). The mean dietary carbohydrate and vitamin D intake 
were lower than reported for the corresponding age group in the recent National 
Dietary and Nutrition Survey (Public Health England, 2016). The mean dietary 
protein and fat intake were above and within the reported values respectively for the 
corresponding age group in the recent National Dietary and Nutrition Survey (Public 
Health England, 2016). 
2.3.3. Baseline plasma 25(OH)D concentrations 
At baseline, 22.2 % (n = 12) of participants had plasma 25(OH)D concentrations ˂ 
25nmol/L, 35.2 % (n = 19) had plasma 25(OH)D concentrations ˂ 30nmol/L and 
64.8% (n = 35) of participants had plasma 25(OH)D concentrations ˂ 50nmol/L 
independent of treatment group (Fig 2.3.2). No significant associations were found 
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between the stratified baseline plasma 25(OH)D concentrations and the 
cardiometabolic markers measured.  
                 
          
 Fig 2.3.2 Box plot of the prevalence of low plasma 25(OH)D concentrations  
 
2.3.4. Effect of supplementation on plasma 25(OH)D and PTH concentrations 
The administration of 5000 IU (125µg) vitamin D3 resulted in a significant increase 
in plasma 25(OH)D concentrations compared to placebo. After 4 weeks intervention, 
mean (±SD) plasma 25(OH)D concentration increased by +25.76 ± 3.63 nmol/L in 
the vitamin D group vs. - 4.02 ± 2.09 nmol/L in those taking placebo. After 8 weeks 
of intervention, plasma mean (±SD) 25(OH)D concentrations increased by +34.12 ± 
0.18 in the vitamin D group vs. -5.14 ± 1.62 (P˂0.001) in the placebo group 
(Fig.2.3.3). There was no significant difference in change in plasma PTH 
concentrations at 4 and 8 weeks between the groups (Table 2.3.6). Vitamin D3 
supplementation increased plasma 25(OH)D concentrations to ≥ 75nmol/L in 45.8 % 
(11/24) of participants in the vitamin D group, whereas no participants (0/24) in the 
placebo group achieved plasma 25(OH)D concentrations ≥ 75nmol/L after 8 weeks 
of intervention.   
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Table 2.3.6. Effect of vitamin D supplementation on plasma 25(OH)D and PTH 
concentrations 
Parameters Time points Vitamin D 
  (n = 24) 
Placebo 
(n = 24) 
P 
Plasma 25(OH)D (nmol/L) 0 vs. 4wks 
0 vs. 8wks 
+ 25.8 ± 3.6 
+ 34.1 ± 0.2 
- 4.0 ± 2.1 
- 5.1 ± 1.6 
< 0.001 
< 0.001 
Plasma PTH (pmol/L) 0 vs. 4wks 
0 vs. 8wks 
+ 0.2 ± 0.0 
- 0.6 ± 0.5 
+ 0.2 ± 0.0 
+ 0.7 ± 0.3 
 0.893 
 0.112 
Values are presented as mean ± standard deviation 
 
 
 
 
**P < 0.001 represents difference at each time points between vitamin D 
and placebo group. 
Fig.2.3.3. Effect of vitamin D supplementation on plasma 25(OH)D 
concentrations (± SD) at week 0, 4 and 8 weeks. 
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2.3.5 Effect of vitamin D supplementation on plasma sE-selectin concentrations 
and haemodynamic measures 
Vitamin D3 supplementation significantly decreased mean (±SD) brachial pulse 
pressure by − 4.2 ± 5.3 vs. - 0.3 ± 2.8 mmHg, (P = 0.011) at 4 weeks and decreased 
by − 2.9 ± 3.4 vs. + 0.3 ± 2.8 mmHg, (P = 0.027) at 8 weeks in the vitamin D 
compared to placebo group (Table 2.3.7). No significant changes were observed in 
plasma sE-selectin concentration (Fig.2.3.4.), PWV (Fig.2.3.5.), AIx and the other 
arterial stiffness indices in both treatment groups at 4 and 8 weeks despite increased 
25(OH)D concentrations in vitamin D group. However, within groups, there was a 
significant mean decrease of -21.8 and -32.9 ng/mL (P < 0.001) in plasma sE-
selectin concentrations between weeks 4 and 0 in the vitamin D and placebo group 
respectively. Similarly, there was also a significant mean decrease of -18.8 and -32.4 
ng/mL (P < 0.001) in plasma sE-selectin concentrations between weeks 8 and 0 in 
the vitamin D and placebo group respectively. 
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Table 2.3.7. Effect of supplementation on plasma sE-selectin concentrations and 
haemodynamic measures 
Values are presented as mean ± standard deviation 
*P< 0.05 
 
 
 
 
 
Parameters                           Time 
points 
Vitamin D 
(n = 24) 
Placebo 
(n = 24) 
P 
SBP (mmHg)                                                  0 vs. 4wks 
0 vs. 8wks 
-2.0 ± 0.8 
-0.9 ± 0.1 
2.9 ± 0.1 
4.3 ± 0.2 
0.096 
0.099 
DBP (mmHg)                                                  0 vs. 4wks
0 vs. 8wks 
-1.0 ± 0.9 
0.0 ± 0.7 
1.3 ± 0.1 
2.1 ± 0.5 
0.570 
0.522 
PWV (m/s) 0 vs. 4wks 
0 vs. 8wks 
-0.1 ± 0.1 
-0.1 ± 0.2 
- 0.2 ± 0.2 
- 0.2 ± 0.1 
0.581 
0.423 
PP (mmHg)                                                  0 vs. 4wks
0 vs. 8wks 
-4.2 ± 5.3 
-2.9 ± 3.4 
-0.3 ± 2.8 
1.6 ± 0.5 
0.011* 
0.027* 
MAP (mmHg)                                                  0 vs. 4wks
0 vs. 8wks 
-1.7 ± 0.9 
-0.9 ± 0.9 
0.1 ± 0.4 
1.3 ± 0.7 
0.796 
0.413 
Aix (Brachial) (%) 0 vs. 4wks 
0 vs. 8wks 
5.8 ± 1.1 
15.4 ± 13.3 
6.0 ± 9.1 
6.1 ± 8.9 
0.631 
0.940 
AIx (Aortic) (%) 0 vs. 4wks 
0 vs. 8wks 
3.5 ± 0.5 
3.1 ± 0.7 
-1.22 ± 4.0 
-0.2 ± 3.2 
0.682 
0.705 
SBPao (mmHg)                                                  0 vs. 4wks 
0 vs. 8wks 
-1.6 ± 0.3 
-0.7 ± 0.2 
-0.1 ± 2.1 
1.9 ± 1.8 
0.484 
0.347 
PPao (mmHg)                                                  0 vs. 4wks
0 vs. 8wks 
-1.1 ± 1.3 
-0.7 ± 1.5 
0.1 ± 2.1 
1.7 ± 1.8 
0.645 
0.280 
HR (bpm) 0 vs. 4wks 
0 vs. 8wks 
-1.1 ± 0.6 
-0.6 ± 0.6 
1.1 ± 0.8 
0.0 ± 0.2 
0.518 
0.904 
RT (m/s) 0 vs. 4wks 
0 vs. 8wks 
0.6 ± 2.4 
1.1 ± 3.7 
5.3 ± 2.7 
1.9 ± 2.4 
0.339 
0.715 
Soluble E-selectin 
(ng/mL) 
0 vs. 4wks 
0 vs. 8wks 
-13.7 ± 1.7 
-10.8 ± 1.4 
-18.3 ± 1.3 
-17.1 ± 2.9 
0.915 
0.733 
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Fig. 2.3.4. Effect of vitamin D supplementation on plasma mean (±SD) sE-
selectin concentration 
              
 
Fig. 2.3.5. Effect of vitamin D supplementation on mean (±SD) PWV 
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2.3.6. Effect of vitamin D supplementation on plasma hs-CRP, 8 -Isoprostanes, 
renin and angiotensin II concentrations 
There were no significant changes in plasma renin, angiotensin II, hs-CRP and 8-
isoprostanes concentrations between vitamin D and placebo group at 4 and 8 weeks 
despite improved vitamin D status (Table 2.3.8). However, within groups, there was 
a significant mean decrease of -133.46 and -261.26 pg/mL (P < 0.001) in plasma 
renin concentrations between weeks 8 and 0 in the vitamin D and placebo group 
respectively. 
Table 2.3.8. Effect of vitamin D supplementation on plasma hs-CRP, 8-
Isoprostanes, renin and angiotensin II concentrations 
Parameters  Vitamin D  
(n = 24) 
Placebo 
(n = 24) 
P 
Plasma hs-CRP  
(mg/L) 
0 vs. 4wks 
0 vs. 8wks 
-0.5 ± 3.4 
-0.2 ± 3.3 
0.3 ± 0.03 
0.2 ± 0.02 
0.678 
0.264 
Plasma 8-Isoprostanes 
(pg/ml) 
0 vs. 4wks 
0 vs. 8wks 
5.3 ± 2.4 
3.4 ± 2.8 
6.9 ± 6.8 
7.5 ± 8.5 
0.653 
0.222 
Plasma Renin 
 (pg/mL) 
0 vs. 4wks 
0 vs. 8wks 
-79.9 ± 41.8 
-96.3 ± 49.5 
-153.2 ± 167.4 
-223.5 ± 224.2 
0.781 
0.610 
Plasma angiotensin II 
(pg/mL) 
0 vs. 4wks 
0 vs. 8wks 
-1.3 ± 2.9 
-1.5 ± 2.1 
 0.9 ± 2.7 
-3.9 ± 2.5 
0.163 
0.390 
Values are presented as mean ± standard deviation 
 
2.3.7. Effect of vitamin D supplementation on metabolic profile biomarkers 
There was a significant decrease in change in plasma glucose concentration of -0.3 
vs. 0.2 in the placebo but not in vitamin D group at 4 weeks, however, this decrease 
did not persist at 8 weeks (Table 2.3.9).    
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Table 2.3.9.  Effect of vitamin D supplementation on metabolic profile markers 
Values are presented as mean ± standard deviation 
 
2.3.8. Effect of vitamin D supplementation on lipid profile markers 
In the present study, there were no significant changes between groups in plasma 
concentrations of the lipid profile markers measured (Table 2.3.10). 
Table 2.3.10. Effect of vitamin D supplementation on lipid profile markers 
 
Values are presented as mean ± standard deviation 
 
 
Parameters  Vitamin D 
 (n = 24) 
Placebo 
(n = 24) 
P 
Plasma Insulin  
(pmol/L) 
0 vs. 4wks 
0 vs. 8wks 
  -2.9 ± 0.8 
  -0.5 ± 10.4 
6.2 ± 5.4 
3.5 ± 2.9 
0.779 
0.897 
HOMA-IR 0 vs. 4wks 
0 vs. 8wks 
   0.0 ± 0.1 
   0.1 ± 0.8 
0.0 ± 0.7 
0.0 ± 0.3 
0.635 
0.680 
Plasma glucose 
 (mmol/L) 
0 vs. 4wks 
0 vs. 8wks 
   0.2 ± 0.1 
   0.1 ± 0.6 
-0.3 ± 0.1 
-0.0 ± 0.3 
0.011 
 0.209 
Parameters  Vitamin D 
 (n = 24) 
Placebo 
(n = 24) 
P 
Plasma TC (mmol/L) 0 vs. 4wks 
0 vs. 8wks 
 0.6 ± 0.3 
 1.3 ± 0.2 
0.4 ± 0.4 
0.9 ± 0.1 
0.787 
0.216 
Plasma TAG (mmol/L) 0 vs. 4wks 
0 vs. 8wks 
 -0.1 ± 0.0 
 0.0 ± 0.1 
-0.1 ± 0.0 
-0.1 ± 0.1 
0.607 
0.445 
Non- HDL-C (mmol/L) 0 vs. 4wks 
0 vs. 8wks 
 -0.7 ± 0.7 
  0.1 ± 0.9 
-0.6 ± 0.4 
-0.0 ± 0.7 
0.892 
0.740 
Plasma HDL-C (mmol/L) 0 vs. 4wks 
0 vs. 8wks 
  0.0 ± 0.0 
   0.1 ± 0.0 
-0.1 ± 0.1 
-0.1 ± 0.1 
0.317 
0.250 
LDL–C (mmol/L) 0 vs. 4wks 
0 vs. 8wks 
   0.5 ± 0.0 
   0.2 ± 0.9 
 0.5 ± 0.0 
 0.0 ± 0.6 
0.807 
0.416 
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2.3.9. Effect of vitamin D supplementation on anthropometric measures 
There were no significant changes in weight, WC and BMI between vitamin D and 
placebo groups after 4 and 8 week intervention despite improved vitamin D status 
(Table 2.3.11).  
Table 2.3.11. Effect of vitamin D supplementation on anthropometric measures 
   
Parameters  Vitamin D 
(n = 24) 
Placebo 
(n = 24) 
P 
Body weight (kg) 0 vs. 4wks 
0 vs. 8wks 
-0.5 ± 0.4 
-0.2 ± 0.8 
- 0.8 ± 0.0 
0.3 ± 0.3 
0.836 
0.468 
BMI (kg/m2) 0 vs. 4wks 
0 vs. 8wks 
 0.1 ± 0.2 
 0.2 ± 0.3 
0.2 ± 0.3 
0.1 ± 0.2 
0.095 
0.068 
Waist circumference (cm) 0 vs. 4wks 
0 vs. 8wks 
 3.6 ± 10.9 
 3.7 ± 12.7 
0.5 ± 0.8 
1.0 ± 1.4 
0.138 
0.098 
Values are presented as mean ± standard deviation 
 
2.3.10. Differences in haemodynamic measures between overweight and obese 
participants 
A significant difference was observed in mean (±SD) SBP and DBP between 
overweight and obese participants at week 4. SBP and DBP was lower in the 
overweight (n = 14) compared to the obese (n = 10) group (123.1 ± 9.8 vs. 131.8 ± 
9.2 mmHg, P = 0.037) (Fig.2.3.6) and (71.5 ± 8.1 vs. 82.5 ± 9.2 mmHg, P = 0.008) 
respectively (Fig.2.3.7).  A significant difference was observed in mean (±SD) MAP 
between the overweight and obese group at week 4, MAP was lower in the 
overweight compared to the obese group (88.8 ± 8.2 vs. 99.7 ± 9.7 mmHg, P = 
0.008). However, no significant difference was observed in SBP, DBP and MAP at 
week 0 and 8. 
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Fig.2.3.6. Mean (±SD) of SBP between overweight and obese participants in the 
vitamin D group at week 4 
 
   
Fig.2.3.7. Mean (±SD) of DBP between overweight and obese participants in the 
vitamin D group at week 4 
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2.3.11. Associations between plasma 25(OH)D concentrations and 
cardiometabolic markers 
Baseline plasma 25(OH)D concentration of all participants (n = 54) was inversely 
associated with plasma insulin (r = -0.307, P = 0.024) (Fig 2.3.8A) and HOMA-IR (r 
= -0.276, P = 0.043) (Fig 2.3.8B) irrespective of treatment group. Change in plasma 
25(OH)D concentrations at week 4 was inversely associated with change in plasma 
glucose (r = -0.408, P = 0.048, n = 24) (Fig.2.3.9A), with baseline 25(OH)D 
concentrations (r = - 0.714, P˂0.001) (Fig.2.3.9B), with change in aortic central 
pulse pressure (r = -0.517, P = 0.010, n = 24) (Fig. 2.3.9C) and change in HDL-C (r 
= -0.459, P = 0.024) (Fig. 2.3.9D). 
Change in plasma 25(OH)D concentration at week 8 was inversely associated with 
baseline 25(OH)D concentrations (r = - 0.603, P=0.002, n = 24) (Fig.2.3.10A), 
change in plasma glucose concentration (r = -0.513, P = 0.010, n = 24) 
(Fig.2.3.10B). Change in plasma 25(OH)D concentrations at week 8 was inversely 
associated with changes in brachial augmentation index (r = -0.446, P = 0.029, n = 
24) (Fig. 2.3.10C). 
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Fig 2.3.8 Baseline associations between plasma 25(OH)D concentrations with 
plasma insulin concentrations (A) and HOMA-IR (B) 
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Fig.2.3.9 Associations between Δ plasma 25(OH)D concentration and (A) Δ plasma glucose concentration, (B) 
baseline plasma 25(OH)D concentration, (C) Δ aortic central pulse pressure and (D) Δ plasma HDL-C concentration at 4 weeks 
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Fig.2.3.10 Associations between 8 week change in plasma 25(OH)D with baseline plasma 25(OH)D (A), change in plasma glucose 
(B) and change in brachial augmentation index (C) 
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2.4 DISCUSSION 
To our knowledge, this is the first RCT investigating the effect of daily 5,000IU 
(125µg) vitamin D3 for 8 weeks on a broad range of cardiometabolic risk markers in 
overweight and obese adult males. Although all study participants had suboptimal 
plasma 25(OH)D concentrations at baseline, 22.2 % (n = 12), 35.2 % (n = 19) and 
64.8% (n = 35) of participants had plasma 25(OH)D concentrations ˂ 25nmol/L, ˂ 
30nmol/L and ˂ 50nmol/L respectively, independent of treatment group. No 
significant associations were found between the stratified baseline plasma 25(OH)D 
concentrations and the cardiometabolic biomarkers measured. 
This RCT showed that 8 weeks of 5,000IU (125µg) vitamin D3 improved mean 
(±SD) vitamin D concentration significantly from baseline by +25.8 ± 3.6 nmol/L, (P 
˂0.001) at 4 weeks and + 34.1 nmol/L, (P ˂0.001) post intervention in the vitamin D 
group. The present study did not demonstrate a significant effect of vitamin D 
supplementation on the cardiometabolic markers including endothelial function, 
arterial stiffness, blood pressure and RAS, lipid profile, oxidative stress, and 
inflammation and glucose homeostasis parameters between treatment groups. 
However, beneficial effects were observed in brachial pulse pressure at 4 and 8 
weeks in the vitamin D group, mean (±SD) brachial pulse pressure significantly 
decreased from baseline and 4 weeks, -4.2 ± 5.3 vs. -0.3 ± 2.8 mmHg, (P = 0.011) 
and from baseline and 8 weeks, -2.9 ± 3.4 versus 1.6 ± 0.5 mmHg, (P = 0.027) post 
intervention in the vitamin D versus placebo group. The estimated mean (±SD) 
vitamin D intake (2.5 ± 2.6 μg/d) was found to be insufficient compared to the 
recommended RNI of 10µg/d.  
As no significant treatment effect was found with vitamin D3, a secondary hypothesis 
was devised to evaluate the association between improvement in 25(OH)D 
concentration at 4 and 8 weeks with the cardiometabolic markers measured. Thus, 
correlation analysis with change in 25(OH)D concentration with corresponding 
changes in the cardiometabolic markers was secondary analysis. 
Change in plasma 25(OH)D concentration was inversely associated with change in 
plasma glucose concentrations (r = -0.408, P = 0.048), as well as change in HDL-C 
concentrations (r = -0.503, P = 0.012) and positively associated with change in PPao 
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(r = 0.437, P = 0.033) at week 4.  Improved 25(OH)D concentration post intervention 
was inversely associated with change in brachial AIX (r = 0.446, P = 0.029) and 
change in plasma glucose concentration (r = -0.513, P = 0.010).  However, the 
association between change in 25(OH)D and change in HDL-C concentrations, 
change in PPao, were absent at week 8. 
2.4.1. Vitamin D status 
In the present study, a daily dose of 5,000IU (125µg) vitamin D3 supplementation 
increased circulating plasma 25(OH)D concentrations significantly from a baseline 
mean (±SD) concentration of 38.4 ± 15.9 to 64.2 ± 19.5, (P ˂ 0.001) at 4 weeks and 
72.8 ± 16.1nmol/L, (P ˂ 0.001) post intervention. At baseline, all recruited 
participants had plasma 25(OH)D concentration <75nmol/L, of these, vitamin D 
deficiency, defined as plasma 25(OH)D concentrations <25nmol/L (SACN, 2015), 
was present in 22.2% (12/54) and vitamin D deficiency, defined as plasma 25(OH)D 
concentrations <30nmol/L (IOM, 2011) was present in 35.2% (19/54) of the cohort.  
Plasma 25(OH)D concentration <50nmol/L, were present in 64.8% (35/54) of the 
cohort at baseline.  
Only 45.8% (11/24) of participants in the vitamin D group achieved plasma 
25(OH)D concentrations >75 nmol/L post intervention, despite the high daily dose 
administered. Evidence from observational studies has suggested a plasma 25(OH)D 
concentration of at least 75-100nmol/L for extra skeletal benefits (Bischoff-Ferrari, 
2008). The United States Endocrine Society’s Clinical Practice Guideline 
recommended a daily dose of at least 6,000 IU (150µg) to 10,000 IU (250µg) of 
vitamin D to treat vitamin D deficiency and to maintain serum/plasma 25(OH)D 
concentrations above 75nmol/L in obese individuals (Holick, Binkley, Bischoff-
Ferrari, Gordon, Hanley, Heaney, Murad, Weaver, et al., 2011). As observed in the 
present study, a 8 week RCT which administered weekly 50,000IU (1,250µg) 
vitamin D2 to CVD free overweight and obese individuals with plasma 25(OH)D 
concentrations below 50nmol/L found a similar increase in plasma 25(OH)D 
concentrations (Borgi et al., 2016). In this RCT, despite the high weekly 50,000IU 
(1,250µg) vitamin D2, which amounts to a daily dose of 7,142 IU (178.6µg), median 
(range) plasma 25(OH)D concentration in the vitamin D group was 71.8 (63.5-90.8) 
nmol/L at 8 weeks compared to the present study mean plasma 25(OH)D 
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concentration of 72.5 ± 15.7nmol/L. This finding also supports the hypothesis that 
vitamin D metabolism is reduced with increasing BMI (Vimaleswaran et al., 2013). 
Approximately 54.2% (13/24) of participants in the vitamin D group in the present 
study did not reach the 75nmol/L threshold, this could be ascribed to compliance, 
even though, overall compliance in the vitamin D group was 90%, and those with a 
percentage compliance ≤ 80% were excluded (n=1). Regardless of the high 
compliance, a major drawback of calculating compliance from returned tablets as 
was done in the present study, is that it cannot determine whether participants 
consumed the tablets or discarded them (Chesney et al., 2000; Hill, 2005). Inability 
to reach the 75nmol/L threshold could also be ascribed to adipose sequestration, as it 
has been reported in humans that about 17% of orally-administered vitamin D was 
stored in adipose tissue (Heaney, Recker, Grote, Horst, & Armas, 2010). Baseline 
vitamin D status may be another explanation, as it plays an important role in the 
expected response to vitamin D supplementation, however, only 22.2 % (12/54) 
participants in the present study had plasma 25(OH)D concentrations ˂25nmol/L at 
baseline, and intestinal absorption of vitamin D may be higher in vitamin D deficient 
individuals (Apukhovskaia et al., 1990; Heaney, 2012; Holick, Binkley, Bischoff-
Ferrari, Gordon, Hanley, Heaney, Murad, & Weaver, 2011).  
The low expression of the 25-hydroxylase CYP2J2 and the 1-α hydroxylase 
CYP27B1 in obesity may be a potential explanation for the reduced ability of some 
participants in the vitamin D group to achieve plasma 25(OH)D concentrations above 
75nmol/L. The subcutaneous adipose tissue of obese women has been reported to 
express lower 25-hydroxylase CYP2J2, as well as the 1-α hydroxylase CYP27B1 
compared with the subcutaneous adipose tissue of lean women, indicating that both 
25-hydroxylation and 1-α hydroxylation are impaired in obesity (Wamberg, 
Christiansen, et al., 2013). There is evidence that polymorphisms in the VDBP gene 
may have an impact on serum 25(OH)D concentrations, as VDBP polymorphisms 
may reduce the binding capacity of 25(OH)D and thus, reduce circulating plasma 
25(OH)D concentrations (Yousefzadeh, Shapses, & Wang, 2014). Although it has 
been demonstrated that circulating serum VDBP is not affected by adiposity in obese 
women (Winters, Chennubhatla, Wang, & Miller, 2009), VDBP levels have been 
reported to be reduced in acute inflammatory conditions (Waldron et al., 2013). This 
suggests that in obesity, which is characterised by chronic low grade inflammation, 
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circulating VDBP levels may be reduced (Yousefzadeh et al., 2014), resulting in 
decreased plasma 25(OH)D concentrations, as VDBP has a greater binding affinity 
for 25(OH)D compared to 1,25(OH)2D (Gozdzik et al., 2011; Hart, Furniss, Laurie, 
& Durham, 2005). 
VDR genotype polymorphisms are associated with adiposity (Gu et al., 2009; Ochs-
Balcom et al., 2011), and increased production of pro-inflammatory cytokines, as 
observed with increased adiposity, cause a reduction in VDR expression (Al-Daghri 
et al., 2014). VDR genotype polymorphism particularly VDR ff genotype, have been 
reported to have decreased response to vitamin D intake (Neyestani et al., 2013). 
Thus, VDR genotype polymorphism in adiposity may be an additional explanation 
for the reduced individual response to the high dose orally administered vitamin D 
intake in the present study. 
2.4.2. Effect of vitamin D supplementation on plasma PTH concentrations 
Plasma PTH concentrations in this RCT were within the normal range at baseline, 
and there was no significant change in plasma PTH at 4 and 8 weeks between the 
groups after vitamin D supplementation. Although it has been reported that 
serum/plasma PTH concentration is elevated in vitamin D deficiency, serum 
25(OH)D concentrations greater than 25nmol/L are not associated with additional 
change in serum PTH concentrations. Increased serum PTH concentrations have 
been reported with serum 25(OH)D concentrations below 25 nmol/L (Sayed-Hassan, 
Abazid, & Alourfi, 2014), and only 22.2% of present study cohort had a plasma 
25(OH)D concentration below 25nmol/L. This may explain the normal plasma PTH 
concentrations, despite low plasma 25(OH)D concentration. 
2.4.3. Effect of vitamin D supplementation on haemodynamic measures and 
plasma sE-selectin concentrations  
2.4.3.1 Endothelial function 
At baseline, endothelial function, as measured by plasma sE-selectin concentrations 
(mean ±SD) were high in the vitamin D group, 57.9 ± 31.1ng/mL and placebo group 
58.7 ± 19.1ng/mL. This finding supports the evidence that serum sE-selectin 
concentration is increased in the obese compared to the non-obese (Pontiroli, Frige, 
Paganelli, & Folli, 2009; Zanni, Stanley, Makimura, Chen, & Grinspoon, 2010), 
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indicating increasing BMI is associated with endothelial dysfunction in adults. No 
significant effect of vitamin D supplementation was found on endothelial function 
between treatment groups post intervention. Similar to the present study findings, no 
significant change in endothelial function, measured by brachial artery ultrasound, 
was reported following intake of 50,000IU (1,250 µg) vitamin D2 weekly for 8 
weeks in vitamin D deficient CVD-free overweight and obese individuals despite 
improved vitamin D status (Borgi et al., 2016). Similarly, a 16 week RCT conducted 
in Singapore in 64 vitamin D deficient T2DM patients did not find significant 
improvement in endothelial function assessed by reactive hyperaemia index RHI, E-
selectin, von-Willebrand factor, hs-CRP and AIx in both treatment groups after 
administering a daily dose of 4,000IU (100µg) vitamin D3 (Dalan et al., 2016). From 
these observations in addition to the present study findings, it could be deduced that 
low plasma 25(OH)D concentrations may not be the primary cause of endothelial 
dysfunction as reported by observational studies. 
 2.4.3.2 Arterial stiffness indices 
Mean (±SD) PWV (6.5 ± 1.1 m/s), brachial augmentation index (-48.6 ± 25.9%), 
central augmentation index (- 12.6 ± 13.4 %), RT (153.3 ± 24.4 m/s) and heart rate 
(62.3 ± 12.3 bpm) were all within the normal ranges at baseline. High daily dose 
vitamin D3 supplementation did not improve PWV, AIx, and other indices of arterial 
stiffness in the present study. These findings may indicate that overall, participants 
were at low risk of arterial stiffness and cardiometabolic disease. The present study 
findings are consistent with those of a trial completed in Hong Kong which 
administered 5,000IU (125µg) oral vitamin D3 in 100 T2DM patients (Yiu et al., 
2013). This study found no difference in endothelial function determined by FMD, 
PWV or AIx after 12 weeks of intervention (Yiu et al., 2013). However, in this trial, 
the T2DM patients were taking anti-hypertensive and lipid-lowering drugs which 
interfere with vitamin D metabolism (Lynch & Price, 2007; Montagnani et al., 1994). 
Vitamin D is a derivative of cholesterol, and statins lower serum cholesterol 
concentration and therefore reduce vitamin D synthesis (Istvan & Deisenhofer, 
2001). Anti-hypertensive and lipid-lowering drugs may also reduce vitamin D 
metabolism by competing for CYP3A4 enzyme activity. CYP3A4 is a 25-
hydroxylase enzyme that converts inactive to active vitamin D, and is also 
responsible for the metabolism of antihypertensive drugs as well as statins including 
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Atorvastatin, Lovastatin and Simvastatin (Bellosta & Corsini, 2012). These drugs are 
CYP3A4 enzyme inhibitors, and therefore all compete for the same enzyme receptor 
site, with the more potent drug dominating (Zhou, 2008). This may result in the 
decreased metabolism of the competing drug which is vitamin D in this case, 
therefore reducing its efficacy (Zhou, 2008). This could explain the slight increase in 
serum 25(OH)D concentrations despite the large vitamin D doses administered.  
A trial completed in Ireland in 119 vitamin D deficient elderly people did not find 
significant improvement in PWV and AIx after receiving single dose of either 50,000 
IU(1250µg) or 100,000 IU (2,500µg) intramuscular vitamin D3 for 8 weeks between 
treatment groups (McGreevy et al., 2015). Arterial stiffness increases with aging, it 
has been reported to increase between age 50 and 60 years (Cecelja & Chowienczyk, 
2012; Reshetnik, Gohlisch, Zidek, Tölle, & van der Giet, 2016), as structural changes 
in the medial and intimal layer of arteries with increasing age cause the deformation 
of elastin and collagen fibres and these anatomical changes may not occur in young 
adults (O’rourke & Hashimoto, 2007; Wang & Lakatta, 2002). 
2.4.4. Effect of vitamin D supplementation on blood pressure and RAS 
In the present study, mean (±SD) SBP (128.7 ± 11.1 mmHg), DBP (77.0 ± 9.7 
mmHg), PP (53.6 ± 9.2 mmHg), MAP (95.1 ± 9.1), SBPao (118.5 ± 12.9 mmHg), 
PPao (41.6 ± 8.8 mmHg), plasma renin concentration (639.8 ± 294 mmHg) and 
plasma angiotensin II concentrations (32.3 ± 9.6 pg/mL) of overweight and obese 
cohort were within the normal range. Vitamin D supplementation significantly 
reduced mean (±SD) brachial pulse pressure from baseline (52.3 ± 9.2 vs. 53.7 ± 9.2 
mmHg to 49.4 ± 3.9 vs. 53.5 ± 6.4 P = 0.011) at 4 weeks and to (50.6 ± 5.8 vs. 55.8 
± 8.7 mmHg, P = 0.027) post intervention in the vitamin D compared to placebo 
group. Although pulse pressure is closely associated with CVD events compared 
with SBP or DBP (Franklin et al., 2001), it has been reported that central pulse 
pressure may be a better predictor of CVD risk and not brachial pulse pressure 
(Cecelja, Jiang, Spector, & Chowienczyk, 2012; Pini et al., 2008). PPao was within 
the normal range at baseline as mentioned earlier, and remained significantly 
unchanged post intervention in the present study suggesting the arteries were 
compliant and distensible.  
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In the present study, vitamin D supplementation did not significantly reduce SBP, 
DBP, MAP, SBPao, PPao and RAS in the vitamin D group. Consistent with this 
finding, a daily dose of 2,000IU (50µg) vitamin D3 for 6 weeks in 101 stable chronic 
heart failure patients did not significantly change SBP and DBP. However, contrary 
to present study findings, this dose significantly reduced median (range) plasma 
renin concentration from 63 ng/L (38-104) to 55 ng/L (32-93), (P = 0.020) in the 
vitamin D group (Schroten et al., 2013). Similarly, 8 weeks daily supplementation of 
2,800IU (70µg) vitamin D3 in hypertensive patients with low serum 25(OH)D 
concentration showed no significant effect of intervention on SBP, DBP and plasma 
renin concentrations (Pilz et al., 2015).  
In contrast to the present study findings, weekly 50,000IU (1250µg) vitamin D3 
supplementation for 8 weeks significantly reduced mean (±SD) SBP (− 6.4 ± 5.3 vs. 
0.9 ± 3.7 mmHg, P < 0.001), DBP (− 2.4 ± 3.7 vs. 1.0 ± 2.7 mmHg, P = 0.003) and 
MAP (− 3.7 ± 3.6 vs. 0.9 ± 2.5 mmHg, P < 0.001) in the vitamin D compared to 
placebo group of 42 hypertensive and vitamin D deficient Iranian out-patients 
(Mozaffari-Khosravi, Loloei, Mirjalili, & Barzegar, 2015). However, this study did 
not find a significant impact of vitamin D supplementation on pulse pressure 
(Mozaffari-Khosravi et al., 2015). The use of a non-hypertensive cohort at baseline 
may be the possible reason the present study did not find significant changes in SBP, 
DBP and MAP compared to the aforementioned study. The present study used 
participants with normal baseline SBP, DBP and MAP, this suggest that vitamin D 
may provide significant reductions in BP only in hypertensive individuals. In 
agreement with this hypothesis, a meta-analysis of 11 RCTS found non-significant 
reductions in SBP and significant reductions in DBP in the vitamin D group, in 8/11 
RCTs in which mean baseline BP was >140mmHg (Witham, Nadir, & Struthers, 
2009). Findings from an observational study have also demonstrated that low serum 
25(OH)D concentrations were a much stronger predictor of future CVD in people 
with hypertension at baseline compared to normotensive people (Wang, Pencina, et 
al., 2008). It has been demonstrated in vivo, that arterial stiffness is increased by a 
significant rise in blood pressure (Stewart, Millasseau, Kearney, Ritter, & 
Chowienczyk, 2003), and that arterial stiffness is greater in hypertensive individuals 
compared to age–matched normotensive controls (Stewart, Jiang, Millasseau, Ritter, 
& Chowienczyk, 2006). From these observations, the lack of an effect of vitamin D 
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supplementation in the present study, could be attributed to the use of young non-
hypertensive overweight and obese study cohorts, consequently this study cohort 
would have had fewer anatomical changes to their arterial tree as majority of cohort 
were below 50 years. 
2.4.5. Effect of vitamin D supplementation on oxidative stress and inflammation 
The present study observation of high baseline plasma mean (±SD) hs-CRP 
concentrations (2.9 ± 1.9 mg/L) is consistent with findings that increasing BMI, 
characterised with excess adipose tissue is associated with abnormal cytokine 
production and increased secretion of acute phase reactants as well as the 
upregulation of the inflammatory signalling pathway (Berg & Scherer, 2005; Xu et 
al., 2003).  Consistent with this observation, overweight and obese women have been 
reported to have increased serum TNF-α (inflammatory marker) concentrations 
compared to lean women (Olszanecka-Glinianowicz, Zahorska-Markiewicz, 
Janowska, & Zurakowski, 2004). Additionally, subcutaneous and visceral adipocyte 
cell volume demonstrated a higher positive association with serum TNF-α 
concentration in overweight/obese adults compared to lean controls (Winkler et al., 
2003). In the present study cohort, mean (±SD) plasma concentration of 8-
isoprostanes 11.2 ± 8.7 mg/L were within the normal range and this observation was 
unexpected, as increased secretion of fatty acids by adipocytes have been reported to 
induce the production of ROS by upregulating nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, and by downregulating the expression of anti-
oxidative enzymes thereby increasing oxidative stress (Goncharov et al., 2015). The 
present study demonstrated that vitamin D supplementation did not significantly 
reduce plasma hsCRP concentration and significantly change plasma 8-isoprostanes 
concentrations at 4 and 8 weeks. These results are in line with a 12 week trial which 
did not also observe a significant effect of daily 5,000IU vitamin D3 supplementation 
on hs-CRP and 8-isoprostanes in 100 T2DM patients (Yiu et al., 2013). This finding 
may suggest vitamin D supplementation does not reduce or prevent inflammation in 
overweight and obese people. The normal baseline plasma 8-isoprostanes 
concentration may also explain why arterial stiffness indices were within the normal 
ranges, as increased oxidative stress is implicated in the irreversible cross-linking of 
collagen and elastin fibres by advanced glycation end products (Konova et al., 2004). 
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2.4.6. Effect of vitamin D supplementation on anthropometric measurements 
In the present study, despite improvements in vitamin D status, no significant 
reductions were observed in BMI, body weight and waist circumference between 
treatment groups. This observation is consistent with the results of a US RCT which 
demonstrated that a daily dose of either 1,000IU (25µg), 2,000IU(50µg) or 4,000IU 
(100µg) for 3 months did not significantly reduce BMI in 328 overweight African-
Americans (Chandler et al., 2015). Similarly, a meta-analysis of 12 RCTs performed 
in Australia showed no significant effect of vitamin D therapy on body weight, BMI, 
or other adiposity measures in the absence of calorie restriction (Pathak, Soares, 
Calton, Zhao, & Hallett, 2014). Contrary to these findings, an Iranian RCT in 77 
healthy overweight and obese women showed 7% reductions in body fat mass after 
study cohort received 1000 IU (25 µg) vitamin D3 for 12 weeks, however, the 
vitamin D intervention did not significantly affect body weight and waist 
circumference (Salehpour et al., 2012). 
In the present study, obese participants (n = 18) at baseline had plasma mean (±SD) 
25(OH)D concentrations of 37.9 ± 17.2 nmol/L, whilst those in the overweight 
category (n = 36) had slightly higher mean (±SD) plasma 25(OH)D concentrations of 
41.7 ± 20.2 nmol/L. Post intervention, 4 out of the 18 obese cohort, achieved a 
plasma 25(OH)D concentration ≥ 75nmol/L. The present study findings are 
consistent with a bi-directional Mendelian randomisation meta-analysis study using 
genetic markers. This meta-analysis demonstrated that a higher BMI would result in 
a low vitamin D status, but a lower vitamin D status was unlikely to increase BMI in 
21 cohorts of over 42,024 participants (Vimaleswaran et al., 2013). The lack of an 
effect of vitamin D supplementation on BMI, body weight and waist circumference 
may also be attributed to the method used in assessing body fat, the present study 
used BMI in calculating body fat but did not measure body fat distribution. Although 
BMI measurement is inexpensive, quick and easy tool to evaluate obesity trends in 
the general population, it can overestimate or underestimate body fat levels, due to 
inability to distinguish between muscle and lean mass for fat distribution (Ashwell, 
2011; Bhurosy & Jeewon, 2013).  
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2.4.7. Effect of vitamin D supplementation on lipid profile   
Serum mean (±SD) of lipid profile biomarkers reported in the recent NDNS for the 
corresponding sex and age groups are 4.9 ± 1.5, 1.3 ± 0.4 and 3.0 ± 0.9 mmol/L for 
TC, HDL-C and LDL-C respectively. Compared with the general UK male adult 
population, the results of lipid profile markers indicate that participants were at high 
risk of cardiometabolic disease as shown by elevated mean (±SD) TC (6.5 ± 1.5 
mmol/L), LDL-C (5.2 ± 1.5 mmol/L), non-HDL (6.3 ± 1.8 mmol/L),  reduced HDL-
C (0.6 ± 0.1 mmol/L), and borderline serum TAG (1.7 ± 0.4 mmol/L), Lipid profile 
markers have been shown to be unfavourable in the overweight and obese, as serum 
TC, TAG and LDL-C concentrations were found to be higher in the obese compared 
to normal weight individuals, whilst serum HDL -C concentration was lower in the 
obese  compared to non-obese people (Klop, Elte, & Cabezas, 2013; Szczygielska, 
Widomska, Jaraszkiewicz, Knera, & Muc, 2003). Plasma HDL-C and apolipoprotein 
A-1 (the primary protein fraction of HDL-C) concentrations have been reported to 
both significantly decrease with increasing BMI. Increase in BMI is strongly 
associated with reduced serum HDL-C concentration compared to high LDL-
cholesterol concentrations (Klop et al., 2013). The potential mechanisms responsible 
for reduced serum HDL-C concentration in obese states include: Obesity alters the 
cardioprotective HDL-C subfractions such as HDL2 apolipoprotein A-I, and pre-β1, 
and reduced serum HDL-C concentrations in obesity have been attributed to both an 
enhanced uptake of HDL2 by adipocytes as well as the increased catabolism of 
apolipoprotein A-I subfraction (Rashid & Genest, 2007). 
There was no effect of vitamin D supplementation on lipid profile markers in the 
vitamin D group. Consistent with the present study, a 16 weeks Iranian RCT in 71 
males and females with metabolic syndrome showed that 50,000IU (1250µg) vitamin 
D3 did not significantly improve serum mean (±SD) TC, HDL-C, and LDL-C 
concentration (Salekzamani et al., 2016). Similarly, a UK trial in 50 chronic fatigue 
syndrome patients who received 100,000IU of vitamin D3 every 2 months for 6 
months did not demonstrate any effect of treatment on lipid profile (Witham et al., 
2015).  Additionally, a 8-week trial in 60 centrally obese people showed that 1,200IU 
(30µg)/day vitamin D3 did not increase serum 25(OH)D concentrations to a desirable 
concentration of ≥75 nmol/L in 61% of participants and there was also no significant 
changes in lipid profile biomarkers (Maki et al., 2011).  
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2.4.8. Effect of vitamin D supplementation on metabolic profile markers 
In the present study, the cohort was non-diabetic and had a normal mean (±SD) 
baseline HOMA-IR (1.6 ± 1.3), fasting plasma mean (±SD) glucose (5.2 ± 
1.5mmol/L) and mean (±SD) insulin concentrations (46.5 ± 27.7pmol/L). There was 
no effect of vitamin D supplementation on fasting plasma glucose and plasma 
insulin, HOMA-IR in the vitamin D group. In agreement with the present study 
findings, supplementation with a weekly dose of 88,865 IU (2,222µg) for 12 months 
had no effect on fasting plasma glucose, insulin secretion and insulin sensitivity in 
overweight people with prediabetes and hypovitaminosis D (25(OH)D < 75nmol/L) 
(Davidson, Duran, Lee, & Friedman, 2013). Similarly, a meta-analysis of 12 RCTs in 
overweight and obese people demonstrated that vitamin D supplementation with 
varying doses, duration and baseline serum 25(OH)D concentration had no 
significant effect on serum/plasma fasting glucose, insulin and HOMA-IR index 
(Jamka, Woźniewicz, Jeszka, et al., 2015).  
The present study may not have observed significant reductions with vitamin D 
supplementation in the glucose homeostasis parameters measured, as the study 
cohort were non-diabetic and had normal baseline HOMA-IR, fasting plasma glucose 
and insulin concentrations. It may be possible that vitamin D supplementation may 
be effective in insulin resistant individuals, as 6 months administration of 4,000IU 
(100µg) vitamin D3 significantly reduced fasting insulin concentration and 
significantly improved insulin sensitivity and resistance in insulin resistant and 
vitamin D deficient (25(OH)D < 50nmol/L) South Asian women (von Hurst et al., 
2010). This RCT also observed that insulin resistance was most reduced at a serum 
25(OH)D concentration of 80-119nmol/L, suggesting a dose response relationship 
between vitamin D status and insulin resistance (von Hurst et al., 2010). 
2.4.9. Associations between plasma 25(OH)D concentration and the 
cardiometabolic markers measured 
In the present study, baseline plasma 25(OH)D concentration was inversely 
associated with fasting plasma insulin concentration (r = -0.307, P = 0.024) and 
HOMA-IR (r = -0.307, P = 0.024), indicating that decreasing 25(OH)D concentration 
is associated with markers of impaired glucose metabolism (Dalgård, Petersen, 
Weihe, & Grandjean, 2011; Forouhi, Luan, Cooper, Boucher, & Wareham, 2008). As 
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observed in the present study, serum 25(OH)D concentration below 50nmol/L was 
inversely associated with HOMA-IR (r = -0.350, P ˂0.001) and with fasting plasma 
insulin concentration (r = -0.350, P ˂0.001) in a cross-section of 50 obese and 36 
normal weight adult non- hypertensive and non-diabetic patients (Stokić et al., 2015). 
Additionally, a cross-sectional study in overweight and obese elderly Faroese 
residents also reported inverse associations between serum 25(OH)D concentration 
with fasting plasma insulin (rs = −0.10; P = 0.01) and HOMA-IR (rs = −0.10; P = 
0.01) (Dalgård et al., 2011). 
In the present study, change in plasma 25(OH)D concentration at week 4 was 
inversely associated with change in plasma glucose concentrations (r = -0.408, P = 
0.048), suggesting increasing 25(OH)D concentration is associated with improved 
glucose metabolism. A cross-sectional study in 80 post menarchal obese adolescents 
showed that serum 25(OH)D concentrations was inversely associated with fasting 
glucose (r = -0.28, P = 0.02) (Ashraf, Alvarez, Gower, Saenz, & McCormick, 2011). 
A cross-sectional study in CVD and systemic disease free severe obese adults also 
found inverse associations between median plasma 25(OH)D concentrations and 
fasting glucose -0.0022 (-0.0091 to -0.0016), (P = 0.033) (Bellia et al., 2013). The 
mechanism by which improved vitamin D status influences metabolic indices of 
glucose directly involves the stimulation of β-cell function which in turn improves 
insulin secretion, insulin sensitivity and insulin-mediated uptake of glucose in 
adipose and muscle tissue (Alvarez & Ashraf, 2009; Bajaj et al., 2014; Mitri et al., 
2011).  
Change in plasma 25(OH)D concentration at week 4 was also inversely associated 
with change in plasma HDL-C concentrations (r = -0.503, P = 0.012). This 
observation is contrary to those of a large cross-sectional study of 4342 non-pregnant 
women who were categorised into abdominally normal, overweight and obese. This 
study found lower serum 25(OH)D concentrations was significantly associated with 
lower HDL-C, suggesting higher serum 25(OH)D concentration would in turn be 
associated with higher serum HDL-C concentrations (Vogt, Baumert, Peters, 
Thorand, & Scragg, 2016). Additionally, in 1534 hyperlipidaemic patients it was 
demonstrated that serum 25(OH)D concentrations was positively associated with 
HDL-C (r = -0.190, P ˂ 0.0001) (Glueck et al., 2016). These observations indicate 
that a higher serum 25(OH)D concentrations are associated with lower CVD risk 
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(Cheng et al., 2010). Additionally, change in plasma 25(OH)D concentration at week 
4 was positively associated with change in aortic central pulse pressure (r = 0.437, P 
= 0.033). Contrary to the observations in the present study, a significant inverse 
association between low serum 25(OH)D and central pulse pressure was 
demonstrated in a cross-section of south African women (r  =  −0.157; P  =  0.025) 
(Kruger et al., 2013). Contrary to these findings, results from the third US National 
Health and Nutrition Examination Survey (NHANES III) did not find an inverse 
association between serum 25(OH)D and central pulse pressure (Scragg, Sowers, & 
Bell, 2007).  
Change in plasma 25(OH)D concentration at 8 weeks was inversely associated with 
change in brachial augmentation index (r = -0.446, P = 0.029). As observed in the 
present study, a study in which brachial and central augmentation index standardised 
to a heart rate of 75bpm was found to be positively associated with bioavailable 
25(OH)D (rho = 0.4, P = 0.004) and free 25(OH)D concentrations (rho = 0.4, P = 0.009) 
in a cohort of 47 post-menarchal, adolescent girls (Ashraf et al., 2014). Taken 
together, these observations suggest that arterial stiffness increases or decreases with 
decreasing or increasing plasma 25(OH)D concentrations. A cross-sectional analysis 
in 190 obese youth with and without T2DM observed an inverse association between 
serum 25(OH)D concentration and AIx in lean and T2DM (both r = −0.24, P < 0.01), 
and increased serum 25(OH)D concentration of 7.5nmol/L in the obese youths with 
T2DM was associated with a 1% reduction in AIx (Jha et al., 2015).  
Potential mechanisms by which improved vitamin D exerts beneficial effects on 
indices of arterial stiffness involves stimulating the production of endothelial nitric 
oxide (Kassi et al., 2013; Norman & Powell, 2005) and by downregulating the renin-
angiotensin system (Li, 2003). Improved vitamin D status exerts beneficial effects on 
LDL-C by modulating inflammatory processes and lipid metabolism (Gonzalez & 
Moschetta, 2014). Vitamin D may also exert beneficial effects by directly regulating 
the VSMC production (Mayer et al., 2012), as well as by obstructing the adverse 
effect of advanced glycation end-products on vascular aging (Talmor et al., 2008).  
Although, this RCT was not designed to investigate the dose response association 
between baseline plasma 25(OH)D concentrations and the prevention of CVD, it is 
important that the optimal serum/plasma 25(OH)D concentrations required to prevent 
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CVD risk be determined, as a threshold effect which varies with different baseline 
serum/plasma 25(OH)D concentrations has been reported (Heaney, 2012; Mozos & 
Marginean, 2015). A meta-analysis consisting of 18 observational studies has shown 
that metabolic risk decreases with increasing serum/plasma 25(OH)D concentration, 
this study compared the association between different serum 25(OH)D concentration 
with metabolic syndrome risk. Metabolic syndrome risk was reported to be 0.89 
(95% CI=0.85–0.93) for a serum/plasma 25(OH)D concentration of 30 nmol/L, 0.84 
(95% CI= 0.74–0.96) of 40 nmol/L, 0.80, 95% CI = 0.73–0.87 for 60 nmol/L 0.70 
(95%CI= 0.56–0.87) for 70 nmol/L, 0.67 (95% CI = 0.52–0.80) for 100 nmol/L, and 
0.60 (95% CI= 0.44–0.82) for 145 nmol/L (Ju, Jeong, & Kim, 2013). Additionally, a 
meta-analysis of 11 observational studies reported that a serum/plasma 25(OH)D 
concentration of 75-87.5 nmol/L reduces the risk of CVD mortality (Zittermann et 
al., 2012). Furthermore, a meta-analysis of 19 observational studies demonstrated 
that the increased CVD risk with low serum 25(OH)D was generally linear over a 
serum 25(OH)D threshold of 20 to 60 nmol/L (Wang, Song, et al., 2012). 
2.4.10 Dietary intake 
Baseline dietary nutrient analysis of mean energy, carbohydrate, protein, fat and 
vitamin D intake based on reported consumption from the 3 day food diary show that 
the mean daily energy intake for males in the cohort aged 19-64 years (n = 42) was 
mean ± SD: 8.23 ± 2.62 MJ/day. These values are comparable to that reported for the 
corresponding sex and age group in the recent NDNS, which is 8.86 ± 2.36 MJ/day 
(Public Health England, 2016). The estimated mean dietary carbohydrate intake of 
(219.4 ± 67.5g/day) was below the DRV and the UK (257 ± 76 g/day) estimated 
average requirement for carbohydrate for males aged 19-64. From the results, it 
could be deduced that the participants did not obtain their average daily total energy 
intake from carbohydrate. Additionally, the reduced estimated mean carbohydrate 
intake by cohort in the present study could be attributed to under reporting, the study 
population were overweight or obese males and hence they may under report to 
prevent judgement of eating too much (Johansson, Solvoll, Bjørneboe, & Drevon, 
1998; Scagliusi, Polacow, Artioli, Benatti, & Lancha, 2003). The mean (±SD) dietary 
protein intake 97.1 ± 46.9 g/day was above those of the general UK adult male 
population of 84.6 ± 17.6 g/day and above the DRV (55.5g/day) for males. This 
result suggests majority of participants obtained their average daily total energy 
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intake from dietary protein. The mean (±SD) dietary fat intake (76.2 ± 23.5g/day) 
was within the range of the general UK adult male population (76.3 ± 5.5 g/day) for 
corresponding age, suggesting, that majority of participants also obtained their 
energy requirements from fat. The estimated mean (±SD) daily intake of vitamin D 
in the present study cohort (2.5 ± 2.6 μg/d) was inadequate compared with the RNI 
value of 10μg/d (SACN, 2016), suggesting the cohort obtained very little vitamin D 
from their diet. However, a 3-day food diary only estimated mean dietary vitamin D 
intake for 3 days of the week, hence, the determination of dietary contribution of 
vitamin D may be underestimated. Under-reporting whilst partaking in a study is 
common with the use of a 3 day diary in the overweight and obese, as they are more 
likely to alter their eating habits and only record socially acceptable food and drinks 
rather than those actually consumed (Ortega, Perez-Rodrigo, & Lopez-Sobaler, 
2015). 
2.4.11. Study strengths  
To the best of my knowledge, this is the first RCT investigating in non-hypertensive 
and non-diabetic overweight and obese adult males the effect of daily 5,000IU 
(125µg) vitamin D3 on a broad range of cardiometabolic risk markers. The 
randomised double- blind, placebo-controlled design is another strength of the 
present study, as it allows causal inferences to be drawn, therefore, it is the strongest 
and reliable evidence of a treatment effectiveness (Levin, 2007). The present study 
collected information about dietary intake using a 3-day food diary, thus, the possible 
influence of a differential vitamin D intake was excluded. Although not a gold 
standard method of measuring total 25(OH)D, the present study measured 95% of 
participants’ plasma 25(OH)D concentration using VIDAS® Total 25(OH)D assay 
kit, which accurately determines both D2 and D3 in human serum or plasma using the 
Enzyme Linked Fluorescent Assay (ELFA) technique. VIDAS® Total 25(OH)D kit 
is very well correlated to the Liquid Chromatography-Mass Spectrometry/Mass 
Spectrometry (LC-MS/MS) reference method, a high positive association was 
recorded (Y=1.00x+ 041, R = 0.86) when 343 samples were tested using 
VIDAS® Total 25(OH)D and LC-MS/MS (the gold standard method). VIDAS® Total 
25(OH)D assay kit also provides the same high degree of precision as the LC-
MS/MS, it is easy to perform in any lab and gives rapid results within 40 minutes 
using the Mini-vidas, a multi parametric immunoanalyser. The laboratory used for 
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the present study is accredited by DEQAS, an accuracy-based program for improving 
the comparability of laboratory measurements for 25(OH)D assays, which have 
values assigned by the NIST reference measurement procedure. A certificate has 
been awarded to our laboratory, as it met the performance targets. 
The measurement of PWVao, AIx and other arterial stiffness indices using the 
Arteriograph (cuff based oscillometric device) is a study strength. The use of 
Arteriograph, is a simpler and less technical method compared to Complior and 
sphygmoCor (applanation tonometry devices), the most often used devices which are 
more complex, require sophisticated equipment and trained personnel that limits their 
use in clinical studies (Baulmann, Schillings, Rickert, Uen, Düsing, et al., 2008), as 
they require the device sensors to be accurately placed on the carotid and femoral 
arteries (Jatoi, Mahmud, Bennett, & Feely, 2009). The use of the Arteriograph or 
oscillometry has been proposed as a new gold standard for PWV measurement, as 
technique is simple to use, reliable and accurate and would be more suitable in 
clinical practice and in clinical studies (Davies et al., 2012; Reshetnik et al., 2016).  
An Arteriograph validation study which measured PWV and AIX 5 times in 51 
patients and repeated measurements after 1 week in 35 patients by comparing it to 
clinically validated broadly accepted systems (SphygmoCor and Complior) showed 
that the correlations of PWV measured by Arteriograph with the values obtained 
using the SphygmoCor (r = 0.67, P<0.001) and the Complior (r = 0.69, P<0.001) 
were highly significant (Baulmann, Schillings, Rickert, Uen, Dusing, et al., 2008). 
AIX values obtained between the Arteriograph and SphygmoCor were very closely 
related (r = 0.92, P <0.001) (Baulmann, Schillings, Rickert, Uen, Dusing, et al., 
2008).  
The measurement of the selected cardiometabolic markers at multiple time points is 
another advantage, as it controls for factors that cause variability between subjects 
and can track an effect overtime (Hoyland, Dye, & Lawton, 2009), as well as 
eliminate error in measuring (Bhutta et al., 2013). 
Sample size calculation for the present study was based on change in FMD, an 
endothelial function/CVD marker, whereas most RCTs investigating the effect of 
vitamin D supplementation on cardiometabolic risk were originally powered based 
on muscle function and skeletal outcomes and not CVD outcomes. The present study 
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used population of overweight and obese adult males with a high prevalence of both 
vitamin D deficiency and increased CVD and metabolic risk, thus, the beneficial 
effect of vitamin D treatment would be significant in this cohort and the likelihood of 
reverse causation would be decreased. The daily high dose administered is additional 
study strength, as most RCTs in the overweight and obese have administered lower 
daily doses or single large doses. When a post hoc was performed using mean (±SD) 
of sE-selectin concentrations post intervention for vitamin D; 47.2 ± 32.5 ng/mL and 
placebo group; 41.7 ± 22.0 ng/mL, given the present study sample size, the achieved 
level of power was 0.20. This indicates that sample size was too small to gain a 
significant value due to PhD time and budget restraints. To achieve a 0.80 power a 
sample size of 40 in each intervention arm would be required and this would be an 
effective future study. 
2.4.12 Study limitations 
There are several possible reasons for the lack of beneficial effects of vitamin D 
supplementation on cardiometabolic risk markers in this trial. Firstly, vitamin D 
supplementation has been reported to be effective in people with low baseline serum 
25(OH)D concentration, and only 22.2% (11/54) and 33.3 % (18/54) of present study 
participants had a plasma 25(OH)D concentration ˂ 25nmol/L and ˂ 30nmol/L 
respectively, independent of treatment group. Thus, it was not possible to test this 
hypothesis from the present study.  A larger dose of vitamin D and a longer duration 
of supplementation may be required, as plasma 25(OH)D concentrations ˃75nmol/L 
are required for optimal extra-skeletal health (Bischoff-Ferrari, 2008). In the present 
study, BMI was measured, but percentage of body fat distribution was not measured 
because as at the time of data collection, equipment for measuring body fat 
distribution was not available. Most of the study participants were ˂50 years and 
physically active, thus they may have less established structural changes in their 
arterial tree as demonstrated by the vascular markers. Since cardiometabolic risk 
increases with age, and only a small number of participants over 50 years were 
recruited, the ability to detect significant differences in this age group was limited. 
Furthermore, evidence suggests that altered vitamin D homeostasis may contribute to 
increased CVD risk with increasing BMI, this association has been observed with 
serum 25(OH)D concentrations ˂43nmol/L (Snijder et al., 2005), and only 53.7% of 
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study participants had plasma 25(OH)D concentrations ˂43nmol/L in both groups at 
baseline. Finally, the present study did not investigate the role of VDR genotype 
polymorphism in determining plasma 25(OH)D concentrations in adiposity (Ochs-
Balcom et al., 2011), as it has been reported to affect individual response to vitamin 
D intake in obese individuals (Neyestani et al., 2013).  
2.4.13. Future perspectives 
It is highly recommended that a threshold value for 25(OH)D concentration be 
determined to prevent atherosclerosis and reduce cardiometabolic risk in overweight 
and obese individuals. No significant improvement in arterial stiffness, as assessed 
by PWV and AIx and other indices using the Arteriograph was observed in this RCT, 
thus, further research using FMD and other devices of measuring arterial stiffness are 
required in this cohort. RCT studies involving a large number of overweight and 
obese people are required to generalise the results of this study. RCT studies using a 
similar population with vitamin D deficiency and CVD disease may show significant 
impact of vitamin D supplementation. It would be important to measure circulating 
VDBP concentrations in the overweight and obese males, as it has been reported to 
be reduced in acute inflammatory conditions. Few RCTs in overweight and obese 
people have focussed on the effect of VDR genotype polymorphisms on circulating 
plasma 25(OH)D concentration. Measuring VDR genotype polymorphisms may be 
significant in understanding the variations in individual response to oral vitamin D 
supplementation in the overweight and obese. 
2.4.14 Conclusion 
Overall, the findings from this RCT demonstrate that a daily dose of 5,000IU 
(125µg) vitamin D3 for 8 weeks increased plasma 25(OH)D concentrations to 
≥75nmol/L in 45.8% of the study cohort, but did not significantly affect the 
cardiometabolic risk markers measured except for brachial pulse pressure. However, 
there is suggestion that baseline plasma 25(OH)D concentration influences the effect 
of vitamin D repletion on cardiometabolic markers. Improved vitamin D status was 
inversely associated with change in plasma glucose concentrations (r = -0.408, P = 
0.048), and with change in HDL-C concentrations (r = -0.503, P = 0.012) and 
positively associated with change in aortic central pulse pressure (r = 0. 437, P = 
0.033) at week 4. Improved vitamin D status post intervention was inversely 
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associated with change in brachial augmentation index (r = -0.446, P = 0.029). 
However, the association between change in 25(OH)D and change in HDL-C 
concentrations, change in PPao, were absent at week 8. 
The absence of a significant treatment effect on the selected cardiometabolic markers 
suggests that vitamin D supplementation cannot be effectively used to prevent 
cardiometabolic disease risk in healthy overweight/obese males. As a result, the 
present study does not support the hypothesis that high daily dose vitamin D 
supplementation reduces or prevents cardiometabolic disease risk in a cohort of non-
hypertensive and non-diabetic overweight and obese adult males. The estimated data 
for mean dietary intake of vitamin D in the cohort was inadequate compared to the 
recommended RNI for vitamin D in the general UK population. As a result of the 
variations in vitamin D metabolism in overweight and obese people compared to 
normal weight people, and a reported low mean dietary vitamin D intake, it is 
important that a specific higher daily dose of vitamin D be recommended for the 
overweight and obese. Finally, the association between serum/plasma 25(OH)D 
concentrations and various health outcomes as reported among systematic reviews 
and meta-analyses from observational studies and RCTs provides little evidence of 
an association between vitamin D and various obesity-related outcomes including 
cardiometabolic disease (Theodoratou et al., 2014). A possible explanation for this 
difference may be that obesity-related clinical disease leads to decreased vitamin D 
concentrations, producing insufficiency, rather than causing ill health (Theodoratou 
et al., 2014). 
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3.0 VITAMIN D STATUS AND CARDIOVASCULAR DISEASE RISK IN A 
COHORT OF CALCIUM OXALATE KIDNEY STONE DISEASE 
PATIENTS. 
3.1 INTRODUCTION 
Kidney stones are hard crystalline mineral deposit that develops within the kidney or 
urinary tract. They are formed when urine becomes supersaturated with the salt and 
minerals secreted by the kidneys due to an imbalance between the precipitation and 
solubility of these salts (Han, Segal, Seifter, & Dwyer, 2015; Reid, Jackson, Duer, & 
Rodgers, 2011). Kidney stone disease are highly prevalent systemic disorder with a 
major health and economic burden (Keddis & Rule, 2013). There is a gradual 
increase in kidney stone incidence and prevalence globally (Romero, Akpinar, & 
Assimos, 2010), and approximately 1-5% of populations in Asia, 5-9% in Europe, 
10-15% in the USA and 20-25% of populations in the Middle East are affected, with 
the smallest prevalence been recorded in Japan and Greenland (Najeeb et al., 2013). 
Over the last 10 years there has been a 63% growth in the prevalence, with 720,000 
people estimated to be living with kidney stones in the UK (Romero et al., 2010; 
Turney, Reynard, Noble, & Keoghane, 2012).  
Kidney stone incidence is influenced by age, sex, race and ethnicity, formerly, 
Caucasian males between the ages of 20 and 60 had a higher incidence compared to 
young African American females (Dawson & Tomson, 2012; Lieske et al., 2006; Romero 
et al., 2010). However, recently the gap has closed, as the incidence in females is 
almost equivalent to that of males, around 3 in 20 males and 1 in 20 females develop 
kidney stones in the UK (Turney et al., 2014). Without medical treatment there is a 
50% risk of kidney stones reoccurring within 5-10 years and 75% likelihood within 
20 years, however, in most cases this depends on the disease causing the stone 
formation (Dawson & Tomson, 2012). The incidence of kidney stones depends on 
risk factors including dehydration, urinary tract infections, low urine volume and 
calcium intake, geographical, genetic and dietary factors amongst others (Dawson & 
Tomson, 2012; Fakheri & Goldfarb, 2011; Wang, Chen, Song, Caballero, & 
Cheskin, 2008). The incidence of kidney stones is expected to rise following the 
global increase in people being overweight and obese and the improvement in 
socioeconomic status of the population (Najeeb et al., 2013). 
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Kidney stone disease is a risk factor for chronic renal disease, as kidney stones can 
result in the development of chronic tubule-interstitial nephritis, estimated to account 
for 15-30% of end stage chronic insufficiency known to give rise to end stage renal 
disease (Dardamanis, 2013). Polymorphisms and mutations of CYP24A1 genes have 
been implicated as a further factor responsible for the high risk of kidney stones 
(Dinour et al., 2013), because variants of the CYP24A1 gene have been identified in 
a small number of calcium kidney stones formers (Sayers, Hynes, Rice, Hogg, & 
Sayer, 2013). 
3.1.1 PATHOMECHANISMS OF KIDNEY STONE FORMATION 
Urinary supersaturation is the primary stimulus for crystallisation (Aggarwal, Narula, 
Kakkar, & Tandon, 2013). A solution is considered saturated when it has reached a 
particular concentration beyond which no further dissolution is possible (Aggarwal et 
al., 2013). At this degree of saturation if more salts are added to the saturated 
solution, it will precipitate and form crystals as long as the temperature and pH 
remain constant and if inhibitors of crystallisation do not act at this stage kidney 
stones will be formed (Aggarwal et al., 2013). The pathomechanisms of stone 
formation include crystal nucleation, aggregation and crystal growth, although a 
mechanism for the high degree of supersaturation of stones differs depending on the 
stone type (Dardamanis, 2013). 
3.1.1.1 Crystal nucleation 
Nucleation is the initial step in the change from a liquid to a solid phase in a 
supersaturated solution (Dardamanis, 2013). The nucleus is produced from 
microcrystals formed by the supersaturation of stone forming salts such as calcium, 
oxalate and cysteine in the urine (Sakhaee, 2009). The nucleus usually forms on 
existing surfaces in urine, a process known as heterogeneous nucleation, although it 
is also capable of forming on epithelial cells, urinary casts, red blood cells, amongst 
others in urine (Dardamanis, 2013). The degree of saturation required for 
heterogeneous nucleation is much less than for homogenous nucleation (Smith, 
1990). Once a nucleus is formed and anchored, crystallisation possibly occurs at 
lower chemical pressures than that required for the formation of the initial nucleus 
(Fasano & Khan, 2001). Renal tubular cell injury is capable of inducing the 
crystallisation of CaOx crystals by providing substances for their heterogeneous 
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nucleation (Aggarwal et al., 2013). Following renal tubular cell injury, in vitro cell 
degradation produces several membrane vesicles, reported to be good nucleators of 
calcium crystals. (Fasano & Khan, 2001). 
3.1.1.2 Aggregation 
Aggregation, a critical step, is the process by which microcrystals (nucleus) in 
solution increase in size to form a large mass made up of proteins, lipids, 
polysaccharides and other cell derived materials by interacting with each other 
(Aggarwal et al., 2013; Dorian, Rez, & Drach, 1996). To have the capacity to cause 
occlusion in the distal nephron, the formed mass must be large. Aggregation also 
involves the secondary nucleation of new crystals on the surface of already formed 
crystals (Gower, Amos, & Khan, 2010; Sandersius & Rez, 2007). For aggregation to 
occur supersaturation of urine, lack of inhibitors of nucleosis and the type of organic 
substrate and epitaxis are required for crystals to adhere to the epithelial surface of 
crystals of a different chemical structure, for example the adherence of calcium 
oxalate crystals onto struvite crystals (Dardamanis, 2013). 
3.1.1.3 Crystal growth and crystal cell interaction 
Crystal growth is an essential phase for kidney stone formation. It is the process by 
which new crystal components are added to an existing crystal. It occurs after a 
crystal must have attained a pathophysiological critical size by aggregation and with 
the relative supersaturation still remaining above one (Hu, Hu, Wang, Lu, & Qin, 
2011). Crystal cell interaction occurs when microcrystals formed from urine 
supersaturation attach and adhere to renal tubular epithelial cells. Crystal-cell 
interactions is also an important early process in the development of kidney stones 
(Khan et al., 1999). 
3.1.2 Promoters of kidney stone formation 
Promoters bring about stone formation, as they increase the rate of crystallisation or 
growth of the constituents of kidney stones (Khan & Kok, 2004). Urinary saturation 
can be raised by increasing the concentration of the reactants. Urine may contain 
substances that are capable of lowering the formation product, however, the 
formation product may also be lowered by the absence of endogenous inhibitors, or 
obstruction to their effects by defects in their structure or other interfering substances 
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(Farell, Huang, Kim, Horstkorte, & Lieske, 2004). Extremely high urinary pH, low 
urine volume and urate/uric acid may promote the formation of heterogeneous 
nucleating substances (Farell et al., 2004; Moe, Abate, & Sakhaee, 2002). 
A highly acidic urine causes the precipitation of uric acid crystals which may lead to 
uric acid stone formation and may also enhance calcium oxalate crystallisation (Moe 
et al., 2002). Highly alkaline urine may also promote secondary nucleation of 
calcium oxalate by precipitation of calcium phosphate (Ratkalkar & Kleinman, 
2011). Reduced urinary volume resulting from either inadequate intake or excessive 
loss of liquid through the intestinal tract or sweating would intensify the saturation of 
all solutes, in turn increasing the risk of the various type of kidney stones formation 
(Moe, 2006). In addition to low urine volume, uric acid or monosodium urate 
enhances the attachment of calcium oxalate to cells whilst promoting heterogeneous 
nucleation (Farell et al., 2004). 
3.1.3 Inhibitors of kidney stone formation 
The various types of kidney stone inhibitors in urine include osteopontin (OPN) 
nephrocalcin (NC), Tamm-Horsfall protein (THP) and urinary prothrombin fragment 
1 (UPTF1) (Ratkalkar & Kleinman, 2011). These inhibitors have been proposed to 
protect the body against kidney stones development ; abnormalities of these 
inhibitors may lead to stone formation, growth and also calcification (Dardamanis, 
2013). 
3.1.3.1 Tamm- Horsefall protein  
THP is a major component of kidney stones regardless of the stone type (van 
Rooijen, Voskamp, Kamerling, & Vliegenthart, 1999), and is capable of inhibiting 
the aggregation of crystals, thus, making them unable to form a mass big enough to 
cause occlusion (Viswanathan et al., 2011). However, THP is also capable of acting 
as a promoter of crystal deposition, depending on the experimental condition 
(Grover, Ryall, & Marshall, 1990; Viswanathan et al., 2011). One isoelectric 
focusing study which chemically desialylated (removal of sialic acid residues) THP 
isolated from a healthy individual showed that desialylated THP promoted calcium 
oxalate monohydrate aggregation, whilst normal THP inhibited aggregation 
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(Viswanathan et al., 2011). It has been hypothesised that the THP of stone formers is 
structurally different from that of the healthy populations (Hess, 1991). 
3.1.3.2 Nephrocalcin    
NC is a principal inhibitor of urinary calcium oxalate (CaOx) crystallisation, as it`s 
activity is responsible for approximately 90% of urine's total inhibitory effect on 
calcium oxalate crystallisation (Aggarwal et al., 2013). NCs potent ability to inhibit 
CaOx crystallisation is mediated through its Gla component (Edson et al., 2013). It 
has been suggested that the absence of Gla component in nephrocalcin isolated from 
CaOx kidney stones could be the reason for the formation of the kidney stones 
(Jonassen, Kohjimoto, Scheid, & Schmidt, 2005). There are at least four isoforms of 
NC, NC-A, NC-B, NC-C, and NC-D (Kurutz, Carvalho, & Nakagawa, 2003). The 
organic matrix of calcium oxalate kidney stones was found to have greater quantities 
of NC-C and NC-D isoforms than those of NC-A and NC-B isoforms found in 
people with normal kidney function (Kurutz et al., 2003).  
3.1.3.3 Osteopontin 
OPN is synthesised within the kidney and is present in the human urine. OPN is a 
negatively charged aspartic acid rich protein significant in bone mineralisation. 
Compared to nephrocalcin, OPN is more abundant in uric acid stones and with both 
calcium oxalate monohydrate and calcium dehydrate crystals (Kaneko et al., 2012). 
In vitro studies have shown that OPN may suppress the nucleation, growth, and 
aggregation of calcium oxalate crystals. In addition, OPN also inhibits the crystal 
adhesion to cultured epithelial cells (O'Brien et al., 1994). OPN may also act as a 
stone promoter because it has been found to increase crystal adhesion when bound to 
the surface of cells (Yamate, Kohri, Umekawa, Iguchi, & Kurita, 1998). A study by 
Nishio et al., (2000) reported reduced concentrations of OPN in urine from kidney 
stones patients compared to normal individuals (Nishio et al., 2000).  
3.1.3.4 Urinary prothrombin fragment 1  
UPTF1, is a potent inhibitor of calcium oxalate crystal aggregation and growth and 
reduces its adhesion to renal cells (Kumar, Farell, & Lieske, 2003; Worcester, 
Sebastian, Hiatt, Beshensky, & Sadowski, 1993). UPTF1 is a primary and minor 
constituent of both CaOx and uric acid crystals respectively (Aggarwal et al., 2013). 
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There is evidence that the amount of UPTF1 in  kidney stones patients is 
significantly greater than in those of healthy subjects (Stapleton, Timme, & Ryall, 
1998). The potent inhibitory effect of UPTF1 on CaOx crystallisation has been 
attributed to the Gla domain of the peptide found to be absent from its thrombin and 
F2 and both PT and F1 fragments (Grover & Ryall, 2002). 
3.1.4 TYPES OF KIDNEY STONE 
Generally, there are four types of kidney stones, with each type being distinguished 
by its own natural history and pathogenesis. 
3.1.4.1 Calcium kidney stones  
Calcium kidney stones account for 80% of all stone types. The majority of calcium 
stones are made up of calcium oxalate, with minimal calcium phosphate contribution 
(15%) (Xu, Zisman, Coe, & Worcester, 2013).  
3.1.4.1.1 Calcium oxalate and phosphate kidney stones  
Calcium oxalate kidney stones are formed when urine in the renal tubule is hyper-
saturated by oxalate and calcium, which together forms crystals of dehydrated 
calcium oxalate (COD) and oxalic calcium monohydrated calcium oxalate (COM) 
(Lieske & Deganello, 1999). Calcium phosphate kidney stones are formed when 
urine pH is persistently alkaline and raised and are characterised by low serum 
bicarbonate concentration, hyperchloraemic metabolic acidosis, and hypokalaemia 
(Goldfarb, 2012). Various pathmechanisms including high calcium excretion in urine 
(hypercalciuria), high oxalate excretion in urine (hyperoxalouria), low citrate 
concentration in the urine (hypocitraturia), excessive concentrations of uric acid in 
urine (hyperuricosuria), reduced urine volume and abnormal urine pH are responsible 
for most calcium kidney stones formation. Systemic diseases including 
malabsorptive disorders (inflammatory bowel disease, severe diarrhoea or the 
resection of the intestine), and primary hyperparathyroidism also leads to formation 
of kidney stones, but to a lesser degree (Sakhaee, Maalouf, & Sinnott, 2012).   
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3.1.4.2 Uric acid stones 
Uric acid stones account for 5% of total kidney stones (Han et al., 2015). 
Hyperuricosuria, characterised by the excessive production of uric acid increases the 
risk for the development of uric acid kidney stones (Ratkalkar & Kleinman, 2011). 
The causes of uric acid formation can be acquired, congenital and idiopathic, with 
idiopathic being the most common cause. A high purine diet, chronic diaorrhea, 
stressful physical exercise and inborn error of metabolism have not been implicated 
in the clinical and biochemical presentation of idiopathic uric acid kidney stones. 
Reducing the consumption of a purine rich diet can lead to marked improvement in 
urinary uric acid elimination (Sakhaee et al., 2012). The primary factors responsible 
for uric acid stone development in addition to hyperuricosuria include reduced urine 
volume and acidic urine (Dardamanis, 2013).  
3.1.4.3 Struvite kidney stones 
Struvite kidney stones, also known as infection stones, account for 15% of kidney 
stones (Dardamanis, 2013). Severe urinary tract infections (UTI), especially urease-
producing bacteria (Klebsiella, Pseudomonas and Proteus) have been implicated as 
the cause as they increase the production of ammonia, carbonate and urinary pH in 
unison. The ensuing increased urine pH and ammonium concentrations promote the 
growth of struvite, either alone, or mixed with pre-existing calcium kidney stones 
(Zisman, Evan, Coe, & Worcester, 2015). Struvite kidney stones are three times 
more prevalent in women than men, since UTIs occur most in women (Flannigan, 
Choy, Chew, & Lange, 2014). Struvite stones may also form on infected UA or 
cystine as well as calcium stones, especially after surgical procedures and are likely 
to grow back after surgical removal because infected fragments of stones have been 
left behind (Trinchieri, 2014). 
3.1.4.4 Cystine kidney stones 
Cystine kidney stones only affect patients with cystinuria, an autosomal recessive 
disorder resulting from the abnormal renal tubule transport of dibasic amino acids, 
including cystine which in turn leads to high excretion of cystine in urine (Dawson & 
Tomson, 2012). It accounts for only 1% of patients with kidney stones in adults but 
is wide spread amongst children and adolescents with kidney stones (Chillaron et al., 
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2010). Cystinuria is equally distributed among males and females, diagnosis can be 
made by finding typical hexagonal crystals in the urine (Fattah, Hambaroush, & 
Goldfarb, 2014; Mattoo & Goldfarb, 2008). Urinary tract infection and obstruction 
are common features of these stones, and is likely to reoccur every 1-4 years (Han et 
al., 2015). 
3.1.5 KIDNEY DISEASE AND VITAMIN D SYNTHESIS 
Vitamin D and PTH are the key regulators of calcium homeostasis, and the kidneys 
are the primary target organs affected by calcium regulatory hormones. The 
development of kidney disease is characterised by a decline in functional nephrons 
and glomerular filtration rate (GFR), which in turn decreases the renal excretion of 
phosphate, leading to increased serum calcium and phosphate concentrations (Gal‐
Moscovici & Sprague, 2007; Mozos & Marginean, 2015; Nigwekar, Bhan, & 
Thadhani, 2012). An increased serum phosphate concentration triggers the 
production of serum FGF-23, which downregulates the expression of renal 1α-
hydroxylase (CYP27B1) and upregulates 24-hydoxylase (CYP24A1) activity, 
resulting in reduced serum vitamin D concentrations (Fig 3.1) (Wolf et al., 2011). 
The reduced serum vitamin D concentrations cause a reduction in ionised serum 
calcium concentrations and an increase in serum PTH secretion (Secondary 
hyperparathyroidism) (Brito Galvao, Nagode, Schenck, & Chew, 2013). Under 
normal physiologic conditions, increased serum PTH concentrations upregulates the 
activity of CYP27B1, which causes an increase in vitamin D concentrations. 
However, in late CKD due to loss of functional tubules, increased serum PTH has 
been reported to be unable to regulate vitamin D synthesis (Brito Galvao et al., 2013) 
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Fig 3.1 Role of reduced kidney function in vitamin D synthesis 
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3.1.5.1 Impaired vitamin D synthesis in kidney disease 
Kidney disease patients have low vitamin D concentrations due to the increased 
secretion of FGF-23 from osteocytes (Hasegawa et al., 2010). The increase in FGF-
23 as previously mentioned impairs vitamin D metabolism by reducing renal 
CYP27B1 mRNA expression and activity (Perwad & Portale, 2011). An increased 
circulating FGF-23 concentration in early CKD has been observed (Hasegawa et al., 
2010). Rats with progressive CKD that were not treated with anti-FGF-23 
neutralising antibody were found to have raised circulating FGF-23, PTH, and were 
vitamin D deficient and insufficient, thus demonstrating that higher FGF-23 leads to 
reduced vitamin D concentrations in early stage CKD. Low renal CYP27B1 
expression, and raised renal CYP24A1 expression were also observed (Hasegawa et 
al., 2010). However, on administering FGF-23 antibodies, renal CYP27B1 mRNA 
expression increased, renal CYP24A1 mRNA expression decreased, and circulating 
vitamin D was restored to normal levels (Hasegawa et al., 2010), even though low 
serum vitamin D have not been consistently linked with decreases in renal CYP27B1 
(Helvig et al., 2010). 
Renal CYP27B1 activity may possibly be suppressed by acidic, hyperuricaemic, and 
uraemic milieu (Takahashi et al., 1998), as kidney abnormalities including high uric 
acid, are likely  to decrease CYP27B1 expression (Vanholder, Patel, & Hsu, 1993).  
A study which investigated the effect of the uraemic toxin, uric acid on plasma 
concentrations of vitamin D in 9 renal failure patients found that uric acid, which is 
often raised in renal failure inhibits CYP27B1 activity and the synthesis of vitamin D 
(Vanholder et al., 1993). 
Increased circulating FGF-23 in kidney disease also promotes the transcription of 
CYP24A1 which leads to an increase in 25(OH)D and 1,25(OH)2D catabolism 
(Jones et al., 2012; Petkovich & Jones, 2011). Given the effects of FGF-23 on 
CYP27B1 and CYP24A1 transcription, observations from studies that have assessed 
the significance of CKD on renal CYP27B1 and CYP24A1 expression and activity 
have shown conflicting results. A study in nephrectomised rats, which investigated 
the changes in mRNA levels of CYP27B1 and CYP24A1, showed significant 
increase in CYP27B1 and decrease in CYP24A1 mRNA expression (Takemoto et al., 
2003). Another study in a rat model aimed at evaluating whether CYP24A1 and 
CYP27B1 expression is altered in uraemia and in normal, adenine-induced CKD, as 
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well as in renal biopsy tissue from patients with kidney disease reported high 
circulating CYP24A1 mRNA expression in diseased compared to healthy renal tissue 
(Helvig et al., 2010). Results from this study suggested that the increase may be 
induced by factors associated with the uraemic state, which may have significant 
effects on vitamin D status and possibly affect tissue responsiveness to vitamin D 
therapy. This study also reported increased renal CYP27B1 mRNA and protein 
concentrations in the adenine-induced CKD rats, suggesting that the observed 
reductions in vitamin D concentrations were not due to changes in CYP27B1 
expression and activity (Helvig et al., 2010). 
The reduced vitamin D synthesis observed in kidney disease may also be due to 
disruptions in 25(OH)D transport to CYP27B1 in the renal proximal tubule by 
megalin and cubulin, as megalin expression in renal tubules declines in kidney 
disease (Bosworth & de Boer, 2013). It has been observed that less 25(OH)D is 
filtered following diminishing GFR, thus, leaving little 25(OH)D available for 
reabsorption into the proximal tubules of the kidneys. The decline in the expression 
of megalin in kidney disease may hinder filtration of 25(OH)D and may cause 
albuminuria (Takemoto et al., 2003). Due to the ensuing albuminuria presence in 
kidney disease, the filtered 25(OH)D which normally goes through proximal tubular 
reabsorption may be lost in urine (Thrailkill, Jo, Cockrell, Moreau, & Fowlkes, 
2011). Albuminuria may also be accompanied by high urinary loss of VDBP, leading 
to increased renal loss of all vitamin D metabolites (Andress, 2005). In  non–
haemodialysis patients with CKD stages 1 to 5, Gonzalez et al. found that 10 of 11 
patients with nephrotic albuminuria had remarkably low serum concentrations of 
25(OH)D (Gonzalez, Sachdeva, Oliver, & Martin, 2004). Even though 25(OH)D 
substrate is well absorbed into the proximal tubules, conversion to 1,25(OH)2D may 
be hindered by diminished CYP27B1 activity (Levin et al., 2007), or by the reduced 
metabolic capacity of the proximal tubular cells due to oxidative stress or a reduction 
in functioning nephrons (Granata et al., 2009). Furthermore, the increased PTH 
concentrations associated with low vitamin D concentrations depletes vitamin D 
body stores by promoting 24, 25-dihydroxylases (Shimada, Hasegawa, et al., 2004).  
Several factors independent of renal function have been implicated for vitamin D 
deficiency in kidney disease (Nigwekar et al., 2012). Patients with kidney disease are 
likely to have reduced sun exposure (Hu et al., 2011) and impaired skin synthesis of 
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vitamin D after UVB irradiation, despite having normal epidermal content of 7DHC 
(Nigwekar, Tamez, & Thadhani, 2014). Advancing kidney disease is associated with 
diverse cutaneous abnormalities including hyperpigmentation (Udayakumar et al., 
2006). The hyperpigmentation is caused by  increasing melanin, in the epidermis due 
to an increase in the uraemic toxin known as non-dialysable middle molecules 
(Robinson-Bostom & DiGiovanna, 2000). The progressive retention of this uraemic 
toxin in the epidermis that absorbs UVB irradiation resulting in hyperpigmentation 
may be responsible for the reduced vitamin D synthesis in kidney disease 
(Abdelbaqi-Salhab, Shalhub, & Morgan, 2003; Kim & Kim, 2014). Furthermore, 
intake of foods rich in vitamin D such as dairy products and egg yolk are reduced in 
patients with kidney disease because of the dietary restrictions advised to kidney 
disease patients. The purpose of the diet restrictions is to maintain the levels of 
electrolytes, minerals, and fluids and to limit the accumulation of waste products in 
the body of kidney disease patients (Cuppari & Garcia-Lopes, 2009). Dysfunctional 
kidneys have also been reported to impair gastrointestinal vitamin D absorption 
(Nigwekar et al., 2012). Kidney disease is also characterised by a gradual loss of 
VDR in the parathyroid gland resulting in vitamin D resistance (Fukuda et al., 1993). 
In addition, low concentrations of vitamin D further lead to impaired binding of 
vitamin D to VDR, as well as in the binding of the vitamin D/VDR complex to the 
VDRE in kidney dysfunction compared with normal kidney function (Patel, Ke, 
Vanholder, Koenig, & Hsu, 1995). This could mean that vitamin D may not be able 
to exert its primary biological effects on tissues and organs in kidney disease or VDR 
activity is reduced in kidney disease. 
3.1.6. KIDNEY STONE, VITAMIN D AND CVD RISK 
There is impaired renal function in kidney stone disease (Zisman, Evan, Coe, & 
Worcester, 2015), thus kidney stone disease is a risk factor for CKD, as it has been 
reported that the risk for developing CKD among kidney stone patients was 50-67% 
higher, compared to controls with normal kidney function (Rule et al., 2009). CKD is 
characterised by low serum 25(OH)D concentrations and increased CVD risk (Kim 
& Kim, 2014). The increased risk of CKD in kidney stones patients would 
predispose them to increased CVD risk (Rule et al., 2010). CVD risk is higher in 
kidney disease patients compared to patients with normal kidney function. A study in 
4,564 kidney stone disease formers and 10,860 age and gender matched controls 
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showed that kidney stone disease formers had increased risk of myocardial infarction 
compared with the controls (Rule et al., 2010). Kidney stone disease formers have 
also been reported to be more likely to have baseline diagnosis of dyslipidaemia, 
hypertension, diabetes and obesity (Hamano et al., 2005). The increased CVD risk in 
kidney stone disease patients may be attributed to sharing common pathomechanisms 
with CVD (Rule et al., 2010). Uraemia, characterised by fluid, electrolyte and 
hormone imbalance, as well as metabolic anomalies, develops with the decline of 
kidney function (Odabaei, Kaysen, & Ananthakrishnan, 2014). Uraemia has been 
reported as the established link between CVD and kidney disease, as it increases 
CVD burden (Fahal, 2014). The increase in CVD risk in kidney disease, may be due 
to several risk factors including impaired calcium and phosphate, low serum 
25(OH)D concentrations, elevated PTH, renal inflammation, endothelial dysfunction, 
increased oxidative stress and dyslipidaemia (Brunet et al., 2011; Nakano et al., 
2010).  
In the kidneys, besides regulating renal inflammation and fibrosis (Wang et al., 
2006), vitamin D exerts important renal reclamation of filtered 25(OH)D, important 
in maintaining sufficient serum/plasma 25(OH)D concentrations. Sufficient serum 
25(OH)D concentration is important for the pleiotropic actions of vitamin D in 
endothelial cells, cardiac and vascular smooth muscle, mediated through the 
autocrine/paracrine pathways that impart the health of these tissues (Brito Galvao et 
al., 2013; Hur et al., 2009). However, these important cardioprotective functions of 
vitamin D are lost with declining kidney function leading to reduced serum 25(OH)D 
concentrations and increased CVD risk (Kim & Kim, 2014).  
3.1.6.1 Vitamin D, impaired calcium-phosphate product and CVD 
As previously mentioned, vitamin D together with PTH, acts to maintain serum 
phosphate and calcium concentrations within normal limits, thus sustaining an 
optimal calcium-phosphate product for bone mineralisation without deposition in soft 
tissues (Moe, 2008). Since calcium and phosphorus are critical elements in vascular 
calcification, the association between vitamin D deficiency and CVD risk in human 
kidney disease may in part be mediated through disruptions in calcium-phosphate 
homeostasis (Moe, 2008). The pathological pathways responsible for kidney stone 
formation are also involved in coronary artery calcification or calcium (CAC) that 
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leads to atherosclerosis (Yiu, Callaghan, Sultana, & Bandyopadhyay, 2015). 
Increased serum calcium-phosphate product may result in kidney stone formation 
(London et al., 2007) and may as well cause the precipitation and deposition of 
calcium and phosphate in arteries resulting in arterial calcification (Covic, 
Voroneanu, & Goldsmith, 2010). A study which investigated the distribution of 
calcium-phosphate in all kidney stone types, found that whilst increased serum 
calcium concentrations stimulated the mineralisation of VSMC, increased serum 
phosphate concentrations enhanced the mineralisation (Parks, Worcester, Coe, Evan, 
& Lingeman, 2004).  Increased serum calcium and phosphate product have also been 
reported to facilitate calcification in CKD (Cozzolino, Brancaccio, Gallieni, & 
Slatopolsky, 2005). Based on the hypothesis that vitamin D regulates calcium and 
phosphate product, inverse associations between vitamin D status and arterial 
calcifications (r =−0.18; P = 0.024) were reported in a cross section of 173 people at 
risk for coronary heart disease (Watson et al., 1997). Serum FGF-23 concentrations 
are also involved in arterial calcification, as vitamin D induces FGF-23 secretion and 
is in turn inhibited by increased FGF-23 concentrations (Zisman & Wolf, 2010). 
Additionally, an increased circulating FGF-23 concentration is associated with 
arterial calcification in patients with all stages of CKD, even though its function is 
not well understood (Shimada et al., 2010). 
Associations between coronary artery calcification determined by coronary artery 
calcium (CAC) in recurrent kidney stone have been reported in a USA multi-ethnic 
study in 6,814 men and women free of CVD from 2010-2012 (OR 1.80, 95% CI 
1.22-2.67) (Hsi et al., 2015). Vascular calcification in kidney disease may also result 
from the imbalance between promoters and inhibitors of kidney stone formation 
(Shanahan, 2005). Kidney stone patients compared with non–stone forming people, 
are more prone to vascular calcifications due to decreased concentrations of 
uropontin, a glycoprotein that inhibits calcification in urine (Kleinman, Wesson, & 
Hughes, 2004). Hence, it may be possible that vascular calcification is present in 
kidney stone patients, particularly calcium oxalate kidney stone patients, as mice 
deficient in this glycoprotein have been reported to develop calcium oxalate stones 
after hyperoxaluria was induced (Wesson et al., 2003). It was hypothesised that 
increased plasma OPN concentrations may be associated with the presence of aortic 
valve calcification and stenosis. A study in 30 elderly (> 65 years) patients with 
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(n=23) and without (n=7) aortic stenosis, showed that patients with aortic stenosis 
had higher osteopontin levels compared with patients without aortic stenosis (652.2 ± 
218.7 vs 379.7 ± 159.9 ng/mL, P < .01) (Yu et al., 2009).  
Furthermore, the constant exposure of VSMCs to increased concentrations of 
calcium and phosphate directly induce the osteogenic transformation of VSMCs, 
initiating and promoting vascular calcification. This conversion is mediated by the 
activation of osteogenic/chondrogenic gene expression including Runt-related 
transcription factor 2 (RUNX2), alkaline phosphatase (ALP), osterix and OPN, and 
the subsequent downregulation of smooth muscle lineage gene expression (SMα 
actin, SM22α) (Shanahan, Crouthamel, Kapustin, & Giachelli, 2011). In addition to 
increased calcium and phosphate concentration, the increased production of ROS 
observed in calcium oxalate kidney stones have also been implicated in the 
osteogenic transformation of VSMC by also regulating RUNX2 transcription (Byon 
et al., 2008). 
3.1.6.2 Vitamin D, PTH and CVD risk in kidney disease 
Vitamin D impart benefits in kidney disease patients by lowering PTH concentration 
(Slatopolsky & Delmez, 1996). The FGF-23-mediated decrease in vitamin D 
synthesis stimulates PTH secretion and initiates secondary hyperparathyroidism 
(Seiler, Heine, & Fliser, 2009), which occurs prior to the development of 
phosphaturia observed in kidney disease (Folsom et al., 2014). PTH functions to 
regulate vitamin D, calcium and phosphate concentrations and to maintain skeletal 
integrity, as it stimulates the synthesis of vitamin D following a decline in vitamin D 
concentrations (Hagstrom et al., 2009; Hu et al., 2011). PTH performs extensive 
roles in health and diseases involving different organs and systems including the CV 
system. The presence of PTH receptors and PTH- related peptides in the myocardium 
and vasculature suggest a potential role of PTH in CVD (Potthoff et al., 2011).  A 
large observational study of a US cohort of CKD patients have shown that low serum 
25(OH)D  and elevated serum PTH concentrations are common with reduced kidney 
function (Levin et al., 2007). A meta-analysis of 17 observational and 5 RCT studies, 
showed significant improvement in serum/plasma 25(OH)D concentrations (MD 
24.1 ng/ml, 95% CI 19.6 to 28.6) and an associated reduction in serum/plasma PTH 
concentration (MD 41.7 pg/ml, 95% CI 55.8 to 27.7) amongst observational studies. 
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A significant improvement in serum/plasma 25(OH)D concentrations (MD 14 ng/ml, 
95% CI 5.6 to 22.4), with reductions in serum/plasma PTH concentrations (MD 31.5 
pg/ ml, 95% CI 57 to 6.1) were reported among the RCTs in CKD patients (Kandula 
et al., 2011). Similarly, in 14,289 unselected US CKD stages 3-5 patients, increased 
serum 25(OH)D concentrations, resulted in low serum PTH concentrations (Ennis, 
Worcester, Coe, & Sprague, 2016). These observations suggest that low serum 
25(OH)D concentrations observed in kidney disease will subsequently lead to 
increased serum PTH concentrations. 
Studies have also shown that severe increase in PTH concentration is associated with 
increased CV events including, hypertension, cardiac hypertrophy and myocardial 
infarction (Saleh, Schirmer, Sundsfjord, & Jorde, 2003; Snijder et al., 2007). The 
findings from a meta-analysis of 15 observational human studies conducted between 
1947 to October 2012, found an association between high PTH and a 1.45 fold 
increase in CVD events incidence compared with low levels of PTH HR 1.45 (1.24-
1.71; P < .001) (van Ballegooijen, Reinders, Visser, & Brouwer, 2013). A cross 
section of 558 men with high serum PTH had a significantly higher risk of 
calcification of the abdominal aorta compared with men in the low serum PTH group 
(OR 4.03, CI 1.50–10.83, P = 0.01) (Buizert et al., 2013). 
Elevated serum PTH concentrations have also been implicated in lipid abnormalities, 
as it promotes atherosclerosis in kidney disease. Associations have been reported 
between secondary hyperparathyroidism and the increased intima media thickness of 
both carotid and femoral arteries in CKD patients undergoing haemodialysis 
(Nishizawa, Shoji, Kawagishi, & Morii, 1997). Findings from this study showed that 
hyperparathyroidism adversely inhibits hepatic triglyceride lipase, a lipid-regulating 
enzyme that performs essential functions in HDL-C metabolism. However, a large 
community study of Whites and African Americans that measured PTH in stored 
serum samples from 1990 to 1992 did not demonstrate that elevated serum PTH 
concentration was associated with any CVD outcome marker (Folsom et al., 2014).  
Potential explanations for the association between high serum PTH concentration 
and CV mortality in kidney disease include the following: Firstly, the relationship 
between PTH and atherosclerosis is mediated through its association with endothelial 
dysfunction, raised aortic pulse pressure and decreased large artery elasticity 
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(Bosworth et al., 2013). Additionally, PTH exerts detrimental effects on the 
myocardium by inducing left ventricular hypertrophy, cardiac calcification and 
fibrosis (Andersson, Rydberg, & Willenheimer, 2004; Ellero et al., 2010). Finally, 
higher PTH is associated with inflammatory markers as it induces cytokine release 
from VSMCs and lymphocytes (Martin-Ventura et al., 2003). Thus, the interaction 
between high PTH levels due to vitamin D deficiency and cardiovascular mortality in 
kidney disease is complex. 
3.1.6.3 Vitamin D, inflammation and endothelial dysfunction in kidney disease 
Kidney diseases are characterised by renal inflammation, suggesting an important 
association between kidney disease and CVD (Tripepi, Mallamaci, & Zoccali, 2005). 
Patients with acute renal inflammation determined by urinary MCP-1 have been 
reported to have low serum 25(OH)D concentrations (Zehnder et al., 2008), which 
triggers both vascular and systemic inflammation (Yadav, Banerjee, Lal, & Jha, 
2012).  A cross-sectional study in 101 stage 4-5 non-dialysis CKD patients and 40 
healthy controls found higher mean (±SD) serum hs-CRP concentrations of 90.7 ± 
5.8 vs. 50.1 ± 8.6 µg/mL, (P ≤ 0.0001) with lower mean (±SD) serum 25(OH)D 
concentrations 44.8 ± 4.8 vs 67.3 ± 8.8 nmol/L, (P ≤ 0.0001) in the CKD patients 
compared with controls. The serum hsCRP concentration was inversely associated 
with serum 25(OH)D concentrations (r = -0.2, P = 0.047) in CKD patients (Yadav et 
al., 2012). 
Uraemia, which is observed in kidney disease causes endothelial dysfunction that 
downregulates NO synthesis, reducing the vasodilatory property of the endothelium 
resulting in early atherosclerosis (Brunet et al., 2011; Nakano et al., 2010). High 
occurrence of atherosclerosis in renal disease has been reported (Tonelli et al., 2001), 
a cross-sectional study of 126 autopsy samples showed that the incidence of 
advanced atherosclerotic lesions increased gradually as kidney function determined 
by eGFR decreased (33.6%, 41.7%, 52.3%, and 52.8% for eGFRs > or = 60, 45-59, 
30-44, and <30 mL/min/1.73 m respectively; P = 0.006) (Nakano et al., 2010). The 
uraemic toxin indoxyl sulphate, derived from dietary proteins has been shown to 
cause endothelial dysfunction by inducing leukocyte-endothelial interactions through 
the up-regulation of E-selectin (Ito et al., 2010). The assessment of the in vivo effect 
of indoxyl sulphate in nephrectomised CKD model mice demonstrated that indoxyl 
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sulphate magnified leukocyte-endothelial interactions through the up-regulation of E-
selectin, probably via the JNK- and NF-κB-dependent pathway (Ito et al., 2010).  
Additionally, another uraemic toxin, asymmetric dimethylarginine (ADMA), an 
inhibitor of NO synthase has been linked to reduced kidney function and increased 
atherosclerotic events. The study investigating the relationship between plasma 
ADMA and markers of atherosclerosis including carotid intima-media thickness 
(IMT), soluble vascular cell adhesion molecule-1 (sVCAM-1) in 93 patients with 
mild-to-moderate renal failure, found that kidney function was inversely associated 
with increased plasma ADMA (r = -0.342, P = 0.023). Increased plasma ADMA was 
in turn positively associated with carotid intima media thickness (r = 0.444, P < 
0.0001) and plasma sVCAM-1 concentration (r = 0.242, P = 0.022) (Nanayakkara et 
al., 2005).  
Low vitamin D concentrations observed in kidney disease patients have been shown 
to stimulate endothelial dysfunction resulting in early atherosclerotic vascular disease 
(Chitalia, Recio-Mayoral, Kaski, & Banerjee, 2012). A study which assessed the 
relationship between serum 25(OH)D concentrations and endothelial function 
determined by FMD in 50 non-diabetes patients with mild to moderate CKD, found 
that low serum 25(OH)D (≤37.5nmol/L) concentration were associated with low 
FMD (r = 0.44, P = 0.001) compared to patients with 25(OH)D  >37.5nmol/L, mean 
(±SD), 4.4 ± 2.5% vs. 2.5±1.6%, (P = 0.007) (Chitalia et al., 2012).  Another study in 
117 non-dialysis CKD patients showed that FMD was reduced in vitamin D deficient 
and insufficient compared to the vitamin D sufficient groups, with the lowest value 
observed in the vitamin D-deficient group (Zhang et al., 2015). This study also 
demonstrated that serum sVCAM-1 and sE-selectin were higher in the vitamin D 
deficient and insufficient groups compared to the vitamin D sufficient group, with 
the highest value been observed in the vitamin D deficient group. There was a 
positive association between FMD and serum 25(OH)D concentration (r = 0.556, 
P < 0.001) and inverse associations between serum 25(OH)D concentrations with 
serum sVCAM-1 (r = −0.549, P < 0.001) and sE-selectin concentrations (r = −0.360, 
P < 0.001) (Zhang et al., 2015). These observations suggest that low serum 25(OH)D 
concentrations are a significant factor linking CKD to CVD (Pilz et al., 2011). 
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3.1.6.4 Vitamin D, oxidative stress and CVD risk in kidney disease 
The release of ROS, resulting in oxidative stress in kidney dysfunction, has been 
implicated as the primary contributor of CVD in renal disease (Khan, 2014). Calcium 
oxalate kidney stones are excreted or retained in different parts of the urinary tract 
during their formation, and this retention usually obstructs the renal tubules (Joshi, 
Peck, & Khan, 2013). The obstructed renal tubules, in turn disrupt cellular functions 
by damaging cell membranes, and releasing both lipid mediators and ROS (Joshi et 
al., 2013). The release of ROS results in oxidative stress that in turn lead to renal 
injury, inflammation, decreased and impaired renal function and end stage renal 
disease (Joshi et al., 2013). Oxidative stress is responsible for the production of 
advanced glycation products and endothelial dysfunction (Sebekova et al., 2015), as 
it depletes NO signalling pathway resulting in the conversion of NO to peroxynitrite, 
a potent oxidant that oxidises anti-oxidants such as tetrahydrobiopterin. Absence of 
tetrahydrobiopterin leads to endothelial NOS uncoupling, which in turn modifies this 
enzyme from being vasoprotective to being an oxidative stress enzyme (Joshi et al., 
2013). Reduced NO may intensify inflammation and activate NF-kB pathway, which 
mediates severe inflammation and fibrogenesis through the modulation of cytokines, 
chemokines and adhesion molecules including IL-6, MCP-1, and TNF-α expression. 
The severe inflammation results in the expression of adhesion molecules such as E-
selectin on the endothelium and the proliferation of VSMC (Guijarro & Egido, 2001; 
Lassegue et al., 2001). Oxidative stress also increases uric acid production by the 
endothelium and kidneys that alters renal function. Increased uric acid production 
promotes severe inflammatory response in renal epithelial cells, whilst decreasing 
NO synthesis and activating NF-kB, thus, increasing the risk of CVD (Gersch et al., 
2008; Han et al., 2007; Umekawa, Chegini, & Khan, 2003). 
There is evidence that vitamin D deficiency increases the risk for diseases that are 
caused by oxidative stress as is observed in kidney disease, although such studies 
that reported a relationship between vitamin D status and oxidative stress to the best 
of my knowledge are absent in renal disease patients. A study in 1488 school 
children ages 7 to 11 years aimed at investigating 25(OH)D concentrations and its 
association with oxidative stress determined by superoxide dismutase found that the 
low serum concentration 25(OH)D <50nmol/L group had lower mean (±SD) 
concentrations of serum superoxide dismutase compared with those in the vitamin D 
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sufficient group, 95.38 ± 12.22 vs. 127.62 ± 15.98 U/mL, (P < 0.001) (Zhang et al., 
2014). 
3.1.6.5 Vitamin D, Dyslipidaemia and CVD risk in kidney disease 
Dyslipidaemia contributes to the associations between kidney disease and the onset 
of atherosclerosis (Moradi, Vaziri, Kashyap, Said, & Kalantar-Zadeh, 2013), as it is  
characterised by low plasma HDL, high TAG, TC, LDL-C and lipoprotein A 
concentrations (Hu, Lu, Hu, & Du, 2009; Vaziri & Moradi, 2006). The 
hypercholesterolemia observed in kidney dysfunction has been ascribed to increased 
hepatic synthesis of apolipoprotein B (apoB), whilst increased triacylglycerol 
concentrations results from impaired catabolism of TAG-rich lipoproteins (Vega, 
Toto, & Grundy, 1995). Dyslipidaemia is not only involved in increased CVD risk, it 
also accelerates the development of kidney dysfunction (Ritz & Wanner, 2008). 
Additionally, HDL-C performs essential roles in maintaining the integrity of the 
vasculature (Barter et al., 2007), and this function differs with varying clinical 
conditions (Sorrentino et al., 2010). The primary vasoprotective property of HDL-C, 
is its role in reverse cholesterol transport, which is the recovery and transport of 
excess cholesterol from extrahepatic tissues for clearance in the liver (Vaziri & 
Norris, 2011). 
The cholesterol clearance capacity of HDL-C has been reported to be decreased in 
patients with kidney disease compared to healthy individuals (Yamamoto et al., 
2012). Kidney disease which is linked with advanced glycation, oxidative stress, 
inflammation and uraemic toxins can alter HDL-C function by changing its lipid and 
protein composition (Holzer et al., 2011). Kidney dysfunction also stimulates 
posttranslational changes of HDL`s protein cargo (Zheng et al., 2004) by interacting 
with the HDL-C particle non-covalently (Speer et al., 2013). A dysfunctional HDL-C 
loses its ability to reverse cholesterol transport and its cardio-protective functions. 
Several studies have reported dyslipidaemia in kidney stone formers. A retrospective 
analysis of a random cohort of 60,000 patients found low concentrations of HDL-C, 
47 versus 50 mg/dL, (P = 0.001) to be associated with kidney stone compared with 
non-kidney stone patients (Masterson et al., 2015). A study aimed at evaluating the 
lipid profile of 49 kidney stone patients compared with the controls showed that 
mean (±SD) TC 218.6 ± 45.7 vs.195.4 ± 36.4 mg/dL, (P ˂ 0.05) and mean (±SD) 
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TAG 243.6 ± 200.2 vs. 127.5 ± 63.8 mg/dL (P ˂ 0.01) concentrations were 
significantly higher in kidney stones patients compared with the control (Inci, 
Demirtas, Sarli, Akinsal, & Baydilli, 2012). The study aimed at assessing the 
association between dyslipidaemia in 655 stone formers and 1965 controls found out 
that stone formers had significantly higher mean (±SD) TAG (166.9 ± 80.2 vs 138.0 
± 67.2 mg/dL, (P ˂ 0.001) with low mean (±SD) HDL-C concentrations 48.1 ± 12.3 
vs. 52.5 ± 13.1mg/dL, (P ˂ 0.001) compared with controls (Kang et al., 2014). One 
study which explored the regulators of cholesterol synthesis that results in lipid 
accumulation in human diabetic nephropathy, found significant downregulation of 
cholesterol efflux genes and APO E and the activation of most lipoprotein receptors 
(Herman-Edelstein, Scherzer, Tobar, Levi, & Gafter, 2014). These alterations in 
cholesterol metabolism gene expression are responsible for mediating increased 
cholesterol influx, whilst impairing cholesterol efflux and this is the possible 
mechanism for renal lipid accumulation in renal dysfunction (Herman-Edelstein et 
al., 2014). HDL-C dysfunction begins in early CKD and continues as renal function 
reduces, the endothelial properties of HDL-C as well as its cholesterol efflux 
capacity are potently impaired in children with early CKD (Shroff et al., 2014). The 
HDL-C alterations were also observed in early CKD without any underlying 
inflammatory, diabetes, or coronary artery disease, suggesting that CKD itself 
changes HDL into a toxic pro-atherogenic particle that facilitates endothelial 
dysfunction (Shroff et al., 2014).  
Most studies in kidney stone disease patients have been unable to demonstrate an 
association between serum or plasma 25(OH)D concentration and lipid profile 
markers. However, there is evidence that vitamin D is associated with dyslipidaemia 
in kidney disease (Khajehdehi, 2000). A significant inverse association has been 
reported between plasma 25(OH)D and triacylglycerol concentrations (r = –0.14, 
P = 0.001) in 495 non-diabetic CKD patients (Seiki et al., 2012).  
3.1.7. Prevalence of vitamin D deficiency in kidney stone patients  
Serum 25(OH)D concentration has been reported to be significantly reduced in 
chronic estimated GFR reduction compared with those in participants with normal 
kidney function (Chonchol & Scragg, 2007). A case control study in 884 idiopathic 
calcium kidney stones patients and 967 controls, found that the prevalence of vitamin 
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D deficiency (serum 25(OH)D<50nmol/L) was 56% in the kidney stones formers and 
44% in controls with mean concentration of 45nmol/L vs. 57.5 nmol/L, (P = 0.02) 
respectively (Ticinesi et al., 2016). Similarly, Giron-Prieto et al., found a 28% 
prevalence of vitamin D deficiency (25(OH)D <50 nmol/L) in calcium stone-forming 
patients compared to 15.7% in non-formers by 64.3 vs. 71 nmol/L, (P = 0.02). 
Additionally, a retrospective study aimed at assessing the prevalence and metabolic 
abnormalities of 101 vitamin D deficient and insufficient (25(OH)D <50 nmol/L and 
52.5-72.5 nmol/L, respectively) patients presenting with kidney stones found 33.7% 
and 46.5% of stone formers were vitamin D deficient and insufficient respectively 
(Elkoushy, Sabbagh, Unikowsky, & Andonian, 2012). Another retrospective review 
of 169 kidney stone formers, carried out in Rhode Island and Boston stone clinics 
also discovered that 18.9% and 34.9% were vitamin D deficient and insufficient 
(25(OH)D <50 nmol/L and 52.5-72.5 nmol/L) respectively (Eisner, Thavaseelan, 
Sheth, Haleblian, & Pareek, 2012).  
Furthermore, a third of 236 patients with recurrent kidney stone have also been 
reported to have vitamin D insufficiency (25(OH)D < 50nmol/L) (Pipili & 
Oreopoulos, 2012). In contrast, one study using data from the third National Health 
and Nutrition Examination Survey (NHANES) to determine the association between 
serum 25(OH)D concentration and prevalent kidney stone disease in 16,286 men and 
women aged 18 years or older. The study found no significant difference in serum 
25(OH)D concentrations amongst kidney stone patients compared to people with 
normal kidney function  (Tang, McFann, & Chonchol, 2012). 
3.1.8 STUDY RATIONALE 
Data from observational and experimental studies have shown that patients with 
kidney disease often have low concentrations of serum 25(OH)D and increased CVD 
risk. Due to the loss of nephron mass and reduced GFR in kidney disease, calcium 
and phosphate homeostasis are disrupted. This imbalance stimulates the osteocytes to 
secrete more FGF23 in order to maintain homeostasis, as a result the increased FGF-
23 leads to reduced vitamin D synthesis as FGF23 inhibits and facilitates both 
CYP27B1 and CYP24A1 expression and activity respectively. Reduced vitamin D 
concentrations would in turn increase PTH concentrations implicated in CVD events.  
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Additionally, the increase in the uraemic toxin uric acid also reduces vitamin D 
synthesis, as well as VDR and the vitamin D/VDR interaction, thus the beneficial 
effects vitamin D exerts through its autocrine and paracrine mechanism through 
increased VDR activity would be reduced in the VSMC, endothelium and 
cardiomyocytes in kidney disease which may in turn increase CVD risk. Given the 
multiple reported effects of vitamin D on PTH, inflammation, endothelial 
dysfunction and other CVD risk factors, we hypothesise that kidney stone patients 
would be vitamin D deficient and this deficiency would be associated with specific 
CVD outcome measures. Furthermore, evidence about the potential association 
between serum 25(OH)D concentrations and CVD markers in kidney stone disease 
patients, particularly calcium oxalate kidney stone patients are so far lacking. Hence, 
the need for a cross-sectional study establishing such relationship. 
3.1.8.1 RESEARCH PURPOSE 
To determine the prevalence of vitamin D deficiency and CVD risk in calcium 
oxalate kidney stone patients. 
3.1.8.2 OBJECTIVES 
• To assess the vitamin D status in male and female patients with calcium 
oxalate kidney stone. 
• To assess individual CVD risk factors in male and female patients with 
calcium oxalate kidney stone. 
• To investigate the association between vitamin D status and specific CVD 
risk factors in male and female calcium oxalate kidney stone patients. 
3.1.8.3 HYPOTHESES  
H1:  Male and female calcium oxalate kidney stone formers will be vitamin D 
deficient with serum 25(OH)D ˂ 50 nmol/L. 
H0:  Male and female calcium oxalate kidney stone formers will not be vitamin D 
deficient with serum 25(OH)D ˂ 50 nmol/L. 
H1: Male and female calcium oxalate kidney stones formers will be at increased risk 
of CVD. 
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H0: Male and female calcium oxalate kidney stone formers will not be at an 
increased risk of CVD 
H1: There will be an association between vitamin D status and the CVD risk 
biomarkers in male and female calcium oxalate kidney stone patients 
H0: There will not be an association between vitamin D status and the CVD 
biomarkers male and female calcium oxalate kidney stone patients.  
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3.2 STUDY DESIGN FOR KIDNEY STONES STUDY 
This is a non-interventional cross-sectional study of a cohort of kidney stone disease 
patients, about to undergo shock wave lithotripsy (SWL) treatment from the local 
hospital (Wrexham Maelor and Glan Clywd Hospital, United Kingdom). Ethical 
approval for this study was sought from the Wales Research Ethics Service (REC) 4 
Committee (REC4:12/WA0117). This study retrospectively analysed stored baseline 
serum samples collected from 24 (15 males and 9 females) patients diagnosed with 
calcium oxalate kidney stones, patients were recruited after written informed consent 
from September 2013 to May 2015. Those who had a pre-existing clinical condition 
or are receiving treatment for any other ailment were excluded from the study. The 
data collected includes age, gender and the medications they were taking.  
3.2.1. Blood sampling 
The serum samples prior to SWL were collected in serum separator tubes, stored at -
80ºC until analysed. Blood sampling for this study was performed by a research 
student. 
3.2.2 Biochemical measurement 
Material Safety Data sheets and COSHH information were adhered to for each 
analyte. Prior to the experiments all reagents, microplate wells, and samples were 
brought to room temperature according to appropriate kit instruction booklet. To 
avoid cross contamination, pipette tips were changed during each standard 
preparation, and screw caps were also not interchanged. Multiple freeze thawed 
samples were not used, and all ELISAs were performed in duplicate. To ensure 
accurate results, only calibrated pipettes were used, kits were used before expiration 
date and reagents were not mixed with those from other sources or lots. Plasma 
samples which had concentrations that exceeded the highest standard were further 
diluted and repeated.  
Prior to use of each ELISA kit, a QC was run 8 times to obtain the intra-assay CV, 
and the inter-assay CV was obtained from commercial control assay. These CVs 
were calculated using the formula: 
 
× 100CV = 
S.D 
Mean 
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3.2.2.1 Total serum 25(OH)D concentration determination 
Plasma total 25(OH)D was measured using mini VIDAS® (BioMẻrieux, Hampshire, 
UK), a compact multi-parametric automated immuno-analyser based on the enzyme 
linked fluorescent assay principles. The 25(OH)D total assay kit contained a ready to 
use solid phase receptacle (SPR) and stabiliser strips coated with vitamin D. Plasma 
(100 µL) was pipetted into each SPR well and inserted in machine. After 40 minutes 
run time, 25(OH)D concentration was obtained. The intra and inter assay CV were 
2.0 % and 7.3 % respectively. 
 3.2.2.2 Serum calcium concentration determination 
Calcium concentration was determined using a calcium colorimetric detection kit. 
Prior to the assay serum samples were diluted in a 1:1 ratio (25 µL sample + 25 µL 
deionised water). Calcium standard was diluted by adding 10 µL of the 500 mM 
standard to 990 µL deionised water to produce a stock solution which was further 
diluted serially. Each of the six serial dilutions was brought to a final volume of 50 
µL per well by adding deionised water. 
Following sample and reagent preparation, 90 µL of chromogen reagent was pipetted 
into each well containing the standard, control and sample. Following this, 60 µL of 
calcium assay buffer was pipetted into each well, plate was mixed thoroughly and 
incubated for 5-10 minutes at room temperature. Calcium concentration was 
determined at a wavelength of 575nm and obtained concentrations were multiplied 
by the corresponding dilution factor (see appendix for example standard curve. The 
intra and inter assay CV was 4.3% and 9.8% respectively. 
3.2.2.3 Serum PTH concentration determination 
A solid phase direct sandwich ELISA kit (Calbiotech, Spring valley, USA) precoated 
with streptavidin, quantitatively determines PTH concentration in plasma. Prior to 
the assay, 25 mL of 1x wash buffer was added to 475 mL deionised water to yield a 
final volume of 500 mL. Stock enzyme conjugate (0.5 mL) was added to assay 
diluent (9.5 mL). 
Following reagent preparation, standard, blank, control and samples (25 µL each) 
were pipetted into appropriate wells. Anti-PTH-biotin reagent (50 µL) and anti-PTH- 
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HRP conjugates (50 µL) were pipetted into all wells respectively. The microplate 
was covered with adhesive strip and incubated at room temperature on a plate shaker 
set at 500-600 rpm for 90 minutes.  
Following incubation, wells were washed 4 times with 300 µL wash buffer, decanted 
and blotted dry on clean absorbent paper towels. Following the wash step, 100 µL of 
TMB substrate was pipetted into all wells, and incubated for 15 minutes at room 
temperature. Stop solution (50 µL) was pipetted into each well and optical density 
was determined within 15 minutes at a wavelength of 450nm (primary) and 630nm 
(reference). PTH concentrations were obtained from a standard curve (see appendix 
9 for example standard curve).  Intra and inter assay CV were 4.7% and 2.6% 
respectively. 
 3.2.2.4 Serum hs-CRP concentration determination 
A solid phase direct sandwich ultra-sensitive ELISA kit (Calbiotech, Spring valley, 
USA) precoated with anti-CRP monoclonal antibody, quantitatively determined hs- 
C reactive protein concentration in plasma. Prior to the assay, samples and controls 
were diluted 1:100 fold by adding 5 µL of sample to 495 µL sample diluent. Wash 
buffer (25 mL) was added to 475 mL deionised water to yield a final volume of 500 
mL. 
Following reagent preparation, 10 µL standard, blank, control and sample were 
pipetted into appropriate wells. Enzyme conjugate (100 µL) was pipetted into each 
well, which were covered with adhesive strip, tapped gently on bench top to ensure 
thorough mixing and incubated for 1 hour at room temperature. Wells were washed 
three times with 300 µL wash buffer, decanted and blotted dry on absorbent paper 
towels. TMB substrate (100 µL) was pipetted into all wells, and incubated for 15 
minutes at room temperature. Stop solution (50 µL) was pipetted into each well, after 
which optical density was determined within 15 minutes at a wavelength of 450nm. 
Concentration of hs-CRP were obtained from standard curve (see appendix 9 for 
example standard curve), and obtained concentration was multiplied by the 
corresponding dilution factor. The intra and inter assay CV were 6.0% and 2.3% 
respectively. 
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3.2.2.5 Plasma TAG concentration determination 
The quantitative enzymatic TAG determination kit measured glycerol, true and total 
TAG concentration in plasma (Sigma-Aldrich, Dorset, UK). Prior to the assay, free 
glycerol reagent (powder) was reconstituted by adding 40 mL of deionised water, the 
solution was mixed thoroughly by inversion and protected from light using foil. TAG 
reagent (powder) was reconstituted by adding 10 mL of deionised water. The 
solution was mixed thoroughly by inversion and protected from light using foil. 
Spectrophotometer wavelength was set at 540nm and water was used as reference.  
Following reagent preparation, 800 µL of free glycerol reagent was pippeted into 
each cuvette. Water, standard, sample and control (10 µL each) were pipetted into 
labelled cuvettes respectively and incubated for 5 minutes at 37oC. Initial absorbance 
(IA) of blank, standard, sample and control were read at 540nm versus water as 
reference. After reading, 200 µL of reconstituted TAG reagent was pippeted into 
each cuvette, mixed thoroughly by inversion and incubated for a further 5 minutes. 
Final absorbance (FA) was read after last incubation at 540 nm versus water as 
reference. 
Concentrations of total TAG were calculated using the formula: 
(FAsample – FAblank)         
(FAstandard – FAblank) 
Intra and inter assay CV for TAG were 2.6% and 6.2% respectively 
3.2.2.6 Serum HDL-C concentration determination  
Plasma HDL-C was measured using a quantitation kit (Sigma-Aldrich, Dorset, UK). 
Samples for HDL-C were first separated by adding equal volumes of precipitation 
buffer (100 µL) with sample (100 µL).  The mixture was micro-centrifuged for 10 
minutes at 2000 x g to ensure proper mixing, followed by incubation for 10 minutes. 
After incubation, tubes were further centrifuged for 10 minutes at room temperature, 
after this, the supernatant or HDL fraction was transferred to a new tube. Cholesterol 
standard solution (20 µL) was diluted with 140 µL cholesterol assay buffer to yield a 
0.25 µg/µL standard from which serial dilutions were prepared. Cholesterol esterase 
and enzyme mix were reconstituted separately by adding 220 µL of cholesterol assay 
× concentration of standard 
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buffer to each. The reaction mix contains 44 µL of cholesterol assay, 2 µL each of 
cholesterol probe, reconstituted cholesterol esterase and enzyme mix to yield a final 
volume of 50 µL. 
Following sample and reagent preparation, sample (50 µL) and reaction mix (50 µL) 
were pipetted into each microplate well. This was thoroughly mixed using a 
horizontal plate shaker and incubated for 60 minutes at 37oC whilst protected from 
light. Optical density was read at 570nm. HDL-C concentrations were obtained from 
standard curve (see appendix 9 for example standard curve), obtained concentrations 
were multiplied by the corresponding dilution factor. 
Intra and inter assay CV were 3.4% and 8.1% respectively. 
3.2.2.7 Serum LDL-C concentration determination 
LDL-C was determined using Friedewald formula (Friedewald et al., 1972). 
Serum LDL-C = serum TC – serum HDL-C – (TRG/2.2) 
3.2.2.8 Serum Non-High Density Lipoprotein-C (non-HDL-C) concentration 
determination  
Non –HDL-C was determined using the formula: Non-HDL-C = TC - HDL-C. 
3.2.2.9 Serum Total cholesterol (TC) concentration determination 
The enzymatic-colorimetric cholesterol liquid (Alpha Laboratories, Eastleigh, UK) 
was used to determine TC concentration in plasma. Prior to the assay, 3 mL of 
deionised water was added to calibrator (lyophilised serum) to make a solution from 
which serial dilutions were produced. After this, 3 µL of standard, control and 
sample were pipetted into appropriate sterilised wells followed by the addition of 
reagent 1 (300 µL).  Following this, microplate was incubated for 10 minutes, after 
incubation, optical density was obtained at a wavelength of 505nm (primary) and 
700nm (reference). TC concentrations were obtained from the standard curve (see 
appendix 11 for example standard curve). Intra and inter assay CV were 5.2% and 
6.4% respectively  
3.2.2.10 Serum 8 - isoprostane concentration determination 
A competitive in vitro immuno-enzymatic assay was used for the determination of 8-
isoprostane concentration (Abcam, Cambridge, UK) in plasma. Prior to the assay, 10 
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x wash buffer was mixed with a stir bar whilst applying low gentle heat until a clear 
colorless solution was obtained. Following this, 25 mL wash buffer solution was 
diluted with 225 mL of deionised water to yield a final volume of 250 mL. One vial 
of horseradish peroxidase (HRP) conjugate (12 µL) was diluted with 12 mL of HRP 
buffer to prepare the 1x HRP conjugate. Sample dilution (25 mL) buffer was diluted 
with 225 mL deionised water to yield a final volume of 250 mL. The enclosed 2 µL 
standard vial filled with inert gas was first centrifuged, before 1.998 mL of 1 x 
sample dilution buffer was added to obtain a 2 mL stock solution. Several serial 
dilutions were made from the stock solution 
Following reagent preparation, 200 µL of 1x sample dilution buffer was pipetted into 
blank wells, 100 µL of 1x sample dilution buffer was pipetted into maximum binding 
control wells. Standard, sample or control (100 µL each) was pipetted into the 
appropriate wells. HRP conjugate (100 µL) was pipetted into all wells except blank 
control wells, which wells were covered with adhesive strip and incubated for 2 
hours. Following incubation, wells were washed manually three times with 400 µL 
wash buffer. After the final wash, the microplate was inverted and blotted dry on 
clean absorbent paper towels. After drying microplate, 200µL of 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate was pipetted into all wells, and incubated for 
15-30 minutes at room temperature. Sulphuric acid (2N, 50 µL) was pipetted into all 
wells, mixed thoroughly before optical density was obtained within 30 minutes at a 
wavelength of 450nm (primary) and 570nm (reference). The concentration of 8-
isoprostane was obtained from the standard curve (see appendix 9 for example 
standard curve). The intra and inter assay CV was 5.9% and 11.1% respectively. 
3.2.2.11 Serum sE-selectin concentration determination 
Plasma sE-selectin concentration (collected in heparin tubes) was determined using a 
quantitative sandwich enzyme immunoassay quantikine solid-phase ELISA kit 
(R&D Systems Europe, Abingdon, UK). The 96 well plates were pre-coated with a 
monoclonal antibody specific for naturally occurring human sE-selectin. Prior to 
assay, all samples were diluted 10-fold (30 µL of sample and 270 µL of calibrator 
diluent) to yield a final volume of 300 µL. Wash buffer (20 mL) concentrate was 
diluted by adding 480 mL of deionised water to yield a final volume of 500 mL. 
Substrate solutions (Colour A+B) were mixed together in equal volumes within 15 
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minutes of use and protected from light. The standard was reconstituted with 1.0 mL 
of deionised water and allowed to sit for at least 15 minutes before making serial 
dilutions.  
Following sample and reagent preparation, assay diluent (100 µL) was pipetted into 
each well. Standard, control, and sample (100µL each) were pipetted into appropriate 
wells, which were covered with adhesive strip and incubated for 2 hours. Following 
incubation, wells were decanted and washed four times manually with 400 mL wash 
buffer. After the final wash, the microplate was inverted and blotted dry against 
absorbent paper towels. Conjugate (200 µL) was pipetted into each well and 
incubated for another 2 hours. After incubation, wells were washed four times and 
blotted dry against absorbent paper towels. Substrate solutions (colour A+B) (7 mL 
each) were mixed thoroughly, after which, 200 µL each of the mix was pipetted into 
wells, the microplate was covered with foil paper to protect from light and left to 
incubate for 30 minutes. Following incubation, 50 µL of stop solution was pipetted 
into each well and plate was tapped gently on bench top to ensure thorough mixing. 
The optical density of each well was determined within 30 minutes at 450nm 
(primary) and 570nm (reference) and the sE-selectin concentration was obtained 
from the standard curve (see appendix 8 for example standard curve). Obtained 
concentrations were multiplied by the corresponding dilution factor. Intra and inter 
assay coefficient of variation (CV) were 3.4% and 3.4% respectively. 
3.2.2.12 Statistical analysis 
Statistical analysis was performed using IBM SPSS statistics software (IBM SPSS 
version 22, NYC, USA). Statistical significance was set at p ˂ 0.05). Continuous data 
were summarised as mean ± standard deviation. The distributions of all continuous 
variables were examined for normality using the Shapiro Wilk statistics. For 
continuous variables that were normally distributed such as serum sE-selectin, non-
HDL-C, hs-CRP, TAG, TC, LDL-C, and HDL-C, Pearsons correlation test was used 
to assess the association. For continuous variables that were not normally distributed 
including serum 25(OH)D, calcium, PTH and 8- isoprostanes, Spearmans correlation 
was used to assess the association.  
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3.3 RESULTS 
3.3.1 Patient characteristics  
The patient’s physical characteristics are shown in Table 3.3.1. The proportion of 
males to female was significantly different, as the cohort had more males (62.5%) in 
comparison to females (37.5%).  
Table. 3.3.1 Participants physical characteristics      
Characteristics Mean ± SD 
Age (years) 48.0 ± 18.1 
Male (62.5%); (n = 15) 47.1 ± 18.8 
Female (37.5%); (n = 9) 49.3 ± 18.1 
 
3.3.2. Baseline bone health and CVD biomarker concentrations 
Serum sE-selectin, 8-Isoprostanes, TAG, TC, PTH, HDL-C, calcium, 25(OH)D 
concentrations, as well as LDL-C and non-HDL-C were not significantly different 
between males and females, however, serum hs-CRP concentration was different 
between males and females in the study cohort (Table 3.3.2). Serum mean (±SD) 
25(OH)D concentration in both males (45.3 ± 27.2, n = 15) and females (42.8 ±  
22.2, n = 9) fell under the vitamin D deficient category and was comparable to the 
corresponding sex and age matched general UK population of 42.4 ± 21.0 nmol/L 
and 45.3 ± 21.1 nmol/L respectively for men and women aged 19-64y and was 43.4 
± 19 nmol/L and 47.9 ± 21.8 nmol/L respectively for men and women aged above 
65years (Public Health England, 2016). 
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Table 3.3.2. Baseline bone health and CVD biomarker concentrations 
 
 
          
 
 
Biomarkers Females 
Mean ± SD 
Males 
Mean ± SD 
Normal range References 
Serum 25(OH)D (nmol/L) 42.8 ± 22.2 45.3 ± 27.2 ≥ 75 nmol/L (Holick, 2007) 
Serum PTH (pmol/L) 14.7 ± 22.9 7.9 ± 16.2 1.1-6.8 pmol/L (Lombardi et al., 2008) 
Serum calcium (mmol//L) 2.3 ± 0.3 2.3 ± 0.2 2.1-2.6 mmol/L  (Deng et al., 2014) 
Serum hs-CRP (mg/L) 4.9 ± 3.4 3.2 ± 2.4 ˂ 1.0 mg/L (Buckley et al., 2009) 
Serum 8-isoprostane (pg/mL) 25.2 ± 24.3 32.0 ± 18.5  35 ± 6 pg/mL (Milne et al., 2007) 
Serum sE-selectin (ng/mL) 58.0 ± 23.5 53.3 ± 26.5  Not yet defined 
Serum HDL-C (mmolL) 0.6 ± 0.1 0.5 ± 0.1 1.0 -1.3 (men),1.3-1.5 
mmol/L (women) 
(Glasziou et al., 2008) 
LDL-C (mmol/L) 4.6 ± 0.8 4.6 ± 1.1 ˂ 2.6 mmol/L (Glasziou et al., 2008) 
Serum TAG (mmol/L) 1.8 ± 0.2 2.1 ± 0.4 ˂ 1.7 mmol/L (Alberti et al., 2006) 
Serum TC (mmol/L) 6.1 ± 0.8 6.1 ± 1.1 ˂ 5.2 mmol/L (Glasziou et al., 2008) 
Serum non-HDL-C (mmol/L) 5.8 ± 0.8 5.6 ± 1.0 ˂ 3.4 mmol/L  
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3.3.3. Prevalence of vitamin D deficiency 
Of the 24 calcium oxalate kidney stone patients recruited for this study, 3 (12.5%), 7 
(29.2%) and 18 (75%) had serum 25(OH)D concentrations ≤ 25nmol/L, 30nmol/L 
and 50nmol/L respectively (Fig.3.3.1). Of the cohort, 18 (75%) were vitamin D 
deficient and 4 (16.7%) were within the optimal limits (≥ 75nmol/L) (Holick, 2007). 
  
Fig 3.3.1 Box plot of plasma 25(OH)D concentrations showing prevalence of 
vitamin D deficiency/insufficiency 
 
3.3.4. Association between serum 25(OH)D concentrations with bone and CVD 
biomarkers 
No significant associations were observed between serum 25(OH)D concentration 
and the selected CVD/bone biomarkers. Similarly, no significant associations were 
also observed between serum 25(OH)D concentration and the selected CVD/bone 
biomarkers, when patient serum 25(OH)D concentrations were stratified into 25 
(OH)D ≤ 30nmol/L (n = 7) and 50 nmol/L (n = 18). Furthermore, when serum 
25(OH)D concentration was split into percentiles according to 50% frequency 
distribution into ≥ 33nmol/L and ≤ 33nmol/L groups for both CVD/bone biomarkers 
no significant difference was observed between groups. 
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3.3.5. Association between bone and CVD biomarkers  
Significant baseline positive associations were found between serum calcium and hs-
CRP concentrations (r = 0.58, P = 0.003) (Fig.3.3.2A), serum calcium and sE-
selectin concentrations (r = 0.53, P = 0.007) (Fig.3.3.2B), as well as a significant 
inverse association between sE-selectin and HDL-C (r = -0.49, P = 0.013) 
(Fig.3.3.2C). No significant associations were found amongst the remaining bone 
health and CVD biomarkers.  
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Fig.3.3.2. Scatter plot-showing associations between serum sE-selectin and (A) HDL-C concentration, (B) calcium concentration and (C) 
between serum hs-CRP and calcium concentration 
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3.4 DISCUSSION 
To the best of my knowledge, this is the first cross-sectional study investigating in 
calcium oxalate kidney stone patients, the association between vitamin D status and 
selected CVD risk markers. The present cross-sectional study found a high 
prevalence of low serum 25(OH)D concentrations in the cohort as 3 (12.5%), 7 
(29.2%) and 18 (75%) had serum 25(OH)D concentrations ≤ 25nmol/L, <30nmol/L 
and <50nmol/L respectively. However, the mean (±SD) of 25(OH)D concentration 
are similar to those of the UK population. 
No significant association was observed between serum 25(OH)D concentrations and 
the CVD markers measured. Interestingly, there was increased CVD risk in the study 
cohort, as all mean concentrations of bone health and CVD markers measured were 
above the normal ranges except for serum calcium and 8-isoprostanes concentration 
of which were within the normal range and serum HDL-C concentration which was 
below the normal range. Significant positive associations were observed between 
serum sE-selectin and calcium concentrations (r = 0.53, P = 0.007), serum hs-CRP 
and calcium concentrations (r = 0.58, P = 0.003). Furthermore, modest but 
significant inverse associations were observed between serum sE-selectin and HDL-
C concentrations (r = - 0.49, P = 0.013).  
3.4.1 Vitamin D status 
The present study in a cohort of calcium oxalate kidney stone patients demonstrated 
that low serum 25(OH)D concentrations below 50nmol/L mean (±SD) in males, 33.2 
± 8.8 nmol/L and females, 30.4 ± 4.3 nmol/L were highly prevalent in 75% of the 
cohort. However, no significant association was observed between the low serum 
25(OH)D concentrations and the CVD biomarkers measured. The overall mean 
(±SD) serum 25(OH)D concentrations in the present study for males (45.3 ± 27.2 
nmol/L) and females (42.8 ± 22.2nmol/L) were comparable to the corresponding sex 
and age matched UK population. The mean (±SD) serum 25(OH)D concentration for 
the UK adult population was 42.4 ± 21.0 nmol/L and 45.3 ± 21.1 nmol/L 
respectively for men and women aged 19-64 years and was 43.4 ± 19 nmol/L and 
47.9 ± 21.8 nmol/L respectively for men and women aged above 65years (Public 
Health England, 2016). Among adults in the general UK population, 22% men and 
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15% women aged 19-64 years and 21% men and 9% women above 65 years had 
serum 25(OH)D concentrations below 25nmol/L (Public Health England, 2016). 
These findings complement recent observations suggesting that vitamin D 
insufficiency is strongly associated with kidney stone incidence among adult 
participants. Among 884 idiopathic calcium kidney stones patients and 967 controls 
median (range) serum 25(OH)D <50 nmol/L was lower in the kidney stones patients 
compared with controls 45 (30-60) vs. 57.5 (35-70) nmol/L, (P = 0.02) (Ticinesi et 
al., 2016). Similarly, another case control study found mean (±SD) serum 25(OH)D 
concentrations <50 nmol/L in patients with calcium kidney stone compared to 
healthy controls, 64.3 ± 25.5 vs. 71 ± 23.7 nmol/L, (P = 0.02), and only 28% of the 
kidney stone patients and 15.7% of controls had vitamin D insufficiency (Giron-
Prieto et al., 2016). Compared to these studies which were performed in Italy and 
Spain respectively, the present study cohort had much lower mean serum 25(OH)D 
concentrations and this may be attributed to the UK being a less temperate or sunny 
region compared to Italy and Spain, resulting in the reduced production of vitamin D.  
Several potential mechanisms may be responsible for the low serum 25(OH)D 
concentrations observed in the present study. The reduced renal CYP27B1 activity 
observed in kidney disease is one such mechanism (Vanholder et al., 1993). 
Observations from a study in patients with mild to moderate kidney failure suggest 
that uric acid, a uraemic biologic fluid, suppresses vitamin D metabolism by 
reducing renal CYP27B1 activity which leads to reduced vitamin D synthesis 
(Vanholder et al., 1993). Secondly, increased circulating FGF-23 concentrations 
observed in kidney dysfunction promotes the transcription of CYP24A1, causing 
increased 25(OH)D and 1,25(OH)2D catabolism resulting in low serum 25(OH)D 
concentrations (Jones et al., 2012; Petkovich & Jones, 2011). Findings from rat 
models and renal biopsy tissue from patients with kidney disease have shown a high 
expression of circulating CYP24A1 mRNA in diseased compared to healthy renal 
tissue (Helvig et al., 2010). The low serum 25(OH)D concentration observed in the 
present study cohort could also be ascribed to the albuminuria caused by impaired 
kidney function in stone formation (Rule, Krambeck, & Lieske, 2011). It has been 
suggested that albuminuria may result in high urinary loss of VDBP, leading to 
increased renal loss of all vitamin D metabolites (Andress, 2005). It was reported that 
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in patients with nephrotic albuminuria, there were remarkably low serum 
concentrations of  serum 25(OH)D (˂ 75nmol/L) (Gonzalez et al., 2004). 
3.4.2. Associations between vitamin D status and CVD biomarkers 
No significant associations were observed between serum 25(OH)D concentrations 
and the selected CVD risk biomarkers measured in calcium oxalate kidney stone 
patients. Studies which have investigated the association between serum 25(OH)D 
concentrations and CVD risk biomarkers in calcium oxalate kidney stone patients are 
lacking. However, low vitamin D concentrations have been reported to be associated 
with increased CVD risk in CKD patients. A cross-sectional study in 101 stage 4-5 
non-dialysis, CKD patients and 40 healthy controls found that serum hs-CRP 
concentration was inversely associated with low concentrations of serum 25(OH)D ˂ 
50nmol/L (r = −0.2, P = 0.047) in the CKD patients compared to controls with 
normal kidney function (Yadav et al., 2012). The inverse association found in this 
study may be attributed to the fact that stage 4-5 CKD patients are more likely to 
have severe vitamin D deficiency compared with calcium oxalate kidney stone 
patients (Jabbar et al., 2009). This is because there are more significant reductions in 
vitamin D metabolism as a result of more severe proteinuria in stage 4-5 CKD 
(Cuppari, Carvalho, & Draibe, 2008) compared to kidney stone disease (Rule et al., 
2009). The small sample size in the present study pilot may be another reason why 
an association was not observed between serum 25(OH)D concentrations and CVD 
risk biomarkers. 
3.4.3. Increased CVD risk in the study cohort 
In the present study, there was increased CVD risk, as mean concentrations of all 
biomarkers were above the normal range except for a normal range serum calcium 
and 8-Isoprostanes concentration, however, serum HDL-C concentration that was 
below the normal range. Consistent with the present study findings of a normal 
serum mean ± (SD) calcium concentration in males 2.3 ± 0.2 mmol/L and in females 
2.3 ± 0.3 mmol/L, a study performed in 236 kidney stone patients also found normal 
serum mean ± (SD) calcium concentrations (Pipili & Oreopoulos, 2013). Similarly, 
no significant difference was found between serum mean (±SD) calcium 
concentrations of kidney stone disease patients compared to those without kidney 
stone disease 8.87 ± 0.65 vs. 8.65 ± 0.60 mg/dL, P = 0.180) (Hasna et al., 2015). 
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These observations suggest that despite the disturbance in calcium homeostasis 
observed with kidney dysfunction, serum and intracellular calcium concentrations 
are tightly regulated, as several vital metabolic processes are unable to tolerate a 
significant deviation from the normal range (Moe, 2008). Serum mean (±SD) PTH 
concentrations were observed to be high in males 14.7 ± 22.9 pmol/L and females 
7.9 ± 16.2 pmol/L in the present study. Similar to the present study, a study in 236 
recurrent kidney stone disease patients also reported increased serum PTH 
concentrations (> 7.5pmol/L) in a quarter of the cohort (Pipili & Oreopoulos, 2013). 
Oxidative stress, determined by serum 8-Isoprostanes concentration in the present 
study were within the normal range mean (±SD) in males, 32.0 ± 18.5 pg/mL and in 
females 25.2 ± 32.0 pg/mL. This observation in the present study was unexpected as 
calcium oxalate kidney stone patients have been reported to excrete increased 
amount of α-glutathione S-transferase (α-GST), MDA and Thiobarbituric acid 
reactive substances (TBARS) in their urine, demonstrating increased oxidative 
stress (Huang, Ma, Chen, & Chen, 2003). Additionally, in comparison to people 
with normal kidney function, kidney stone patients have been shown to have high 
oxidative stress markers such as higher plasma and urinary MDA and reduced anti-
oxidants such as glutathione (GSH), cellular glutathione peroxidase (cGPx) 
activity, protein thiol and vitamin E (Tungsanga, Sriboonlue, Futrakul, Yachantha, 
& Tosukhowong, 2005). Furthermore, serum 8-hydroxydeoxyguanosine 
concentration, a marker of oxidative damage of the DNA has been reported to be 
increased in the urine of kidney stone patients compared with controls (Boonla, 
Wunsuwan, Tungsanga, & Tosukhowong, 2007).  
Kidney stone disease is characterised by low-grade inflammation (Shoag & Eisner, 
2014), and in the present study, inflammation measured by serum mean ± (SD) hs-
CRP concentrations were above the normal range in males, 3.2 ± 2.4 mg/L and 
females, 4.9 ± 3.4 mg/L. Consistent with this observation, a significant increase in 
serum mean ± (SD) hs-CRP concentration has also been reported in T2DM patients 
with kidney stone disease compared with T2DM patients without kidney stone 
disease 115.3 ± 50.9 vs. 79.4 ± 54.6µg/L (Hasna et al., 2015). Additionally, 
significantly higher mRNA expression of IL-6 and MCP-1 (inflammatory 
biomarkers) have been reported in 29 renal biopsy tissue collected from kidneys 
containing stones compared to the 30 renal biopsy tissue of healthy participants 
190 
 
(Boonla et al., 2008). These observations indicate that the impaired renal function 
observed in kidney stone disease is associated with increased inflammatory 
biomarkers. 
Exposure of the proximal tubule epithelial cells to calcium oxalate has been shown 
to be associated with renal cell injury and inflammation (Evan et al., 2010), as 
calcium oxalate deposition was found to attract several inflammatory cells including 
leukocytes, monocytes, and macrophages in male Sprague-Dawley rats (Khan, 
Glenton, & Byer, 2006). Additionally, in rat kidney cell culture, the exposure of the 
renal epithelium to calcium oxalate crystals caused the increased secretion of MCP-1 
suggesting calcium oxalate kidney stone patients would have increased inflammation 
(Umekawa, Chegini, & Khan, 2002; Umekawa et al., 2003).  
In the present study, mean (±SD) serum concentrations of soluble E-selectin were 
increased in both males 53.3 ± 26.5 ng/mL and females 58.0 ± 23.5 ng/mL. Although 
a normal range of serum 8-isoprostanes concentration was reported, endothelial 
dysfunction in calcium oxalate kidney stone patients is in part mediated by oxidative 
stress (Khan, 2014; Weiss et al., 2000). One of the mechanisms by which oxidative 
stress lead to endothelial dysfunction is by disrupting the NO signalling pathway, as 
a result, NO losses its anti-inflammatory, vasodilatory, as well as its vasoproctective 
properties resulting in endothelial dysfunction (Förstermann, 2010).  Additionally, on 
exposure of the renal epithelium to ROS, NO is converted to peroxynitrite, a 
powerful oxidant that causes the oxidation of anti-oxidants such as cysteine 
tetrahydrobiopterin and glutathione (Szabó, Ischiropoulos, & Radi, 2007). 
Peroxynitrite, causes reduced production of NO by inducing the oxidation of the zinc 
thiolate centre of NO synthase (Joshi et al., 2013), and a decrease in NO production 
will subsequently lead to endothelial dysfunction.  
3.4.4. Increased risk of dyslipidaemia in calcium oxalate kidney stone patients 
In the present study, serum mean (±SD) TC concentrations, in males and females, 6.1 
± 1.1 and 6.1 ± 0.8 mmol/L, serum mean (±SD) TAG concentrations in males and 
females 1.8 ± 0.2 mmol/L and 2.1 ± 0.4 mmol/L were slightly above the normal 
range. Additionally, mean (±SD) LDL-C concentrations in males and females 4.6 ± 
1.1 and 4.6 ± 0.8 mmol/L and mean (±SD) non-HDL-C concentration in males and in 
females 5.8 ± 0.8 and 5.6 ± 0.8 mmol/L were also above the normal range. However, 
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serum mean (±SD) HDL-C concentration was decreased in both males and females: 
0.5 ± 0.1 and 0.6 ± 0.1 mmol/L respectively. Consistent with the present study 
findings, a cross-sectional study of 60 T2DM patients with and without kidney stone 
demonstrated significantly increased serum mean (± SD) TC concentration, 163.6 ± 
46.7 vs. 137.2 ± 28.0 mg/dL, (P = 0.010). This study showed increased) serum mean 
(±SD) TAG concentration, 143.5 ± 61.1 vs. 91.7 ± 24.5 mg/dL, (P < 0.001), mean 
(±SD) LDL-C concentration 105.6 ± 44.4 vs. 81.7 ± 24.6 mg/dL, (P = 0.011). The 
cross-sectional study also showed decreased serum mean (±SD) HDL-C 
concentration 29.1 ± 5.4 vs. 37.8 ± 12.5 mg/dL (P = 0.0012) in the T2DM patients 
with kidney stones compared to T2DM patients without kidney stones (Hasna et al., 
2015).  
Similarly, in 13 patients with recurrent kidney stones, a significant increase in serum 
TC, TAG, LDL-C and decrease in HDL-C concentration was reported in the kidney 
stone patients compared with the healthy controls (Abate, Chandalia, Cabo-Chan, 
Moe, & Sakhaee, 2004). Furthermore, a study in 49 kidney stone patients and 
controls demonstrated that serum TC and TAG concentration were increased in the 
kidney stone patients (Inci, Demirtas, Sarli, Akinsal, & Baydilli, 2012). These 
observations in addition to those of the present study suggest kidney stone disease is 
associated with altered lipid profile. It has also been suggested that inflammation 
may lead to an increase in circulating serum lipid concentrations by reducing 
peripheral lipoprotein lipase activity (Castrillo et al., 2003). Cytokines may also 
stimulate the liver to increase the secretion of very-low density lipoproteins (VLDL), 
resulting in  dyslipidaemia (Esteve, Ricart, & Fernandez-Real, 2005). 
Kidney disease is associated with low serum HDL-C concentration, as observed in 
the present study. A study in 2442 kidney stone patients also reported a low serum 
HDL-C concentration which was associated with increased oxalate (Torricelli et al., 
2014). The beneficial properties of HDL-C have been reported to be altered even in 
early CKD and show a graded association with eGFR (Shroff et al., 2014). More 
emphasis is laid on serum HDL-C concentrations as HDL-C exerts cardio-protective 
function in the vasculature by preventing the development of endothelial dysfunction 
and through the suppression of LDL-mediated oxidative damage to the arterial wall 
(Kim, Montagnani, Chandrasekran, & Quon, 2012). HDL-C also exerts anti-
inflammatory action on the vasculature by suppressing the expression of E-selectin 
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induced by interleukins (Barter et al., 2004; Cockerill et al., 2001), through the 
inhibition of sphingosine kinase, an enzyme involved in the modulation of 
endothelial adhesion molecule by TNF-α (Argraves & Argraves, 2007; Sattler & 
Levkau, 2009). Thus, a low serum HDL-C concentration indicates increased CVD 
risk in the present study cohort.  
3.4.5. Associations between CVD biomarkers 
There was a significant positive association between serum sE-selectin and calcium 
concentration (r = 0.53, P = 0.007) in the present study. No association between 
serum sE-selectin and calcium concentration has been reported in calcium oxalate 
kidney stones patients to the best of my knowledge, this may be attributed to the fact 
that serum calcium concentrations are tightly regulated (Moe, 2008). Additionally, 
the blood is not a major store of body calcium, 99.9% of body calcium is stored in 
the bone and could also be deposited in the intima and media of arteries in people 
with renal disease (Moe & Chen, 2008). Furthermore, the constant exposure of 
VSMCs to increased concentrations of calcium and phosphate directly induce the 
osteogenic transformation of VSMCs, initiating and promoting vascular calcification 
(Shanahan et al., 2011). 
There is evidence that impaired calcium homeostasis in kidney disease patients 
results in arterial calcification particularly coronary artery calcification that reflects 
intense atherosclerosis (Amann, 2008; Nakamura et al., 2009). The pathological 
pathways responsible for kidney stone formation are also implicated in coronary 
artery calcification (CAC) that leads to atherosclerosis (Yiu et al., 2015). A cross 
sectional study in 984 people without CVD or diabetes found coronary artery 
calcium (CAC), a marker of coronary artery damage in atherosclerosis to be 
associated with increased serum E-selectin concentrations (de Almeida-Pititto et al., 
2016). This observation supports the present study finding of a positive association 
between serum sE-selectin and calcium concentration. 
The present study also found significant positive associations between serum hs-CRP 
and calcium concentration (r = 0.58, P = 0.003), suggesting inflammation plays a 
significant role in calcium deposition in arteries, as vascular calcification has been 
shown to be induced by inflammatory cytokines such as TNF-α and CRP (Moe & 
Chen, 2005). CAC was not assessed in the present study, as this study was a 
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retrospective cross-sectional pilot, however, measuring CAC may have explained the 
association better, as a study in kidney stones patients reported increased risk of 
vascular calcification (Kleinman et al., 2004). A study of 14,584 Korean 
normotensive, pre-hypertensive and hypertensive subjects found increasing serum 
hs-CRP concentration (˃2mg/L) following increasing CAC score > 0 in normal and 
pre-hypertensive subjects. High serum hs-CRP concentration was significantly 
associated with CAC score in the normotensive group (OR 1.55, 95% CI 1.11–2.16, 
P = 0.010) but not in the prehypertensive group (Sung et al., 2014).  
Furthermore, modest but significant inverse associations were observed between 
serum sE-selectin and HDL-C concentrations (r = - 0.49, P = 0.013,) which indicates 
an increased risk of endothelial dysfunction and atherosclerosis with low 
serum/plasma HDL concentrations. Increased sE-selectin concentration may possibly 
be the mechanism by which reduced serum/plasma HDL-C concentrations promotes 
atherogenesis and causes severe athero-thrombotic events (Calabresi et al., 2002). 
One study, incubated human aortic endothelial cells along with HDL isolated from 
CKD and healthy children to measure the endothelial properties of HDL. This study 
demonstrated that the healthy HDL-C increased endothelial NO production, whilst 
CKD HDL-C markedly repressed endothelial NO production and increased 
endothelial VCAM-1 expression (Shroff et al., 2014). Consistent with this 
observation, low  serum HDL-C concentration was found to be inversely associated 
with serum sE-selectin concentration in individuals with low serum HDL-C 
(Calabresi et al., 2002). Additionally, it has also been reported that the serum 
concentrations of sE-selectin are high in people with low HDL-C concentration 
(Soro‐Paavonen, Westerbacka, Ehnholm, & Taskinen, 2006). 
A study aimed at determining whether the modification of HDL-C in CKD patients 
leads to alterations of its endothelial effects by modulation of the innate immune 
system, observed that CKD HDL-C lost its endothelial-protective properties and 
became a toxic particle that induced endothelial dysfunction compared to healthy 
HDL-C (Speer et al., 2013). It was also observed that symmetric-dimethylarginine 
(SDMA), a uraemic toxin in the HDL-C fraction was responsible for the detrimental 
vascular action of this toxic HDL-C. Additionally, this study demonstrated that the 
altered HDL-C induced an endothelial TLR-2 response via a TLR-1- and TLR-6-
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coreceptor and NF-κB-independent pathway resulting in increased endothelial 
superoxide production and reduced NO bioavailability (Speer et al., 2013). 
All of the patients in this cohort were diagnosed with calcium oxalate stones, which 
injure cells and obstruct cellular functions by damaging cell membranes, producing 
lipid mediators such as prostaglandins and releasing of ROS leading to oxidative 
stress. Although little is known about the association between serum 25(OH)D 
concentration and kidney stone disease, it may not be correct to attribute the high 
prevalence of low vitamin D status observed in the present study to the presence of 
kidney stones. This is because the mean serum 25(OH)D concentration of the cohort 
was comparable to that of the general UK population. Findings from a large US 
population based cross-sectional study in 16286 adults with previous kidney stones 
and non-kidney stone formers did not demonstrate a significant difference in serum 
25(OH)D concentrations amongst kidney stone patients and healthy controls (Tang et 
al., 2012).  
3.4.6. Study limitations   
As this study is a retrospective analysis of stored serum samples collected in a cross-
section of calcium oxalate kidney stone disease patients, sample size was small, and 
the bone health/CVD parameters were only evaluated at one-time point 
(baseline/pre-operation). Secondly, aged matched controls to make comparisons 
were lacking, as serum samples were collected retrospectively. Renal function and 
circulating FGF23 concentrations were not determined. Measuring eGFR and 
circulating FGF23 concentrations in the present study cohort may explain better the 
reductions observed in serum 25(OH)D concentrations. Finally, due to budget 
constraints, only some surrogate biomarkers of CVD were studied, a more 
comprehensive assessment of cardiovascular outcomes may demonstrate some 
associations.  
3.4.7. Future perspectives 
Further research using a larger population with age-matched controls is required. 
Research investigating indices of atherosclerosis such as CAC would likely provide 
distinct information regarding CVD risk in calcium oxalate kidney stones patients. 
Further studies are also required to investigate whether calcium oxalate kidney stone 
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formers have reduced concentrations of urinary osteopontin, as a deficiency leads to 
vascular calcification, and to date only one study in humans is available (Bautista, 
Denstedt, Chambers, & Harris, 1996).  Vitamin D supplementation in this population 
is required, as this may not only decrease PTH secretion, it would also improve VDR 
expression and activities that would in turn exert reno-protective effects by 
downregulating RAS activity. Additionally, assessing renal function and circulating 
FGF-23 concentration in a similar population is required. Studies evaluating the 
effect of vitamin D supplementation in order to improve deficient vitamin D levels to 
the optimal serum 25(OH)D concentration and the dose of vitamin D required for 
preventing CVD in this cohort needs further research. Given its reported safety 
together with its beneficial reno-protective effects, there is optimism that correcting 
vitamin D deficiency may lead to better outcomes for patients with calcium oxalate 
kidney stone disease.  
3.4.8. Conclusion 
Overall, this cross-sectional study demonstrated that in calcium oxalate kidney stones 
patients, the prevalence of vitamin D deficiency determined by serum 25(OH)D 
concentration was high. However, the mean (±SD) of 25(OH)D concentration are 
similar to those of the UK population. No significant association was found between 
the low serum 25(OH)D concentrations and the CVD biomarkers measured. There 
was increased CVD risk in the study cohort and significant associations were 
observed between sE-selectin with calcium, hs-CRP with calcium and with sE-
selectin with HDL-C.  
 
 
 
 
 
 
 
196 
 
 
 
 
 
 
 
 
 
 
 
 
4.0 GENERAL DISCUSSION AND 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
197 
 
4.0. GENERAL DISCUSSION AND CONCLUSION 
 
Vitamin D deficiency (serum 25(OH)D concentrations ˂ 25nmol/L) is highly 
prevalent in the UK. It affects a fifth of adults aged 19 years and above and a sixth of 
children aged 11 to 18 years  (Bates et al., 2014). CVD is responsible for 26% of all 
deaths in UK whilst, diabetes has been reported to affect 4.5 million people in the 
UK, 90% of which suffer from T2DM (Public Health England, 2015). Vitamin D 
deficiency has been implicated in the pathomechanism of different diseases including 
diabetes mellitus, cancer, kidney disease and CVD. Potential consequences of 
vitamin D deficiency include bone disease, inflammation, increased insulin 
resistance and oxidative stress, endothelial dysfunction, hypertension and arterial 
stiffness (Menezes et al., 2014). Vitamin D deficiency has also been greatly 
associated with increasing adiposity (Vimaleswaran et al., 2013), possibly the result 
of enhanced adipocyte sequestering, as well as suppressed 25(OH)D synthesis by 
adipocytokines secreted by adipose tissue (Ding et al., 2010). The kidneys are the 
primary target organs affected by calcium regulatory hormones such as vitamin D, 
and a decline in kidney function has been reported to reduce vitamin D synthesis 
(Bosworth & de Boer, 2013). The reduction of vitamin D synthesis in kidney disease 
have been attributed to increased production of FGF-23, which downregulates the 
expression of renal 1α-hydroxylase (CYP27B1) and upregulates 24-hydoxylase 
(CYP24A1) activity (Hasegawa et al., 2010). 
 
Given the high prevalence of vitamin D deficiency and cardiometabolic disease in 
the general UK population, particularly in overweight/obese people and the inverse 
associations between low vitamin D and cardiometabolic disease, improving vitamin 
D status by supplementation has been proposed as a favourable strategy for 
cardiometabolic disease prevention (Wang, Song, et al., 2012), as few foods 
naturally contain vitamin D (Lu et al., 2007). It has therefore become increasingly 
important to investigate the effect of vitamin D3 therapy in cohorts reported to be at 
increased risk of both vitamin D deficiency and cardiometabolic disease as most 
available RCT trials have tested low daily doses or large single doses.  Similarly, it is 
also important to assess participant’s dietary status in order to determine the possible 
influence of dietary supplementation. 
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The present PhD research comprises of 2 studies aimed at investigating the effect and 
association of vitamin D with metabolic and CVD markers. The primary purpose of 
the first study was to investigate whether the administration of 5,000IU (125µg) 
vitamin D3 for 8 weeks would significantly improve vitamin D status and the 
selected cardiometabolic markers measured in overweight and obese adult males. 
Additionally, a further hypothesis was to investigate whether improved vitamin D 
status would be significantly associated with the selected cardiometabolic markers 
measured. The administration of 5,000IU (125µg) vitamin D3 for 8 weeks increased 
mean (±SD) plasma 25(OH)D concentrations significantly from a baseline 
concentration of 38.4 ± 15.9 to 64.2 ± 19.5 nmol/L (P ˂ 0.001) at 4 weeks and 72.8 
± 16.1nmol/L, (P ˂ 0.001) post intervention. All study participants recruited for this 
study had a baseline plasma 25(OH)D concentration <75nmol/L, of these, vitamin D 
deficiency, defined as plasma 25(OH)D concentrations <25nmol/L by SACN, 2015, 
was present in 22.2% (12/54) of participants. Vitamin D deficiency, defined as 
plasma 25(OH)D concentrations < 30 nmol/L by IOM, 2011 was present in 35.2% 
(19/54) and plasma 25(OH)D concentration <50nmol/L concentrations was present 
in 64.8% (35/54) of the cohort at baseline. 
 
Following 8 weeks vitamin D supplementation, 45.8% (11/24) of participants in the 
vitamin D group achieved plasma 25(OH)D concentrations >75 nmol/L post 
intervention, whilst the remaining 54.2% (13/24) did not achieve plasma 25(OH)D 
concentrations >75 nmol/L despite the high daily dose administered. This 
observation suggest 54.2% (13/24) of cohort in the vitamin D group did not achieve 
the optimal plasma 25(OH)D concentrations required for non-skeletal benefits 
(Bischoff-Ferrari, 2008). This finding also supports the hypothesis that vitamin D 
metabolism is diminished with increasing BMI (Vimaleswaran et al., 2013). The 
lipid component of a meal has been suggested to improve vitamin D absorption 
(Mulligan & Licata, 2010), and the participants mean dietary fat intake were within 
those of the DRV and age matched UK male population. This indicates that 
participants consumed enough fat to improve vitamin D absorption, thus, the reduced 
plasma 25(OH)D concentration would be ascribed to other unknown factors and not 
inadequate fat consumption. 
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The inability of a greater percentage of study participants to reach the 75nmol/L 
threshold could also be ascribed to adipose sequestration, as it has been reported in 
humans that about 17% of orally-administered vitamin D was stored in adipose tissue 
(Heaney et al., 2010). Baseline vitamin D status may be another explanation, as only 
22.2% (12/54) participants had plasma 25(OH)D concentrations ˂25nmol/L at 
baseline, and intestinal absorption of vitamin D may be higher in vitamin D deficient 
individuals, suggesting that the benefits or risks of vitamin D supplementation may 
depend on initial levels of 25(OH)D (Apukhovskaia et al., 1990; Holick, Binkley, 
Bischoff-Ferrari, Gordon, Hanley, Heaney, Murad, & Weaver, 2011).  
The reduced expression of both 25-hydroxylase CYP2J and 1-α hydroxylase 
CYP27B1 in adiposity could be another potential explanation for the reduced ability 
of some participants in the vitamin D group to achieve plasma 25(OH)D 
concentrations above 75nmol/L. (Wamberg, Christiansen, et al., 2013). Circulating 
VDBP may be another potential explanation for the reduced plasma 25(OH)D, as 
circulating VDBP, which has a greater binding affinity for 25(OH)D compared to 
1,25(OH)2D (Gozdzik et al., 2011; Hart et al., 2005) is decreased in acute 
inflammatory conditions as is observed with increasing BMI (Waldron et al., 2013; 
Yousefzadeh et al., 2014).  
Furthermore, VDR genotype polymorphisms is reported to be associated with 
adiposity (Gu et al., 2009; Ochs-Balcom et al., 2011). VDR genotype polymorphism 
particularly VDR ff genotype have been reported to have decreased response to 
vitamin D intake (Neyestani et al., 2013). Thus, VDR genotype polymorphism in 
adiposity may be an additional explanation for the reduced individual response to the 
high dose orally administered vitamin D in the present study. 
The change in 25(OH)D concentration was inversely associated with change in 
plasma glucose concentrations (r = -0.408, P = 0.048), as well as change in HDL-C 
concentrations (r = -0.503, P = 0.012) and positively associated with change in aortic 
central pulse pressure (r = 0.437, P = 0.033) at week 4. Improved 25(OH)D 
concentration post intervention was inversely associated with change in brachial 
augmentation index (r = 0.446, P = 0.029). These observations suggest a link 
between decreasing/or increasing plasma 25(OH)D concentration with 
increasing/improved insulin resistance, dyslipidaemia and arterial stiffness. 
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No significant effect of vitamin D supplementation was observed in the 
cardiometabolic markers including endothelial function, arterial stiffness, blood 
pressure and RAS, lipid profile, oxidative stress, and inflammation and glucose 
homeostasis parameters between treatment groups. However, vitamin D 
supplementation significantly reduced mean (±SD) brachial pulse pressure from 
baseline (52.3 ± 9.2 vs. 53.7 ± 9.2 mmHg to 49.4 ± 3.9 vs. 53.5 ± 6.4 mmHg (P = 
0.011) at 4 weeks and to 50.6 ± 5.8 vs. 55.8 ± 8.7 mmHg (P = 0.027) post 
intervention in the vitamin D but not in the placebo group. Additionally, despite 
improvements in vitamin D status, BMI, body weight and waist circumference 
remained unchanged by vitamin D therapy, indicating vitamin D does not reduce 
body weight. 
Potential explanations for the lack of beneficial effects of vitamin D supplementation 
include the following. Firstly, the optimal serum/plasma 25(OH)D concentrations 
required to prevent CVD risk has not been established, as a threshold effect which 
varies with different baseline serum/plasma 25(OH)D concentrations has been 
reported (Heaney, 2012; Mozos & Marginean, 2015). The wide range of baseline 
plasma 25(OH)D concentration among participants could also potentially produce 
heterogeneous biological effects.  
Secondly, the use of a non-hypertensive and non-diabetic cohort at baseline may be 
the possible reason the present study did not find significant changes in SBP, DBP 
and MAP compared to studies which did (von Hurst et al., 2010; Witham et al., 
2009). Thirdly, the use of young cohort below 50 years could be another reason, as a 
majority would have had fewer anatomical changes to their arterial tree, since major 
changes to the arterial tree occurs between ages 50-60 (Reshetnik et al., 2016). 
Additionally, the lack of an effect of vitamin D supplementation on BMI, body 
weight and waist circumference may be attributed to using BMI to assess body fat, as 
BMI does not measure body fat distribution.  
The assessment of vitamin D is further complicated by the fact that CVD is a 
heterogeneous category, and it is possible that vitamin D has a different effect in a 
specific cardiometabolic outcome (Rosen et al., 2012). The estimated mean (±SD) 
vitamin D intake (2.5 ± 2.6 μg/d) was insufficient compared to the recommended 
RNI of 10µg/d, suggesting that vitamin D supplementation would be required to 
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raise the habitual intake in the UK to 10µg/d, particularly in the overweight and 
obese. 
The second study in the present project was aimed at investigating the prevalence of 
vitamin D deficiency, and its association with selected CVD risk markers in a cross-
section of calcium oxalate kidney stone patients. This study demonstrated that out of 
the 24 calcium oxalate kidney stone patients recruited for this study, 3 (12.5%), 7 
(29.2%) and 18 (75%) had serum 25(OH)D concentrations ≤ 25nmol/L, ≤ 30nmol/L 
and ≤ 50nmol/L respectively. Of the cohort 3 (12.5%), 7 (29.2%) and 18 (75%) were 
vitamin D deficient respectively according to definitions by the Scientific Advisory 
Committee on Nutrition (SACN, 2016), Institute of Medicine (IOM, 2011) Holick, 
(2007). However, 2 (8.3%) were insufficient and only 4 (16.7%) were within the 
optimal limits (≥ 75 nmol/L) (Holick, 2007). These observations suggest a high 
prevalence of low serum 25(OH)D concentrations in this cohort. 
 
Potential mechanisms responsible for the low serum 25(OH)D concentrations 
observed in the study cohort include increased circulating FGF-23 concentrations 
(Jones et al., 2012). Increased circulating FGF-23 concentrations in renal disease has 
been reported to stimulate the transcription of CYP24A1, resulting in increased 
25(OH)D and 1,25(OH)2D catabolism and low serum 25(OH)D concentrations 
(Jones et al., 2012). Albuminuria caused by impaired kidney function in stone 
formation could be another explanation, as albuminuria leads to high urinary loss of 
VDBP, leading to increased renal loss of all vitamin D metabolites (Andress, 2005). 
No significant associations were observed between serum 25(OH)D concentrations 
and the selected CVD risk biomarkers measured in calcium oxalate kidney stone 
patients as hypothesised. This observation may suggest that clinical disease decreases 
serum vitamin D concentration causing insufficiency but does not cause ill health 
(Theodoratou et al., 2014). Interestingly, there was increased CVD risk in the study 
cohort, as all biomarkers except for serum calcium and 8-Isoprostanes concentration, 
which was within the normal range and serum HDL-C concentration that was below 
the normal reference range, all the other CVD biomarkers measured were above the 
normal reference range. These observations, particularly the increased serum 
inflammatory and endothelial function, TC, TAG, non-HDL-C and LDL-C as well as 
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reduced serum HDL-C markers are similar to findings of other studies in kidney 
stones patients (Evan et al., 2010; Hasna et al., 2015; Khan, 2014). 
Significant positive associations were observed between serum sE-selectin and 
calcium concentrations (r = 0.53, P = 0.007), suggesting the disturbance observed 
with declining kidney function may result in the deposition of calcium in the arteries 
resulting in coronary artery calcification that leads to atherosclerosis (Yiu et al., 
2015). Positive association between serum hs-CRP and calcium concentrations (r = 
0.58, P = 0.003) were observed, indicating a role for inflammation in vascular 
calcification (Moe & Chen, 2005). Coronary artery calcification or calcium levels 
were not assessed in the present study, which may have explained the association 
better, as a study in humans have reported kidney stones patients to be at increased 
risk of vascular calcification (Kleinman et al., 2004). 
Furthermore, inverse associations were observed between serum sE-selectin and 
HDL-C concentrations (r = - 0.49, P = 0.013), indicating an increased risk of 
endothelial dysfunction with low serum HDL concentrations. Similar to this finding, 
human aortic endothelial cells incubated with HDL isolated from children with CKD, 
demonstrated that CKD HDL-C markedly repressed endothelial NO production and 
increased endothelial VCAM-1 expression (Shroff et al., 2014). 
Although little is known about the association between serum 25(OH)D 
concentrations and calcium oxalate kidney stone disease, it may not be appropriate to 
attribute the high prevalence of vitamin D deficiency and insufficiency observed in 
this cohort to the presence of kidney stone disease, as vitamin D deficiency is highly 
prevalent in the general UK population. 
Additionally, in the cross-sectional study, the low serum 25(OH)D concentrations 
was not associated with markers of oxidative stress, endothelial function, 
inflammation, dyslipidaemia and bone health. This could suggest that low serum 
25(OH)D concentrations is a consequence of kidney disease, but is not the cause for 
increased CVD markers (Theodoratou et al., 2014). Thus, low serum 25(OH)D 
concentrations is of limited importance for the development of CVD in calcium 
oxalate kidney stone patients 
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4.1 CONCLUSION 
Taking the studies together, although there may be a possibility that vitamin D 
supplementation may improve cardiometabolic risk, as several observational studies 
have demonstrated that low vitamin D status is associated with cardiometabolic 
disease. However, there are limitations to applying observational data to clinical 
practice, as they are subject to confounding and do not draw causal inferences. 
Consistent with the finding of the present study, there is insufficient evidence from 
clinical trials recommending vitamin D supplementation for lowering CVD risk 
(Theodoratou et al., 2014). This is because high quality systematic reviews and meta-
analyses of RCTs have not shown a consistent effect of vitamin D supplementation 
on cardiometabolic outcomes or that improving vitamin D status prevents non-
musculoskeletal outcomes (Bolland, Grey, Gamble, & Reid, 2014; Theodoratou et 
al., 2014; Zuk et al., 2016). Thus, low vitamin D concentrations may be a marker of 
poor health rather than the cause of poor health (Theodoratou et al., 2014).  It may be 
more beneficial to improve cardiovascular risk factors by consuming a healthy and 
balanced diet, maintaining a healthy body weight (BMI 20-25 kg/m2), avoiding 
smoking and a sedentary life style. 
Future research particularly from RCTs are required to fill a gap for the RCT study 
by examining whether there is a dose-response relationship between vitamin D 
supplementation and cardiometabolic risk outcomes. Research using larger dose of 
vitamin D and a longer duration of supplementation may be required, as plasma 
25(OH)D concentrations ˃75nmol/L are required for optimal extra-skeletal health 
(Bischoff-Ferrari, 2008). Further research is also required using overweight or obese 
males above 50 years and a serum/plasma 25(OH)D concentration below 25nmol/L. 
Research measuring VDR genotype polymorphisms may be significant in 
understanding the variations in individual response of the overweight and obese to 
oral vitamin D supplementation. 
For the cross-sectional kidney stone study, possible future studies using a larger 
population with age-matched controls is required. Research investigating indices of 
atherosclerosis such as coronary artery calcium would likely provide distinct 
information regarding CVD risk in calcium oxalate kidney stone patients. 
Additionally, vitamin D supplementation in this population is required as this might 
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not only decrease serum PTH secretion (Lee et al., 2013), it would also improve 
VDR expression and activities that would in turn exert reno-protective effects by 
downregulating RAS activity. Vitamin D supplementation in this cohort would 
establish whether with optimal vitamin D status, CVD risk would be reduced. 
Finally, a study assessing circulating FGF-23 concentration to determine the extent 
of kidney dysfunction in calcium oxalate kidney stone patients’population is also 
required. 
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registry 
 
Protocol 24 Where the full trial protocol can be 
accessed, if available 
 
Funding 25 Sources of funding and other support 
(such as supply of drugs), role of funders 
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APPENDIX 4 
 
Participant information sheet 
EFFECT OF VITAMIN D SUPPLEMENTATION ON CARDIOMETABOLIC RISK FACTORS IN A 
COHORT OF OVERWEIGHT AND OBESE ADULT MALES IN THE UK 
You are invited to take part in a research study.  Before you decide, it is important 
for you to understand why the research is being carried out and what it will involve.  
Please take time to read the following information carefully and discuss it with others 
if you wish.  Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part.  
What is the purpose of the study? 
The project is aimed at investigating whether supplementing the diet with oral 
vitamin D (1 small tablet per day) at a dose of 5000IU/d (125µg) over 8 weeks, will 
increase vitamin D status, and improve cardiometabolic risk markers such as: blood 
pressure, inflammation and cholesterol levels.  
Why have I been chosen? 
You have been chosen because you satisfy the inclusion criteria for the study. 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form.  If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect you in any way. 
What will happen to me if I take part? 
You will attend four clinic sessions on four separate days and also you will be 
expected to fast (abstain from food, caffeine, alcohol and cigarettes for at least eight 
hours prior to each clinic day). 
 
Screening Session: Participants will complete a screening questionnaire after 
which weight, height will be measured. 1mL of blood will then be collected for 
vitamin D status screening to see if you are eligible for the study. Eligible 
participants who are vitamin D insufficient will be randomly assigned to receive 
either vitamin D supplements or placebo (supplements without the active 
ingredient). You will be asked to complete a three - day food diary and physical 
activity questionnaire. 
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Clinic 1 (week 0): Weight, height, waist circumference and blood pressure 
measurements will be performed. 15mL of blood will then be collected to assess the 
cardiovascular risk markers. 
 
Clinic 2 (week 4): The procedure performed at clinic 1 will be repeated in this clinic. 
 
Clinic 3 (Week 8): The procedure performed at clinic 2 will be repeated in this clinic. 
 
Each clinic will last approximately 30 minutes. 
 
What are the possible disadvantages and risks of taking part? 
There is little or no risk involved in taking part in the study except minor discomfort 
during blood-taking and taking the supplements.  
What are the possible benefits of taking part? 
By taking part, you will be contributing to the advancement of knowledge in the role 
of vitamin D in the prevention of cardiovascular disease. Moreover, other benefits 
include free vitamin D status test and free dietary analysis and a £25 Amazon/Tesco 
voucher on completion of the study. 
What if something goes wrong? 
If you wish to complain or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, please contact 
Professor Sarah Andrew, Dean of the Faculty of Life Sciences, University of 
Chester, Parkgate Road, Chester, CH1 4BJ, 01244  513055. 
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will be 
kept strictly confidential so that only the researcher carrying out the research will 
have access to such information.   
What will happen to the results of the research study? 
The results will be written up into a dissertation for my PhD thesis. Individuals who 
participate will not be identified in any subsequent report or publication. 
Who is organising the research? 
The research is conducted as part of a PhD research project in Human Nutrition 
within the Department of Clinical Sciences and Nutrition at the University of Chester. 
The study is organised with supervision from the department, by Tari Agbalalah. 
Who may I contact for further information? 
For more information please contact: 
Tari Agbalalah 
vitaminDstudy@chester.ac.uk 
Thank you for your interest in this research. 
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APPENDIX 5 
 
 
CONSENT FORM TO PARTAKE IN STUDY 
Title of Project:  Effect of vitamin D supplementation on cardiometabolic 
risk factors in a cohort of overweight and obese adult males in the UK 
 Name of Researcher: Tari Agbalalah 
Please tick box 
 
1. I confirm that I have read and understand the information sheet  
      for the above study and have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to  
      withdraw at any time, without giving any reason and without my  
      legal rights being affected. 
 
3. I agree to take part in the above study.    
 
___________________                _________________   _____________ 
Name of Participant Date  Signature 
 
 
Researcher Date Signature 
1 for participant; 1 for researcher 
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APPENDIX 6 
 
SCREENING TEST QUESTIONNAIRE 
 
EFFECT OF VITAMIN D SUPPLEMENTATION ON CARDIOMETABOLIC RISK FACTORS 
IN A COHORT OF OVERWEIGHT AND OBESE ADULT MALES IN THE UK 
 
Name of participant: …………………………………………………………………………………  
ID: ……………………………………………………………………………………………………………. 
Email address: ………………………………………………………………………………………….. 
Contact number: ………………………………………………………………………………………. 
Test date: …………………………………………………………………………………………………. 
DOB: ………………………………………………………………………………………………………… 
Ethnicity: …………………………………………………………………………………………………… 
 
For the reliability and validity of this research study, it is highly relevant that each 
participant be screened for potential confounders or factors that may affect the results 
negatively. 
 
Section One 
 
Do you take medications for blood pressure?                                                                                            
YES/NO 
Do you take medications for diabetes?                                                                                                        
YES/NO                                                                             Are you currently partaking in a weight-
reduction programme                                                              YES/NO 
Are you taking medication for/ or are you being treated for the following conditions: Bone, 
kidney, liver or gastrointestinal disease?                                                                                                                            
YES/NO                                                                                                                                                
Section Two (further information) 
Do you take any nutritional supplements?     YES/NO                                                                                              
If yes please list: 
……………………………………………………………………………………………………………………. ……………………….                                                                                         
Are you currently on any other regular medications?   YES/NO                                                                              
If yes please list: ……………………………………………………………………………………................................. 
……………………………………………………………………………………………………………………………………………… 
Do you smoke?     YES/NO                                                                                                                                            
If yes, how many cigarettes per day on average? 
Do you drink alcohol?          YES/NO                                                                                                                           
If yes, how many units of alcohol on average do you consume per week?   1-10         11-20          
21-30         30+ 
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Use the example below to assist you with completing your food diary 
  
Time Location Description of 
food/drink  
consumed  
Brand Amount/  
Portion Size 
  
7.50am 
Home Bran flakes with semi 
skimmed milk. Banana 
Tesco Bran 
Flakes. 
1 cup cereal,  1/2 cup 
milk 
1/2 banana 
12.30pm Work Sandwich 
Tuna 
Light mayo  
Tomato 
Flapjack 
Hovis 
wholemeal,  
Tesco tuna 
Tesco mayo,   
Homemade 
flapjack (See 
recipe, serves 
15) 
2 medium slices. 
1 can tuna 
2 tbsp. mayo 
1 tomato 
2 servings flapjack 
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              Day:                                                          Date:      
          
Time Location Description of food / drink consumed Brand Amount/Quantity 
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APPENDIX 8 
 
PROTOCOL FOR VENEPUNCTURE 
 
Objectives of venepuncture: 
• To obtain a blood sample of adequate volume for the test requested. 
• Avoiding pre-analytical interference 
• Into the correct tubes for analysis 
• Safely 
• With minimum discomfort to patient 
 
Procedure: 
1. Approach patient and explain the procedure, and thereafter, allow patient to 
ask questions and discuss any problems which have arisen previously. 
2. Identify patient, making sure the information matches the details on the 
requisition form. 
3. Reassure patient that the minimum amount of blood required for testing will 
be drawn 
4. Assemble the necessary equipment 
5. Wash hands or use sanitizer, allow to dry before wearing gloves  
6. Position patient with the chosen arm extended to form a straight- line from 
shoulder to wrist, with the patient assisting by clenching and unclenching the 
fist. 
7. Select appropriate vein for venepuncture and do not attempt a venepuncture 
more than twice. 
8. Apply the tourniquet 3-4 inches above the collection site, if a tourniquet is 
used for preliminary vein selection, release it and reapply after two minutes 
and never leave tourniquet on for over one minute. Clean puncture site by 
making a smooth circular pass over the site with the 70% alcohol pad, allow 
to dry. Do not repalpate the insertion site. 
9. Anchor vein by applying manual traction and the insert needle smoothly at an 
angle of 20-300. 
10. Holding the hub securely, insert the first vacutainer tube following proper 
order of draw into the large end of the hub penetrating the stopper. Blood 
should flow into the evacuated tube, after blood starts to flow release the 
tourniquet and ask patient to unclench hand. 
11. When blood stops flowing, remove the tube by holding hub securely and 
pulling the tube off the needle. 
12. If multiple tubes are needed, the proper order of draw to avoid cross 
contamination and erroneous results is as follows: 
13. Blood culture vials or bottles, sterile tubes 
14. Coagulation tube (light blue top) 
15. Serum tube with or without clot activator or silica gel (Red or Gold) 
16. Heparin tube (Green top) 
17. EDTA (lavender top) 
18. Glycolytic inhibitor 
19. Each coagulation tube (light blue top) should be gently inverted 4 times after 
being removed from the hub. Red and gold tops should be inverted five times 
from the hub. All other additive containing tubes should be gently inverted 8-
10 times. 
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20. Place a gauze pad over the puncture site and remove the needle, and 
immediately apply slight pressure .ask the patient to apply pressure for at 
least 2 minutes, when bleeding stops, apply a fresh bandage, gauze or tape. 
21. Properly dispose of hub with needle attached into a sharps bin- label all tubes 
with patient labels, initials, date and time. 
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APPENDIX 9 
 
 
 
Example calibration curve obtained for plasma sE-selectin concentration 
 
      4- & 5-Parameters-Logistics Curve Fit
All rights reserved A.Swart 2013
STEP 1 Set Extras/Macro/Security to medium (for SOLVER), close, reopen and activate
STEP 2 Enter the standard concentrations in the blue column [std] in the order of increasing concentration, for 0 set 0,0000001
STEP 3 Enter the corresponding standard readings in the yellow  column
STEP 4 Optional w eighting: set value of B for w eighting. For no w eighting set B = 0. 0 <-- enter value here
STEP 5 start optimizing by clicking f irst the 4-PL button. Note the goodness of f it: MAE and the distribution of error in the plot. 
Click the 5-PL button and compare the goodness of f it.
STANDARDS
[std] Reading Fit Recalc. Conc. % Recovery WSE         ERROR PLOT
0.125 0.021 0.026187 0.082457525 65.9660203 2.6905E-05 -0.005187 0.005187
0.25 0.044 0.04395437 0.250296964 100.118786 2.0823E-09 4.5633E-05 4.563E-05
0.5 0.091 0.08624021 0.526046427 105.209285 2.2656E-05 0.00475979 0.0047598
1 0.192 0.18478748 1.034477884 103.447788 5.202E-05 0.00721252 0.0072125
2 0.393 0.40362628 1.952544293 97.6272147 0.00011292 -0.0106263 0.0106263
4 0.846 0.84148883 4.021621048 100.540526 2.0351E-05 0.00451117 0.0045112
8 1.559 1.55971583 7.995249907 99.9406238 5.1242E-07 -0.0007158 0.0007158
7 7                       SUM OF WEIGHTED SQUARED ERRORS 0.00023536 error abs error
        PARAMETERS
4.002940607 (max) a rdg. of asymptotic maximum
-1.27289732 (slope) b slope at inversion point
11.46029286 (IC50) c concentration at inversion point (4-PL)
0.013547194 (min) d rdg. of asymptotic minimum
1 (sym f) s asymmetry factor (if  s = 1, f it is 4-PL)
R2 0.99288032 MEAN ABSOLUTE ERROR   (MAE) 0.00472260
STEP 6 Enter your sample readings below  in the light blue column. Your results w ill appear in the w hite column to the right.
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 1 2 3 4 5 6 7 8 9
Reading
Fit
4-PL
4-PL
5-PL
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Example calibration curve obtained for plasma angiotensin II concentration 
 
      4- & 5-Parameters-Logistics Curve Fit
All rights reserved A.Swart 2013
STEP 1 Set Extras/Macro/Security to medium (for SOLVER), close, reopen and activate
STEP 2 Enter the standard concentrations in the blue column [std] in the order of increasing concentration, for 0 set 0,0000001
STEP 3 Enter the corresponding standard readings in the yellow  column
STEP 4 Optional w eighting: set value of B for w eighting. For no w eighting set B = 0. 0 <-- enter value here
STEP 5 start optimizing by clicking f irst the 4-PL button. Note the goodness of f it: MAE and the distribution of error in the plot. 
Click the 5-PL button and compare the goodness of f it.
STANDARDS
[std] Reading Fit Recalc. Conc. % Recovery WSE         ERROR PLOT
0 1.384 1.38118082 7.9478E-06 0.00281918 0.0028192
0.1 1.303 1.30547255 0.104454827 104.454827 6.1135E-06 -0.0024725 0.0024725
1 1.02 1.02208761 1.010037846 101.003785 4.3581E-06 -0.0020876 0.0020876
10 0.439 0.43316755 9.761961502 97.619615 3.4017E-05 0.00583245 0.0058324
100 0.066 0.07864111 119.4003939 119.400394 0.0001598 -0.0126411 0.0126411
1000 0.001 -0.0075496 609.9795939 60.9979594 7.3096E-05 0.00854964 0.0085496
6 6                       SUM OF WEIGHTED SQUARED ERRORS 0.00028533 error abs error
        PARAMETERS
1.38118082 (max) a rdg. of asymptotic maximum
0.779991501 (slope) b slope at inversion point
3.948631047 (IC50) c concentration at inversion point (4-PL)
-0.02607927 (min) d rdg. of asymptotic minimum
1 (sym f) s asymmetry factor (if  s = 1, f it is 4-PL)
R2 0.99170611 MEAN ABSOLUTE ERROR   (MAE) 0.00573376
STEP 6 Enter your sample readings below  in the light blue column. Your results w ill appear in the w hite column to the right.
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 200 400 600 800 1000 1200
Reading
Fit
4-PL
4-PL
5-PL
Print Curve Plot
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Example calibration curve obtained for plasma renin concentration 
 
 
      4- & 5-Parameters-Logistics Curve Fit
All rights reserved A.Swart 2013
STEP 1 Set Extras/Macro/Security to medium (for SOLVER), close, reopen and activate
STEP 2 Enter the standard concentrations in the blue column [std] in the order of increasing concentration, for 0 set 0,0000001
STEP 3 Enter the corresponding standard readings in the yellow  column
STEP 4 Optional w eighting: set value of B for w eighting. For no w eighting set B = 0. 0 <-- enter value here
STEP 5 start optimizing by clicking f irst the 4-PL button. Note the goodness of f it: MAE and the distribution of error in the plot. 
Click the 5-PL button and compare the goodness of f it.
STANDARDS
[std] Reading Fit Recalc. Conc. % Recovery WSE         ERROR PLOT
31.3 0.011 0.00738653 40.33927967 128.879488 1.3057E-05 0.00361347 0.0036135
62.5 0.017 0.02032955 54.74301273 87.5888204 1.1086E-05 -0.0033295 0.0033295
125 0.045 0.04877239 116.9730658 93.5784527 1.4231E-05 -0.0037724 0.0037724
250 0.115 0.10973309 260.5818232 104.232729 2.774E-05 0.00526691 0.0052669
500 0.232 0.23405397 495.8130034 99.1626007 4.2188E-06 -0.002054 0.002054
1000 0.464 0.46372447 1000.649393 100.064939 7.5919E-08 0.00027553 0.0002755
6 6                       SUM OF WEIGHTED SQUARED ERRORS 0.00007041 error abs error
        PARAMETERS
2.139357162 (max) a rdg. of asymptotic maximum
-1.16200342 (slope) b slope at inversion point
3002.940902 (IC50) c concentration at inversion point (4-PL)
-0.00322279 (min) d rdg. of asymptotic minimum
1 (sym f) s asymmetry factor (if  s = 1, f it is 4-PL)
R2 0.99615499 MEAN ABSOLUTE ERROR   (MAE) 0.00305197
STEP 6 Enter your sample readings below  in the light blue column. Your results w ill appear in the w hite column to the right.
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
0 200 400 600 800 1000 1200
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Fit
4-PL
4-PL
5-PL
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Example calibration curve obtained for plasma 8-isoprostanes concentration 
 
 
 
Example calibration curve obtained for plasma insulin concentration 
 
 
 
y = -16.81ln(x) + 141.12
R² = 0.9919
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Example calibration curve obtained for plasma hs-CRP concentration 
 
 
 
 
Example calibration curve obtained for plasma HDL-C concentration 
 
y = 39.37x + 0.1304
R² = 0.992
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Example calibration curve obtained for plasma glucose concentration 
 
 
 
 
Example calibration curve obtained for plasma TC concentration 
 
y = 0.0022x - 0.0009
R² = 0.9997
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Example calibration curve obtained for plasma PTH concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
y = 0.0026x + 0.0456
R² = 0.9987
0
0.5
1
1.5
2
2.5
3
0 200 400 600 800 1000 1200
A
b
so
rb
an
ce
 @
 4
5
0
n
m
PTH concentration (pmol/l)
311 
 
Appendix 10 
EFFECT OF VITAMIN D SUPPLEMENTATION ON ENDOTHELIAL AND 
INFLAMMATORY MARKERS IN ADULTS. A SYSTEMATIC REVIEW OF 
RANDOMISED CONTROLLED TRIALS. Agbalalah.T., Freeborn.E.J., 
Hughes. S.F., Mushtaq.S. Department of Clinical Sciences and Nutrition, 
University of Chester, Chester, UK. CH1 4BJ. 
   It is evident that vitamin D exerts important pleiotropic effects distinct from its 
primary role in calcium and phosphate homeostasis, and bone metabolism. Deficient 
vitamin D status has previously been associated with increased cardiovascular 
disease risk, therefore the effect of vitamin D supplementation on cardiovascular risk 
markers, especially endothelial dysfunction and inflammation, are important areas 
for investigation. In order to investigate the feasibility of vitamin D supplementation 
as a potential therapy, we systematically reviewed randomised placebo controlled 
trials (RCTs) investigating the effects of vitamin D (D2 and D3) on endothelial 
function and inflammatory markers in adults. Included studies were identified by 
conducting a literature search of randomised controlled trial articles published from 
2008 to 2014, using Cochrane, Pubmed and Medline electronic databases with the 
search terms related to vitamin D and endothelial function. Inclusion criteria were 
RCTs in adult humans with a measure of vitamin D status using serum/plasma 
25(OH)D and studies which administered the intervention through the oral route. 
Among the 1107 studies retrieved, 27 studies met the full inclusion criteria for this 
systematic review. Overall, eight studies reported significant improvements in the 
endothelial/inflammatory biomarkers and parameters measured. However, the 
positive effect disappeared by the second period of measurement in two out of the 
eight studies. The remaining 19 trial studies did not show significant improvements 
in the biomarker/parameters of interest measured.  Although some studies showed 
significant improvement in the markers of interest, evidence from most of the studies 
included in this systematic review did not demonstrate that vitamin D 
supplementation in adults’ results in improvement of circulating inflammatory and 
endothelial function biomarkers/parameters. RCTs of high methodological quality 
and a high daily dose (5000IU to 1000IU) of vitamin D are required especially in 
populations at risk of vitamin D deficiency. 
 
 
